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Abstract 
 
Università degli Studi di Milano 
Arianna Gennari 
 
DESIGN, SYNTHESIS, CHARACTERISATION AND BIOLOGICAL TESTING OF NEW DERIVATIVES OF 
HYALURONAN FOR THE PRECONDITIONING OF STEM CELLS FOR THE THERAPY OF MUSCULAR 
DYSTROPHIES AND THE DEVELOPMENT AND REGENERATION OF SKELETAL MUSCLE 
 
Regenerative medicine is the process of creating living, functional tissues to repair or replace 
tissue or organ functions lost due to age, disease, damage, or congenital defects. Related to 
regenerative medicine is field of tissue engineering. Numerous strategies currently used to 
engineer tissues depend on employing a specific material. These scaffolds serve as a synthetic 
extra cellular matrix thus to direct the growth and the formation of a desired tissue.  
Recent work has suggested application of mesoangioblasts for stem cell therapies for muscular 
dystrophy. Experiments in dystrophic mice and dogs have shown that mesoangioblasts 
transplantation can restore muscle function. Anyway, the possibility of using this novel strategy 
for the cell therapy in genetic diseases is strictly related to the capacity to expand 
mesoangioblasts in culture in a reproducible and efficient way. Hence, the aim of this project is 
to investigate the ability of the hyaluronic acid (HA) to act as a basement for cells culture; cells 
are in fact very sensitive to their environment and the contact with something mimicking the 
extra cellular matrix could, in theory, assure a better proliferation and differentiation. 
Hyaluronan can be chemically modified to introduce drugs, ligands or other bioactive 
molecules, or to cross-link the linear chains affording reticulated networks. Several different 
methods to provide modified HA have been performed in order to develop robust protocols; 
specifically we focused on Sharpless cycloaddition, on the use of diisocyanates as cross-linker 
agents and on the activation of the carboxylic acid moiety towards amines.     
Mesoangioblasts were cultured using HA and its derivatives as substrates to evaluate their 
biological influence on in vitro proliferation and differentiation. 
Furthermore a deep investigation concerning the kinetics of the Michael-type addition was 
performed. Due to its versatility, Michael addition is a precious tool for the bioconjugation 
often used also for HA-derivatisation. Thus we deeply studied the effect of the reagents 
architecture (influence of the Michael donor and acceptor), their stability and that of the 
Michael adducts.   
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1 
1 INTRODUCTION 
1.1 NEW THERAPIES FOR MUSCULAR DYSTROPHY 
Muscular dystrophies are a clinically and molecularly heterogeneous class of genetic disorders 
that are characterized by the primary wasting of skeletal muscle, and hence seriously 
compromise patient mobility and quality of life. In the most severe case, Duchenne muscular 
dystrophy (DMD), respiratory and cardiac functions are affected, leading to wheelchair 
dependency, respiratory failure and premature death. DMD is a severe X-linked recessive, 
progressive muscle-wasting disease affecting 1 in 3500 boys. The average life expectancy for 
patients afflicted with DMD is around 25.  
The mutation affects the proteins that form a link between the cytoskeleton and the basal 
lamina, e.g. the dystrophin (Figure 1). A mutation in one of these proteins often causes the 
disassembly of the whole complex, leading to increased fragility of the sarcolemma, especially 
during intense contractile activity and focal or diffuse damage to the fibers. With time, the 
muscle tissue is progressively replaced by connective and adipose tissue.1 
 
 
 
Figure 1: Dystrophin in normal and dystrophic muscle 
Immunohistochemistry images visualize dystrophin in human muscle taken from healthy controls (first column) 
and from patients with Duchenne muscular dystrophy (second column).
1
 
Muscular dystrophies are among the most difficult diseases to treat: this is due to the fact that 
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skeletal muscle is very abundant in the body and is composed of large multinucleated fibers, 
the nuclei of which have permanently lost the ability to divide. Consequently, any cell or gene 
replacement must restore proper gene expression in hundreds of millions of postmitotic nuclei, 
which are embedded in a highly structured cytoplasm and surrounded by a thick basal lamina. 
Similarly, most pharmacological trials must overcome the complex biochemical mechanism of 
fiber degeneration. Nevertheless, the results that have been accumulated during the last few 
years have opened new perspectives.  
 
 
 
Figure 2: Different delivery strategies of the therapeutic agents 
Different delivery strategies for cells, viral vectors and small molecules. Intramuscular injection will require 
multiple injections for delivery to only a small volume of a given muscle. Systemic delivery would overcome this 
limitation, but crossing the vessel wall and the muscle basal lamina could be a problem. Small molecules will 
usually be administered orally and reach the muscle through the circulation.
3
 
Although muscular dystrophies still lack in an effective therapy, several novel strategies are 
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entering or are ready to enter clinical trials. The different approaches are based on drug, gene 
and cell therapies and clinical experimentation has already begun.2,3  
It is important to underline that each strategy has advantages and limitations: for example, 
strategies that repair the dystrophin gene might be suitable only for a subset of mutations, 
whereas cell and gene therapies are limited by costs related to cell or vector production and 
can be available only for a limited number of patients. A second consideration is that local 
delivery of the therapeutic agent is necessary as proof of principle but real clinical benefit can 
only follow systemic delivery. Similarly, possible adverse events will be apparent following 
systemic delivery only (Figure 2). 
Nevertheless, the results that have been accumulated during the last few years have opened 
new perspectives for all these different approaches. 
1.1.1 The pharmacological approach 
Several pharmacological strategies have been attempted to counteract the consequences of 
the dystrophic process. Among them the most common envisage the use of protease inhibitors, 
calcium blockers and drugs that act on protein and lipid metabolism.4 Only few of these have 
produced promising results in mice and even fewer have entered clinical trials, with modest 
final success.  
These are based on the knowledge about chronic inflammation that accompanies fiber 
degeneration and that leads to sclerosis and reduction of the vascular supply. This starts a 
vicious circle that reduces oxygen supply and increases the degeneration for surviving and 
regenerates fibers.1 Therefore, anti-inflammatory molecules appeared to be the logical 
therapeutic strategy and, for more than a decade, corticosteroids have represented the only 
pharmacological therapy with relatively modest but consistent beneficial consequences. 
Recent data indicate that corticosteroid treatment in DMD can delay the loss of independent 
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ambulation by 2 to 4 years, significantly reduces the risk of developing skeletal defects and 
delays the respiratory and cardiac failure. However, their use is associated with significant side 
effects, such as weight gain and osteoporosis with the risk of bone fractures.5 
Recently, insulin growth factor 1, which is a well known muscle growth factor, and myostatin, a 
negative regulator of muscle growth, have been identified as important factors regulating the 
functionality in muscle tissue. In fact, when mice overexpressing growth factor 1 were crossed 
to mdx mice (a model for DMD), dystrophy was attenuated.6 Similarly, when neutralizing 
antibodies against myostatin were systemically delivered to mdx mice, dystrophic mice showed 
a dramatic delay of muscle wasting.7  
Other proteins have been identified that stimulate muscle regeneration and ameliorate 
dystrophy, such as integrin α7, acetyl-N-galactosamine transferase, and A disintegrin and 
metalloprotease 12.8  
As an alternative approach, a high-throughput screen for small molecules was carried out but, 
so far, no new candidate drugs have been identified. 
Finally, the expression of nitric oxide synthase increased angiogenesis and also resulted in the 
amelioration of the mdx phenotype by counteracting the reduced vascular supply that 
accompanies fiber degeneration, inflammation and sclerosis.9  
In conclusion, considering that muscular dystrophy defects result from the premature 
degradation of proteins that are important for muscle function and maintenance, these 
pharmacological agents might be invaluable for slowing down the progression of the disease, 
ameliorating the quality of life of the patient and, at the same time, increasing the chance of 
success for gene or cell therapy. Anyway, it remains to be seen whether these strategies can be 
applied as a treatment, since the toxicity of these molecules must be assessed. 
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1.1.2 Gene therapy 
As gene therapy are named the strategies act to replace the mutated gene. Common problems 
with this strategy are the immune response to the vectors, and specific to muscular dystrophy 
is the gene delivery to the majority of postmitotic muscle fibers. In fact the task of replacing a 
missing gene in all, or at least in a good proportion, of the post-mitotic nuclei of skeletal muscle 
is clearly daunting.  
Adenoviral are vectors with the property not to be integrated into the genome and not to 
replicated during cell division; they raised much hopes in the past but, because of their great 
immunogenicity and large size (limiting diffusion in the muscle tissue), they are no longer 
used.10 
Adeno-associated vectors instead, are characterized by reduced size and lower immunogenicity 
and are currently the vectors of choice.11 
In France the intramuscular injection in the radial muscle of γ-sarcoglycan-expressing 
adeno-associated viral vectors is already at phase I and II in clinical trials for limb girdle 
muscular dystrophy 2C. 
In the case of dystrophin, two strategies are currently being tested in the dystrophic dog and 
have already entered, or are ready to enter, clinical experimentation: exon skipping and 
expression of dystrophin variants of reduced size. 
Exon skipping is based on the use of small pieces of DNA, called antisense oligonucleotides, 
which act as “molecular patches”; this molecular strategy prevents the transcription of the exon 
containing the mutation. DMD, for example, is characterised by the lack of exon 53 in the gene 
encoding the production of dystrophin, hence the use of a “molecular patch” designed to mask 
exon 53 may be able to reduce the symptoms of DMD by the production of dystrophin protein 
shorter but functional.12 
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In an alternative strategy, minigenes were constructed with reduced number of centrally 
located spectrin-like domains and preserved amino- and carboxy-terminal domains. The 
minigenes have been shown to substitute for the wild-type gene when expressed as trangenes 
in mdx mice, a model for DMD.13 However, the resulting microdystrophins were found to be 
less effective in protecting muscle fiber integrity in larger animals, as indicated by dog studies.14 
1.1.3 Cell therapy 
Satellite cells are small mononuclear progenitor cells found in mature muscle. They are 
precursors to skeletal muscle cells, able to give rise to satellite cells or differentiated skeletal 
muscle cells.15 These cells represent the oldest known adult stem cell niche, and are involved in 
the normal growth of muscle, as well as in regeneration following injury or disease. In 
undamaged muscle, the majority of satellite cells are quiescent; they neither differentiate nor 
undergo cell division. In response to mechanical strain, satellite cells become activated. 
Activated satellite cells initially proliferate as skeletal myoblasts before undergoing 
myogenic differentiation. 
Since the identification of satellite cells, two alternatives appeared: the first one contemplated 
the use of cells obtained from a healthy donor, which express the normal copy of the mutated 
gene but induce an immune rejection, unless the patient is permanently immune suppressed; 
the second one involved the use of cells obtained from the patient, which do not require 
immune suppression but must be genetically corrected in vitro (to restore the expression of the 
mutated protein).  
Satellite cells and cell lines have been used since the late 1970s, mainly through intra-muscular 
injection.3 In a first study, the injection of wild-type myoblasts into mdx mice resulted in the 
conversion of muscles from dystrophin-negative to dystrophin-positive.16 Unluckily, several of 
the subsequent clinical trials failed, mainly because of the poor survival and the very limited 
migratory capacity of injected donor cells. 
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Myogenic cell transplantation was continued and optimized in few laboratories in preclinical 
studies. However, the major problem still faced by this approach, is the lack of dispersion of 
donor cells, which remain in the area of injection, making it difficult to reach an even 
distribution within the whole muscle.  
Anyway, the use of blood-born stem or progenitor cells might overcome the aforementioned 
limitation: in fact circulating cells make possible a systemic delivery, while satellite cells cannot 
cross the endothelial layer. This perspective became theoretically possible in the late 1990s, 
with the demonstration of cells in the bone marrow that could contribute to muscle 
regeneration following bone marrow transplantation;17 even in this case, the extent of 
colonization by donor cells was very small, far from any hope of clinical benefit. However, 
during the last years, several reports have convincingly demonstrated that bone marrow stem-
progenitor cells can be really promising to regenerate muscle. 
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1.2 MESOANGIOBLASTS: VASCULAR PROGENITORS FOR 
EXTRAVASCULAR MESODERMAL TISSUES 
Mesoangioblasts are multipotent progenitors of mesodermal tissues that express the key 
marker of angiopoietic progenitors. These cells are physically associated with the embryonic 
dorsal aorta in avian and mammalian species.18  
Mesoangioblasts have been recently isolated and characterized from mouse, dog and human 
tissues;19 interestingly, when transplanted in vivo, they give rise to multiple differentiated 
mesodermal phenotypes. Moreover, their ability to extensively self-renew in vitro, while 
retaining multipotency, and differentiate into most mesoderm types when exposed to certain 
cytokines or to differentiating cells of a mesodermal tissue, qualifies mesoangioblasts as a novel 
class of stem cells. 
The demonstration that postnatal murine bone marrow contains a transplantable, circulating 
progenitor that can differentiate into skeletal muscle had important basic and applicative 
implications. Previously, skeletal muscle was thought to be capable of limited regeneration 
potential, conveyed by a local population of proliferation-restricted, committed progenitors, 
the satellite cells.20  
Currently, the developmental origin of mesoangioblasts, their phenotypic heterogeneity, and 
the relationship with other mesoderm stem cells are not understood in detail and are the 
subject of active research. However, from a practical point of view, these cells have been 
successfully used in cell transplantation protocols that have yielded a significant rescue of 
structure and function in skeletal muscle of dystrophic mice and dogs. Since the corresponding 
human cells have been recently isolated and characterized, a clinical trial with these cells is 
planned in the near future. 
The intra-arterial delivery of mesoangioblasts is possible because, when injected into the blood 
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circulation, they accumulate in the first capillary filter encountered and then these cells are 
able to migrate outside the vessel, but only in the presence of inflammation, as in the case of 
dystrophic muscle. Indeed, mesoangioblasts express many receptors for inflammatory 
cytokines and are able to migrate in vitro and in vivo in response to nuclear proteins released by 
necrotic cells and acting as potent inflammatory cytokine.21 This property of mesoangioblasts 
was considered particularly interesting because if, in theory, these cells were injected into an 
artery, they would accumulate into the capillary filter and from there into the interstitial tissue 
of downstream muscles. 
To test this possibility, in 2003, Cossu et al. injected wild-type mesoangioblasts into the right 
femoral artery of α-sarcoglycan (α-SG) null mice.22  
The sarcoglycans (SG) are a family of transmembrane proteins involved in the protein 
complex responsible for connecting the muscle fibre cytoskeleton to the extracellular matrix, 
preventing damage to the muscle fibre sarcolemma. Duclos et al. attempted to generate a 
murine model by disrupting the α-SG gene. α-SG null mice developed progressive muscular 
dystrophy and ongoing muscle necrosis with age, a hallmark of the human disease.23  
Following the injection through the femoral artery, tissue distribution of donor cells was 
analyzed after 24 hours; mesoangioblasts were detected outside the vessel wall and within the 
extracellular matrix of all downstream skeletal muscles, especially in areas where degeneration 
and regeneration were occurring.  
The same research group also investigated whether injection of wild-type mesoangioblasts in 
the muscles of α-SG null mice might restore expression of α-SG and of the whole dystrophin 
complex. Very promising results were obtained: in fact, two months after a single injection of 
wild-type mesoangioblasts into α-SG null mice, many areas of the quadriceps, tibialis anterior, 
soleus and gastrocnemius expressed α-SG, whereas the protein was completely absent from 
the muscles of the untreated null mouse (Figure 3). Importantly no immune reaction occurred 
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against reconstituted fibers.  
Furthermore the long-term effect of donor wild-type mesoangioblasts was studied injecting 
wild-type mesoangioblasts three times (at 40-day intervals) into the femoral artery of 2-month-
old α-SG null mice. Animals were then analyzed 4 months after the first injection. Also in this 
case, histological analysis of skeletal muscle tissue of mice treated by three injections showed 
an increased number of apparently normal fibers and reduction of the necrotic areas and of 
cellular infiltrates. Consistent with histology, immunofluorescence analysis revealed the 
widespread presence of α-SG throughout the whole soleus muscle (more than 50% of the 
fibers), in contrast with the total absence of signal in untreated α-SG null mice.  
 
 
 
Figure 3: Expression of α-SG and other dystrophin-associated proteins in α-SG null mice after intra-
arterial delivery of wild-type mesoangioblasts 
(A) Low magnification of quadriceps from control (CTR) mice (left), α-SG null (α-SG KO) mice (centre), and treated 
α-SG null mice (injected with wild-type mesoangioblasts 2 months before killing) (right). Large areas of the treated 
muscle expressed α-SG after staining with a specific antibody (red). Sections were also stained with antibodies to 
laminin (green) and with DAPI (blue). Inset: Higher magnification of treated muscle with centrally located nuclei.
22
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The same paper22 tested whether autologous, genetically corrected stem cells might represent 
a possible model for the therapy of muscular dystrophy: mesoangioblasts were isolated from 
vessels of juvenile dystrophic mice and genetically transduced  to express α-SG. 
Four months after three intra-arterial injections of α-SG dystrophic mesoangioblasts, many 
fibers expressed α-SG on the membrane. In contrast, very few α-SG-positive fibers were 
detected in the contralateral muscles of the noninjected leg. After long-term treatment with 
genetically corrected mesoangioblasts, α-SG null mice had restored specific force and also 
showed an ameliorated motility. 
As already mentioned, intra-arterial transplantation of donor mesoangioblasts was performed 
to ameliorate defective muscle structure and function not only in dystrophic mice, but also in 
dogs.14 
The only animal model specifically reproducing the alterations in the dystrophin gene and the 
full spectrum of human pathology is the golden retriever dog model. Golden retriever muscular 
dystrophy (GRMD) affected animals present a single mutation in intron 6, resulting in the 
complete absence of the dystrophin protein, and early and severe muscle degeneration with 
nearly complete loss of motility and walking ability.24 Death usually occurs at about 1 year of 
age as a result of failure of respiratory muscles. 
To test the efficacy of cell or gene therapy, GRMD dogs were transplanted with either 
autologous genetically corrected or donor wild-type mesoangioblasts, under different regimes 
of immune suppression.14 
Overall, the results showed that donor wild-type mesoangioblasts significantly ameliorate many 
symptoms of canine muscular dystrophy, whereas autologous genetically corrected cells are 
much less effective. 
Specifically, they showed that it is possible to transplant mesoangioblasts into dystrophic dogs 
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and obtain an extensive reconstitution of fibres expressing dystrophin, an improvement in the 
contraction force and, in many cases, a preservation of walking ability. Even if, extensive 
variability exists between dystrophic dogs, this is the situation that will be faced with patients. 
Donor wild-type mesoangioblasts seemed to be more efficient than autologous, genetically 
corrected cells. Four of six dogs treated with donor cells showed clear clinical amelioration; of 
the remaining two, one died early and could not be analysed in detail and the other one 
probably received too few cells. At the end of immune suppression, two of the four dogs 
showing amelioration continued to walk well until the end of the experiment, whereas the 
other two, rapidly lost walking ability. This difference may reflect the different survival of 
transplanted organs after the end of immune suppression. Thus, the work reported really sets 
the logical premise for the start of clinical experimentation that may lead to an efficacious 
therapy for Duchenne muscular dystrophy. 
As said above, isolation and characterization of the human counterparts of mouse 
mesoangioblasts from adult skeletal muscle was accomplished and they have been more 
precisely indicated as “pericyte-derived cells”.25  
Cells derived from blood vessels of human skeletal muscle can regenerate skeletal muscle, 
similarly to embryonic mesoangioblasts. However, adult cells do not express endothelial 
markers, but instead express markers of pericytes, which are cells found in the central nervous 
system. Pericytes are more specifically located surrounding the endothelial cell layers of 
the capillary network in the brain.  
Pericyte-derived cells differentiate into smooth muscle, osteoblasts or adipocytes after 
appropriate stimuli. When skeletal-muscle differentiation was induced by coculturing human 
adult pericyte-derived cells with mouse myogenic cells, a very high percentage (more than 50%) 
of nuclei fused into hybrid myotubes. Moreover, when exposed to muscle-differentiation 
medium, a large proportion (ranging between 20 and 40% in different experiments) of human 
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adult pericyte-derived cells spontaneously differentiated into myosin-positive multinucleated 
myotubes. No significant differences were observed between cells from normal or DMD 
muscle. Under similar conditions, approximately 60% of the myogenic cells derived from 
normal satellite cells differentiated into multinucleated myotubes. (Figure 4) 
This result indicates the high skeletal myogenic potential for human pericyte derived cells. 
 
 
 
Figure 4: In vitro myogenic differentiation of human pericyte derived cells 
Spontaneous differentiation of normal (A) and dystrophic (B) human pericyte-derived cells, cultured in 
differentiation medium on matrigel coated dishes. Normal human satellite cell-derived myotubes are shown in C 
for comparison. A quantitative analysis of the percentage of differentiation is shown in D.
25
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Pericyte-derived cells, when transplanted into severe combined immune deficient–X-linked, 
mouse muscular dystrophy mice, colonize host muscle and generate numerous fibres 
expressing human dystrophin. 
Similar cells isolated from Duchenne patients, and engineered to express human mini-
dystrophin, also give rise to many dystrophin-positive fibres in vivo. These data show that 
myogenic precursors, distinct from satellite cells, are associated with microvascular walls in the 
human skeletal muscle. They may represent a correlate of embryonic ‘mesoangioblasts’ present 
after birth and may be a promising candidate for future cell-therapy protocols in patients. For 
this purpose, from a strictly applicative point of view, the ideal cell population should be: 
present in easily accessible postnatal tissues; expandable in vitro to the large number of cells 
presumably required for systemic treatment; easily transducible with viral vectors; able to 
reach skeletal muscle through a systemic route; able to differentiate into skeletal muscle cells 
in vivo with high efficiency. Parietal cells, isolated from the microvasculature of human skeletal-
muscle cells, were characterised and fulfil all these criteria. 
Anyway, the possibility of using this novel strategy for the cell therapy in genetic diseases is 
strictly related to the capacity of expanding cells in culture in a reproducible and efficient way. 
Furthermore, a major limitation in the translation of stem cell technologies to clinical 
applications is the supply of cells. Advances in biomaterials engineering and scaffold fabrication 
enable the development of ex vivo cell expansion systems to address this limitation.26 Progress 
in biomaterial design has also allowed directed differentiation of stem cells into specific 
lineages.27  
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1.3 BIOMATERIALS APPROACH TO EXPAND AND DIRECT 
DIFFERENTIATION OF STEM CELLS 
Whether cell-based therapies can achieve regeneration through direct tissue replacement or 
regenerative induction in resident tissue, a requirement common to all approaches is the 
organized delivery of cells to the area of interest. The rapidly expanding field of tissue 
engineering may supply the solutions. 
Conventional definitions of tissue engineering focus on the development of biological 
substitutes to restore or replace damaged tissues. Impressive advances have been made in the 
fabrication of biocompatible and biodegradable scaffolds, cell seeding techniques, and 
implantation protocols.28 
The final aim for clinical application is to provide a non-cytotoxic scaffold that acts as a 
template for three-dimensional tissue growth and as support for a variety of tissue types 
including fibrous, vascular, and organ-specific cells. 
It is presumed that, as the seeded cells proliferate and integrate into the recipient tissue bed, 
the scaffold would be degraded, eventually dissolving completely and leaving behind a mature 
construct indistinguishable from the surrounding tissue. Current scaffold designs employ a 
variety of natural (collagen, hydroxyapatite, alginate) and synthetic (polyglycolide, polylactide, 
polylactide-coglycolide) materials as a basis for cell adhesion and differentiation.29  
Incorporation of adhesion peptides such as RGD (Arg-Gly-Asp) into biomaterials and nanoscale 
surface manipulation have enhanced cell adhesion and migration.30-32 The association of 
stimulatory growth factors has enhanced the proliferation of specific cell types.33 It is expected 
that the scaffold would be incorporated into the host and eventually provide support for 
seeded and native cells equally. However, seeding and expanding the scaffold prior to 
implantation requires ex vivo nutrient exchange for the developing construct. 
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As biomaterial design and integration advance, it is important to consider the role of implanted 
materials in manipulating the recipient environment to promote regeneration in adult tissues. 
Growth factor and targeted gene delivery systems have already been used in biomaterial design 
to improve the native wound healing response around the implant.34  
A logical next step in biomaterial design is to further manipulate the native environment to 
expose both seeded and endogenous stem cell populations to stimuli favouring regeneration. 
A fundamental bottleneck that must be overcome to exploit stem cells for tissue engineering is 
the adequate supply of cells. This problem will become more critical when the engineering of 
bulk tissue or complex organs is contemplated, particularly when autologous tissue production 
is desired. Such goals would necessitate the maintenance of large quantities of undifferentiated 
cells to provide sufficient starting material. The long doubling time of most types of stem cell 
weighs directly on this problem. The doubling time of stem cells ranges from 36 h for human 
embryonic stem cells to an estimated 45 days for human hematopoietic stem cells.26 Although 
a number of commercially available cell culture matrices such as Matrigel and Cartrigel have 
produced encouraging results, the animal origin of these products renders them undefined and 
precludes their widespread use in human clinical applications. A recent trend favours the use of 
animal-free products, with recombinant human substitutes for such animal products emerging 
as an attractive alternative. Concerns about exposure of human tissues to xenogenic products 
have been substantiated experimentally. Besides the risk of contamination by adventitious 
infectious agents, there are good evidences to suggest that human cells could incorporate and 
express immunogenic molecules present in animal products. Synthetic biomaterials could play a 
significant role in meeting the demands for well-defined systems for derivation and 
maintenance of stem cells.  
Another important potential clinical application of stem cells is their use in cell replacement 
therapy for inherited genetic disorders. Indeed, using viral vector transduction, stem cells can 
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be manipulated in vitro to correct genetic aberrations or deficiencies. Hence they could be 
transplanted into patients to restore normal tissue function.26  
A problem that must be faced when stem cells are used is the risk of tumorigenicity, due to 
their huge differentiation repertoire. Undifferentiated cells that retain pluripotency give rise to 
tumours known as teratomas. Hence, it is critical for any therapeutic strategy employing a stem 
cell-based approach to ensure complete and irreversible differentiation of stem cells into the 
desired progenitors or terminal target cell type. This may be accomplished by supplementing 
the appropriate trophic factors in the culture medium, or delivering them from a scaffold in a 
controlled manner.35 
The mechanical properties of a scaffold or culture surface can also exert significant influence on 
the differentiation of the seeded stem cells. By exerting traction forces on a substrate, many 
mature cell types such as epithelial cells, fibroblasts, muscle cells, and neurons sense the 
stiffness of the substrate and show dissimilar morphology and adhesive characteristics.36  
Another important role of the scaffolds is to prevent their cellular cargos to be destroyed from 
the host immune system, obviating the need for a harsh immunosuppressive regime to 
promote the survival of grafts. The incorporation of immuno-modulatory molecules into 
biomaterial designs may represent a strategy to tackle the issue of immune-rejection. 
In conclusion, the convergence of two important disciplines, i.e. biomaterials engineering and 
stem cell research, promises to revolutionize regenerative medicine. New applications and 
improvement upon current designs will depend heavily on innovations in biomaterials 
engineering.  
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1.4 HYALURONAN 
A tissue engineered implant has to be designed specifically for a given tissue; it has to match 
the mechanical properties of the receiving body, with limited immuno- or antigenicity, and 
tunable biodegradability. Therefore, in order to optimize the physical and biological 
characteristics of the engineered tissue, the choice of the biomaterial is crucial. This study is 
focused on different methodologies that can be used for the chemical modification of the 
hyaluronic acid (HA), key building block for producing advanced biomaterials.  
Hyaluronic acid (also known as hyaluroran or hyaluronate) (HA) is structurally the simplest 
glucosaminoglycan (GAG). It is composed of alternating units of a repeating disaccharide, 
(1→4)-β linked D-Glucuronic and (1→3)-β linked N-acetyl-D-Glucosamine, alternate in a linear 
chain; in their repetition, they offer alternating hydrophobic and hydrophilic disaccharidic faces, 
which provide an amphiphilic “ribbon” structure to HA (Figure 5).37  
 
Figure 5: Structure of hyaluronan  
The mere unit of the polysaccharide is composed by glucuronic acid (with a charged carboxylic acid at physiological 
pH) and N-acetyl glucosamine. As highlighted in red in this figure, a cluster of hydrogen atoms is on one face of the 
disaccharide, which may confer a more hydrophobic tendency to one face of the polymer as it is bearing on the 
other face hydrophilic groups highlighted in blue. 
 
HA is a major component of the ECM of soft tissue (vitreous humor of the eye, synovial fluid, 
skin, brain, liver), and, in contrast to other GAGs, it is not covalently linked to a core protein.  
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It is synthesized by the hyaluronan synthases, Has1, Has2 or Has3, which are generally localized 
in the inner space of the plasmic membrane. HA is extruded in the ECM as it is synthesized and 
its molecular weights can range from 103 (serum) to 107 Da (eye vitreous humor). 
In dilute solution, HA chains occupy a large volume because of the electrostatic repulsion 
between carboxyl groups, with a considerable amount of water trapped inside the coiled 
structure and the hydrophilic face of the polymer. 
In more concentrated solutions, HA chains entangle, generating a sort of porous non-
crosslinked dynamic network, with intrinsic swelling pressure due to an increasing intra- and 
intermolecular electrostatic repulsion, which allows to rapidly re-swell the material after a 
mechanical action has squeezed the water away. Consequently, HA is capable of profound 
effects on the distribution and movements of water and plays a major role in water 
homoeostasis. This hydrodynamic characteristic provides flexibility to the tissue and 
hyaluronan-rich matrices can generate enough internal pressure to mechanically break 
structures in order to create open spaces for cells to move into. 
Literature evidence points out that HA can have an inhibitory or stimulatory effect on cellular 
proliferation depending on its size and concentration within the tissue.38  
HA has been often regarded as excellent space filler, which can be advantageous for mediating 
deformations during cell proliferation or tissue remodelling. Its viscous properties indeed 
confirm this interpretation.39 
The viscosity of HA homogeneous solutions at very low or null shear rate depends on its 
concentration and molecular weight in a non-linear fashion. This depends on the extent of 
interactions/overlap between polymer coils. Additionally, no clear evidence of HA inter-chain 
association has been discovered to date, confirming,  therefore, that HA macromolecular can 
be seen as largely non-entangled water-rich coils, i.e. efficacious space fillers and shock 
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absorbers.40 
Due to its peculiar physico-chemical properties and rather easy chemical derivatization, HA has 
been used in a number of clinical applications, that can be categorized as follows:41 
1. visco-surgery – to protect delicate tissues and provide space during surgical 
manipulations, as in ophtalmological surgeries; 
2. visco-augmentation – to fill and augment tissue spaces, as in skin, sphincter muscles, 
vocal and pharyngeal tissues; 
3. visco-separation – to separate connective tissue surfaces traumatized by surgical 
procedures or injury, in order to prevent adhesions and excessive scar formation; 
4. visco-supplementation – to replace or supplement tissue fluids, such as replacement of 
synovial fluid in painful arthritis, and to relive pain; 
5. visco-protection – to protect healthy, wounded, or injured tissue surfaces from 
dryness or noxious environmental agents, and to promote the healing of such surfaces. 
Generally, successful clinical biomaterial products should be simple and should have defined 
chemical composition that can be easily used by physicians.42 Moreover the use of biopolymers 
ensures intrinsic biodegradation pathways and recognition by biological systems while many 
commonly used synthetic materials cause some degree of inflammatory response, lack an 
intrinsic biological interaction with delivered cells and host tissues, and are cleared by non-
biological degradation mechanisms.  
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1.5 AIMS AND OBJECTIVES 
A wide range of materials based on HA that have been developed in recent years. The 
versatility in HA macromer synthesis and processing of the materials has transitioned into 
materials with a range of properties useful in applications such as tissue engineering and drug 
delivery.  
Additionally, HA-based derivatives may impart biological activity to cells, as evident by changes 
in cellular behavior, including stem cell differentiation, when interaction occurs with 
biomaterials based on HA compared to other polymers. One area that deserves investigation is 
the potential utility of HA-based materials in translational applications, related in particular to 
the processing capabilities, biocompatibility, and efficacy of these materials.  
The present study is focused on different methodologies that can be used for the chemical 
modification of the HA, key building block for producing advanced biomaterials.  
Our interest merges with that about the biology of skeletal muscle stem cells and seeking to 
harness the information for clinical applications. By learning more about stem cells and other 
mesodermal skeletal muscle progenitors, we can learn how to better use them to repair 
muscle. Considering, however, that the main limitations of stem cells are the loss of “stemness” 
upon culture and an inability to cross the vessel wall for the systemic delivery, a biomaterial 
that could help to overcome these issues would be a key tool for the development of an 
effective cell-based therapy for DMD.  
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2 CHEMICAL MODIFICATION OF THE HYALURONIC ACID 
2.1 INTRODUCTION 
Hyaluronic acid (HA) is a glycosaminoglycan ubiquitous in extracellular tissues of mammalians. 
It is a material of increasing importance to biomaterials science and it is finding applications in 
diverse areas ranging from tissue culture scaffolds to cosmetic materials. Its properties, both 
physical and biochemical, in solution or in hydrogel form, are extremely attractive for various 
technologies concerned with body repair. The fabrication of new HA based scaffolding 
materials has been achieved by a variety of chemical modifications to provide mechanically and 
chemically robust materials. Even if the resulting derivatives might have physicochemical 
properties significantly different from the native polymer, they usually retain the 
biocompatibility and the biodegradability of native HA.  
HA can be chemically modified in two different ways: cross-linking or conjugation. Basically the 
same chemical reactions are used in both cases but, while, in the first case, a compound is 
grafted onto one HA chain by a single bond, in the second case, different HA chains are linked 
together by two or more bonds, as depicted in Figure 6. In addition, there are different types of 
cross-linking procedures: direct crosslinking, crosslinking of HA derivatives and cross-linking of 
different HA derivatives. 
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Figure 6: Chemical conjugation and chemical cross-linking of a polymer 
 
The two available sites to chemically modify the HA are the carboxylic acid group and the 
hydroxyl group (Figure 7). Actually an amino group can also be made available by deacetylation 
of the N-acetyl group1 the conditions required might cause the hydrolysis of the polymer. It is 
not possible to exactly know which of the hydroxy groups reacts, though it is reasonable to 
assume that the reaction occurs mainly at the hydroxyl of the C6 of the N-acetylglucosamine 
moiety of HA because of the better accessibility of primary alcohols for the reagents.  
Although many of the modification techniques employed today have individual advantages, 
there is room for further improvement. 
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Figure 7: Repetitive unit of hyaluronan showing the primary sites for chemical modification 
  
2.1.1 Modification of the carboxylic acid group 
2.1.1.1 Esterification 
Among the different techniques available for the formation of a new ester bond, a considerable 
number of them received particular attention for the derivatisation of HA, in order to provide 
materials suitable for tissue engineering.2 Some examples are reported below. 
2.1.1.1.1 Ester formation by alkylation using akyl halides 
The esterification of HA carboxylic groups using alkyl halides, such as alkyl iodides or bromides, 
was patented in 1986 by Della Valle and Romeo.3 The reaction was performed after the 
transformation of the hyaluronan in its TBA salt (soluble in DMSO and DMF), which was then 
reacted with an alkyl halide in an organic solvent, over a 12 h reaction time at 30 ◦C (Figure 8). 
A similar approach has been used for the congiugation of ceramide, a cellular component, to 
HA. Chloromethyl-benzoyl chloride was chosen as linker; it was firstly reacted with ceramide 
and then with HA leading to the formation of a new ester bond.4  
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Figure 8: HA esterification using alkyl halides 
 
2.1.1.1.2 Ester formation by alkylation using tosylates 
In 2006 the cross-linking of HA by esterification using tetraethylene glycol was performed.5 
Briefly, tetraethylene glycol was converted into its di-tosylate, then the reaction of the latter 
with HA was performed in DMSO solution (Figure 9). 
 
 
 
Figure 9: HA esterification with tetraethylene glycol ditosylate 
 
2.1.1.1.3 Ester formation using diazomethane 
The esterification of HA using diazomethane was reported for the first time by Jeanloz and 
Forchielli in 1950. Also in this case the reaction was performed on the HA-TBA salt in an organic 
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solvent, i.e. DMSO.6  
Further development described the preparation of the methyl ester of HA using trimethylsilyl 
diazomethane (TMSD) as the carboxylic acid group activator (Figure 10).7  
 
 
 
Figure 10: HA esterification using trimethylsilyl diazomethane 
 
2.1.1.2 Amidation 
The activation of the carboxylic acid function of the glucuronic unit has been accomplished by 
using several different methodologies well known in peptide synthesis, employing, in particular 
different activating agents (e.g. carbodiimides and triazolols)  have been used in water on the 
sodium salt,8 in organic solvents on the TBA salt,9 or even under heterogeneous conditions.10  
This section reports only some of the most widely used techniques employed to activate the 
carboxylic acid function of the HA promoting the formation of a new amide. For a more 
exhaustive description, refer to recent reviews.11,12 
2.1.1.2.1 Carbodiimide-mediated HA amidation 
Amidation with carbodiimides in water is one of the most widely used methods for HA 
modification.11 The carbodiimide used is predominantly the 1-ethyl-3-[3-(dimethylamino)-
propyl]-carbodiimide (EDCI) because of its remarkable solubility in water.13 EDCI reacts with 
carboxylic acid, in water, at pH 4.75 to form activated intermediates, which then can react with 
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an amines. Amidation using EDCI offers the advantage related to the possibility of carrying out 
the reaction in water using native HA sodium salt, without preliminary handling. In addition, 
this method does not lead to the hydrolitic cleavage of the HA, maintaining its high molecular 
weight, which is responsible for its valuable viscoelastic properties. 
The reaction mechanism for the formation of amide-based conjugates using carbodiimides 
involves two main steps: the first one is the activation of the carboxylic acid group of HA, where 
the carboxylate anion attacks the central carbon on the carbodiimide to form a reactive O-acyl-
isourea intermediate; the second step involves the attack of a nucleophile onto the reactive O-
acyl-isourea intermediate, resulting in the formation of an amide bond and an urea derivative 
as byproduct. As known, the O-acyl-isourea intermediate is susceptible to hydrolysis and can 
also rearrange to form a stable N-acyl urea by-product, which does not undergo any further 
reactions with amines. (Figure 11) 
The reaction is very delicate as it is strongly pH-dependent and the optimal pH for the two steps 
is different. Indeed, carboxylic acid activation by EDCI is best performed in an acidic 
environment (pH 3.5–4.5), whereas the amide formation is best developed at high pH values, 
when the amine is deprotonated. But at such a high pH, EDCI is more rapidly hydrolyzed into 
the N-acyl urea byproduct and amidation might not occur. The compromise is therefore not 
easy and amines with high pKa values are not smoothly conjugated to HA using this method 
even though contradictory experimental data have been reported: most authors have shown 
evidence of amidation under these conditions, while others reported that no amide linkage was 
formed between the carboxylic acid groups of HA and amino groups. Only the N-acylurea 
byproduct was obtained using the same pH of 4.75 as previously described by some authors.11  
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Figure 11: EDCI-mediated HA amidation 
 
An important milestone in hyaluronan modification chemistry was the recognition that 
hydrazides, which display pKa values between 2 and 4 for the corresponding conjugate acids, 
would retain their nucleophilicity at pH 4.75 and would couple efficiently to carbodiimide-
activated glucuronic acid residues of hyaluronan.14  
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Other strategies reported in order to prevent the formation of the irreversible N-acylurea 
byproduct, contemplated the use of N-hydroxysuccinimide (NHS) or 1-hydroxybenzotriazole 
(HOBt) with EDCI to form more hydrolysis-resistant and non-rearrangeable intermediates.15  
2.1.1.2.2 Chloro-4,6-dimethoxy-1,3,5-triazine (CDMT)-mediated amidation 
More recently, Bergman reported a novel method for HA functionalisation using the carboxylic 
acid activator CDMT in the presence of N-methylmorpholine (NMM) as base.16 The proposed 
reaction mechanism involves the formation of an activated HA-ester intermediate that can 
react with amines to generate the new amide bonds.  (Figure 12) 
 
 
Figure 12: CDMT-mediated HA amidation 
 
Using this amidation method (in a 3:2 water/acetonitrile mixture), a series of different amines 
have been grafted onto HA, resulting in substitution degrees up to 20%. This was achieved by 
employing a HA:CDMT molar ratio of only 1:0.5, and the authors suggested that an even higher 
degree of substitution could be achieved by decreasing this ratio. 
The advantage of this amidation strategy is that the amine coupling efficiency mediated by 
CDMT is significantly higher compared to that typically achieved with carbodiimides and the 
reaction conditions are milder (i.e. pH 7). However, a mixture of both water and organic solvent 
is required for an acceptale solubilisation of CDMT.  
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2.1.1.2.3 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium (DMTMM) 
mediated amidation  
In the same year in which Bergman published his work on CDMT-mediated amidation of HA,16 
the group of Farkaŝ and Bystrický described the use of a more convenient one-step amidation 
reaction using the novel carboxylic acid activating agent DMTMM chloride, the quaternary 
ammonium chloride salt derived from CDMT and NMM (Figure 13).17  
 
Figure 13: Structure of DMTMM 
 
DMTMM allowed the amidation reaction to be carried out in aqueous-media without the need 
of an organic co-solvent and under mild conditions. The reaction mechanism is very similar to 
that of the CDMT-mediated amidation in the presence of NMM. Briefly, DMTMM chloride 
reacts with the carboxylic acid group of HA via an addition-elimination mechanism to form a 
DMTMM-activated HA ester intermediate, with NMM as the leaving group. Amines present in 
solution can then attack the activated ester to form the new amide bond. 
By using this strategy, a number of amines have been linked to HA, reaching degrees of 
substitution up to 74 % using only a slight excess of DMTMM (1.5 equivalents with respect to 
the carboxylic acid groups of HA).  
From these results, it can be concluded that DMTMM is an effective carboxylic acid activating 
mediators, superior to other activating agents such as the carbodiimides or CDMT, since it 
promotes the highest degrees of substitution in a convenient and simple one-step procedure, 
without the need of a large excess of reagents. Furthermore, the DMTMM-mediated amidation 
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of HA, carried out in aqueus media under mild conditions, does not involve the formation of 
concurred undesirable side-products. 
2.1.1.3 Multicomponents reactions 
The carboxilic acid function of HA showed to be active in some multicomponent reactions, like 
Ugi’s and Passerini’s reactions.18 Several authors have described the Ugi condensation for HA 
crosslinking19,20 using a diamine as a cross-linker to form diamide linkages between different 
polysaccharide chains. 
The reaction with formaldehyde, cyclohexyl isocyanide and the diamine is performed in water 
at pH 3. The mechanism involves the initial condensation of the diamine with formaldehyde to 
form a protonated diimine species which then reacts with the cyclohexyl isocyanide. The 
carboxyl group of HA then eliminates the activated cyanide intermediate to form an 
(acylamino) amide bond (Figure 14).  
As a drawback, the use of formaldehyde, which is known to be carcinogenic, requires specific 
handling. However, this method leads to the formation of a secondary amide, adding a second 
pending group, in this case, a cyclohexyl. 
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Figure 14: Proposed structure of the network formed by HA via Ugi’s condensation with aqueous 
formaldehyde, cyclohexylisocyanide and lysine ethyl ester 
 
2.1.2 Modification of the hydroxy group 
The alcoholic moiety present on the hyaluronan scaffold exhibits reactivity towards 
electrophiles and several HA-derivatives have already been synthesised taking advantage of this 
property. It is not very well known which one of the hydroxy groups is the most reactive; 
anyway, it is reasonable to assume, that the reaction occurs mainly at the primary hydroxy 
group, since it is better accessible for reagents. Furthermore its pKa value is sensibly lower than 
that of the other ones (i.e. about 9 for the primary alcohol group and about 13 for the others). 
Some interesting modifications occurring at the alcoholic function are reported. 
 
Chemical Modification of the Hyaluronic Acid 
 
 
______________________________________________________________________________ 
36 
2.1.2.1 Ether formation 
2.1.2.1.1 Ether formation using epoxides 
Epoxide ring opening, to form ether bonds with the HA hydroxy groups, has been reported by 
several authors.11 Bisepoxides have been used to prepare crosslinked HA gels, such as ethylene 
glycol diglycidyl ether and polyglycerol polyglycidyl ether. The reaction is usually performed in 
aqueous solution at high pH values to promote the deprotonation of the hydroxy groups, thus 
increasing its nucleophilicity which should be higher than that of the deprotonated carboxy 
groups (Figure 15). The epoxides, therefore, react preferentially with the hydroxy groups to 
form ether bonds. However, if the pH is lower than the pKa value of the hydroxy group, only a 
small quantity of hydroxy groups is deprotonated and the reactivity of the carboxylate anion is 
predominant, thus promoting the ester bond formation.21 
 
 
Figure 15: HA cross-linking with butanediol-diglycidyl ether in alkaline conditions 
 
2.1.2.1.2 Ether formation using divinyl sulfone 
The cross-linking of HA with divinyl sulfone was patented in 1968.22 The reaction is performed 
at high pH values (0.2M NaOH at pH > 13) at room temperature and creates sulfonyl bis-
ethylene linkages between the hydroxy groups of HA (Figure 16). Interestingly they also found 
that the presence of salts such as NaCl in the reaction medium increases the cross-linking 
degree.  
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Figure 16: HA cross-linking with divinyl sulfone 
 
2.1.2.2 Ester formation 
The reactivity of the HA-alcohoxyde with acyl-chlorides in organic solvents to create new ester 
bonds has been published.  
In 2004 Ventura et al. described a novel method to form mixed butyric and retinoic acid esters 
of hyaluronan.23 Specifically the TBA alcohoxyde of HA-TBA was reacted in dry DMF, at room 
temperature, with the freshly prepared acyl-chlorides of butyric and retinoic acids. The 
synthesized compound afforded a high throughput for cardiogenesis in embryonic stem cells.   
A parallel study presented a similar method to graft poly(lactic acid) oligomers activated by 
chloroacylation with thionyl chloride. In this case HA was previously converted into a cetyl-
trimethylammonium salt, which is soluble in DMSO.24 
HA esterification with anhydrides has been also successfully accomplished. In this case, due to 
the higher stability of anhydrides respect to acyl-chlorides, the reaction can be performed in 
water solution, even at rather high pH value. Methacrylated-HA was prepared by reacting HA 
with methacrylic acid anhydride, in ice cold water solution,for 12 h, at pH 8-10 (Figure 17).25 
 
Figure 17: HA esterification with methacrylic anhydride 
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Moreover, HA was converted into two haloacetate derivatives, HA-bromoacetate (HABA) and 
HA-iodoacetate (HAIA). HABA was obtained by treating HA with bromoacetic acid anhydride 
under basic reaction conditions to favor the deprotonation of the primary alcohol. A high molar 
excess of reactant is required because of the formation of the mixed anhydride between 
bromoacetic acid anhydride and HA, which rapidly hydrolyses to restore the carboxylic acid 
groups. The final product (HABA) was converted into the iodo-derivative by nucleophilic 
substitution reaction with NaI.26 
2.1.2.3 Periodate oxidations 
The oxidation with sodium periodate of vicinal alcohol functions is a standard method for the 
chemical activation of glycoproteins. Reactive bis-aldehyde functionalities have been generated 
from hyaluronan following this strategy.11 The resulting product can undergo reductive coupling 
with primary amines, cross-linking, insertion of peptides containing cell attachment domains or 
immobilized materials. Unfortunately the harsh conditions employed in the oxidative treatment 
also introduces chain fragmentation and potentially immunogenic linkages into the hyaluronan 
biomaterial. 
 
 
 
Figure 18: HA oxidation with sodium periodate 
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2.2 AMIDATION 
2.2.1 INTRODUCTION 
Polysaccharides are of great interest as immunogenic effectors and biocompatible carriers of 
small bioactive molecules and hyaluronan is attractiong today great interest as a biomaterial for 
many medical applications.12 
Obstacles to the development of new treatments taking advantage from its biocompatibility 
and biological effects, are its fast enzymatic degradation and the poor mechanical properties. 
Many chemical modifications and other physical techniques have been extensively described to 
prolong HA’s residence in the body after administration in the body, to graft important 
bioactive molecules or drugs, and also to introduce new reactive groups on the HA scaffold.11  
Carboxylated polysaccharides are suitable for many kinds of chemical modifications. The 
effective activation of the carboxy groups is the critical step. One of the commonly, used 
methods rely on the activation with water-soluble carbodiimides (e.g. EDCI) which form 
intermediates that are able to link the nucleophilic groups of ligands (See 2.1.1.2.1 for a 
detailed description of the mechanism).  
For example, Pasqui reported in 2007 the synthesis of an organo-silane HA derivative obtained 
by EDCI-mediated amidation with (3-aminopropyl)-trimethoxysilane. The reaction satisfactorily 
occurred in a 2-morpholino-ethanesulfonic acid (MES) buffer at pH 4.75, using a large excess of 
amine (Figure 19).8 
The use of hydroxybenzotriazole (HOBt), N-hydroxysuccinimide (NHS) or other nucleophiles 
that react with the O-acyl-isourea intermediate to afford more stable activated species is also 
reported.11  
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Figure 19: Reaction scheme of the synthesis of the organo-silane HA derivative 
 
An alternative synthetic method contemplates the use of alkoxychloro-1,3,5-triazine as the 
carboxy group activator. It was originally used in peptide syntheses in anhydrous solvents.27  
In 2007, the application of these types of activators on HA was reported.  
In particular, Bergman presented a method for the preparation of HA derivatives obtained 
through triazine-activated amidation. A number of amines were successfully employed in HA 
amidation mediated by 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) as an activating species in 
a mixture of water and acetonitrile as solvent, under neutral conditions (See 2.1.1.2.2 for a 
detailed description of the mechanism).16 
Farkaš envisaged the possibility of using the 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-
methylmorpholinium chloride (DMTMM) as a more effective, as well as water soluble, 
condensing agent for the activation of the polysaccharide carboxyl groups.17 It was observed 
that EDCI, under the same conditions, was much less efficient than DMTMM.  Additionally, in 
situ preparation of the reagent primarily prevents the irritant properties of the CDMT 
component. Furthermore DMTMM became recently commercially available. The mechanism of 
the activation mediated by DMTMM involves the reaction of the ammonium salt through a SNAr 
pathway to form a reactive triazinyl ester capable of undergoing the attack of a nucleophilic 
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species (e.g. the amine group). Thus, the two main advantages of using DMTMM over the 
conventional carbodiimides are certainly the structural purity of the products as well as the 
higher reaction yields. Moreover, DMTMM is more stable in water solution, whereas EDCI is 
prone to decompose at lower pH values. 
In conclusion the amidation of HA is a very useful tool to modify the HA scaffold inserting 
bioactive molecules, forming reticulated network or adding new functional groups for further 
use in bioconjugation. Anyway a precise control of the degree of functionalisation remains an 
important issue. Moreover the development of techniques assuring an easy purification of the 
products and granting the chemoselectivity of the whole process is a key point in the study of 
new scaffolds for tissue engineering.  
  
 
Chemical Modification of the Hyaluronic Acid 
 
 
______________________________________________________________________________ 
42 
2.2.2 EXPERIMENTAL PROCEDURES   
2.2.2.1 Materials 
Sodium Hyaluronate (HA) RESILEN-200 (average molecular weight 235 kDa) was gently supplied 
by Kyowa Italiana Farmaceutici s.r.l. (Milan, Italy); HA sodium salt with Mw 35 or 305 kDa was 
purchased from Medipol (SA, Lausanne). 
Spectrum Spectra/Por 6 RC Dialysis Membrane Tubing (10, 50, 100 KDa MWCO) was used to 
dialyse the samples. 
N-(2-aminoethyl)acrylamide hydrochloride was gently synthesised by Dr Enrique Lallana Ozores 
(University of Manchester). 
All reagents and solvents, if not otherwise specified, were purchased from Sigma-Aldrich 
(Milan, Italy or Gilligham, Dorset, UK) used as received. 
2.2.2.2 General methods 
2.2.2.2.1 Molecular characterization 
1H NMR spectra were recorded on a BRUKER AC300 or a BRUKER AC400 spectrometers.  
Infrared spectra were recorded on a Jasco FT/IR 4100 or, in ATR mode (Golden gate), on a 
Tensor 27 Bruker spectrometer. 
Absorbance readings were recorded on a BIOTek® Synergy 2 multi-mode microplate reader 
(NorthStar Scientific Ltd., Leeds, UK).  
2.2.2.2.2 Fluorescamine assay 
The degree of functionalisation of HA derivatives amidated with DMTMM was monitored by 
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measuring the remnant amine (i.e. N-(2-aminoethyl)acrylamide hydrochloride) content in final 
reaction samples. Briefly, an aliquot of 75 μL of each reaction mixture was pipetted into a 96-
wells black plate and diluted 1:2 with 4-(2-hydroxyethyl)-1-piperazinyl-ethanesulfonic 
acid (HEPES) buffer (100 mM, pH 7.4), followed by addition of 50 μL of a freshly-prepared 
fluorescamine solution (3mg/ml) in acetonitrile. After the addition of fluorescamine the plate 
was shaken for 10 minutes, at medium speed, at 30 °C. The fluorescence was then determined 
using a plate reader with a 400 nm, 30 nm bandwidth, excitation filter and a 460 nm, 40 nm 
bandwidth emission filter.  
2.2.2.2.3 Statistics 
Spectrophotometric experiments were carried out in triplicate, and the mean and standard 
deviations calculated for each reaction condition. 
2.2.2.3 Synthetic procedures 
2.2.2.3.1 General procedure for the synthesis of amidated-HA using EDCI 
100 mg of sodium HA (0.25 mmol of carboxy group, Mw: 235 kDa) was dissolved in 10 mL of 
phosphate buffer (100 mM, pH 4.5), to which EDCI (40 mg, 0.25 mmol, 1 eq.) was added, 
followed by addition of 10 eq. of the desired amine. The pH value was adjusted to 4.75 and the 
reaction mixture was stirred at room temperature for 24 h. The product was then transferred 
to a dialysis membrane (MWCO 50 kDa) and dialysed against distilled water for 7 days. The 
product was then freeze-dried to yield 70-78 mg (70-78% wt) of a white solid. 
2.2.2.3.2 General procedure for the synthesis of acrylamidated-HA using DMTMM 
(HA-Acr) 
100 mg of sodium HA (0.25 mmol of carboxy group, Mw: 35, 305 kDa) was dissolved in 10 mL of 
 4-(2-hydroxyethyl)-1-piperazinyl-ethanesulfonic acid (HEPES) buffer (100 mM, pH 7.4), to 
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which DMTMM (4 eq. respect to the desired degree of functionalisation: 0.40, 0.20 and 0.04 
mmol respectively) was added and the mixture was stirred for 10 minutes. Thereafter 
N-(2-aminoethyl)acrylamide hydrochloride was added (1.2 eq. respect to the desired degree of 
functionalisation: 0.12, 0.06 and 0.01 mmol respectively). The reaction was stirred at room 
temperature for 24 hours. Then, the product was precipitated by dropwise addition of cold 
ethanol (approximately 20 times the reaction volume) under constant stirring. After 
centrifugation the supernatant was removed and the product transferred to a dialysis 
membrane (MWCO 10 or 100 kDa) and dialysed. Two different methods to dialyse were 
investigated: 
Method A: the sample was dialysed against distilled water (4 °C) until constant conductivity of 
the outer water (about 3 days). 
Method B: the sample was dialysed against a 1 mM solution of NaCl (4°C) for 24 hours and then 
against distilled water (4 °C) until constant conductivity of the outer water (about 3 days). 
The product was then freeze-dried to yield 80-85 mg (80-85% wt) of a white solid. 1H NMR (400 
MHz, D2O) (δ = ppm): 6.22 (m, 2H on unsaturated carbon), 5.79 (d, J = 8.6 Hz, 1H on 
unsaturated carbon), 4.54 (bs, 2H), 3.91-3.28 (m, 10H), 2.01 (s, 3H). 
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2.2.3 RESULTS AND DISCUSSION 
2.2.3.1 Carbodiimide activation 
It is well known that, to perform a reaction between a carboxy group and a nucleophile, an 
activating agent is required; 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide (EDCI), in 
particular has been widely used in organic synthesis because it shows a good activity also in 
aqueous media. In particular, the formation of amides from carboxylic acids and amines in 
aqueous media using EDCI is generally performed at pH 4.75; at this pH, the carboxylic acid is 
not deprotonated, and a small percentage of the amine may remain as a base in its nucleophilic 
form to produce a covalent adduct.13 We initially tried this kind of reaction by using a set of 
different amines (Scheme 1). 
Different primary amines have been chosen meeting different purposes. In detail, 3-
aminopropanol and 4-aminobutanol have been chosen to take advantage of the higher 
nucleophilicity of a primary amines respect to primary alcohols and, at the same time, to insert 
another nucleophile less sterically hindered respect to the others present on the HA backbone. 
α-Methylbenzylamine was attractive in order to have a well defined 1H NMR signal useful to 
evaluate the degree of functionalisation; furthermore, an interesting possibility was the 
development of a methodology allowing the cleavage of benzyl bonds through hydrogenolysis 
directly on HA-conjugates. A conjugate with lysine methyl ester should have combined both 
biological and chemical new aspects; it would have been a new amine decorating the polymer 
chain and, moreover, HA derivatives obtained by grafting amino-acids pendants, showed 
improved enzymatic stability.28  
Specifically, EDCI and different amines were added to a solution of HA at controlled pH. The aim 
was to modify the hyaluronan with the maximum degree of functionalisation (defined as the 
ratio between modified and unmodified units) of 10%; higher levels of modification of the HA, 
in fact, affect its biological properties. The reagents were used in large excess respect to the 
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desired degree of functionalisation. However, no amide product was produced, the major 
product being the rearranged N-acylurea adducts which was hydrolysed to give back the free 
acid.  
The purification process showed to be particularly challenging. During these experiments we 
found that, after the dialysis of the reaction mixture, part of the amine remains in the sample 
probably as counter ion (Scheme 1). This phenomenon could be observed and quantified by 1H 
NMR analysis. In order to check the importance of the cation in a biological environment, 
different hyaluronate salts have been tested in cultures of human pericyte-derived cells (See 
2.5).  
 
 
Scheme 1: Modification of the HA carbodiimide mediated 
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Figure 20: Evaluation of the amine remained in the HA samples 
After extensive dialysis of the reaction mixture containing HA, EDCI and different amines, part of the amine 
remains in the sample. This phenomenon was quantified by 
1
H NMR analysis. The degree of exchange indicates the 
ratio between the number of moles of amine and the number of moles of repeating disaccharide units of HA.  
 
We clearly demonstrated that no amide formation occurred by repeating the dialysis; in this 
case, the sample was dialysed against against a 1 mM solution of NaCl for 24 hours to promote 
the cation exchange and then against distilled water. Pure HA was recovered after this 
treatment.  
Almost the same degree of exchange was observed for every sample (Figure 20) considering the 
ratio between the number of moles of amine and the number of moles of 
repeating disaccharide units of HA; in fact it was calculated to be 0.79 for 3-aminopropanol, 
0.83 for 4-aminobutanol, 0.81 for α-methylbenzylamine and 42% for lysine methyl ester but, in 
this case, the molecule featured two primary amines and hence two cations. 
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2.2.3.2 Triazolol activation 
Considering the very modest reactivity of amines as nucleophiles at pH 4.75, a different 
strategy has been investigated in order to provide amidation carboxylic acid of HA. 
DMTMM is known to be an effective as well as water stable condensing agent for the activation 
of the polysaccharide carboxy groups and its efficiency in reaction involving HA had already 
been demonstrated.17  
Our aim was to provide a derivative of HA featuring an acrylamide available as acceptor in 
Michael-type addition reaction. In fact, due to its versatility, Michael addition is a precious tool 
for bioconjugating specific bioactive molecules on different polymers. Several strategies for 
modifying and functionalising HA, taking advantage from this reaction, have already been 
reported.29,30 A deep investigation on the factors influencing the outcome of the Michael-type 
addition between different α,β-unsaturated compounds and thiol-containing nucleophiles 
highlighted that acrylamides provide adducts stable in front of the hydrolysis or of the 
retro-Michael reaction for a long time interval. Moreover the kinetics of the addition of N-
acetyl cysteine on the double bond is reasonable for pH values higher than 8. These properties 
identify acrylamides as suitable functions for grafting bioactive molecules (e.g. peptides) to the 
HA scaffold. (See Chapter 3) 
A very important target is the control of the loading of the bioactive molecule on the HA; hence 
a method allowing the modification of the HA with different degrees of functionalisation is 
required; moreover an analytical technique able to give a precise indication about the yield of 
the reaction is necessary. Activation of HA with DMTMM and evaluation of the degree of 
functionalisation with fluorescamine assay permitted to attain the desired target.   
The synthesis of six different derivatives of the HA has been accomplished, specifically we used 
HA characterised by two different average molecular weights (i.e. 35 and 305 kDa), trying to 
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obtain three different degrees of functionalisation (i.e. 1, 5, 10%). As already mentioned, the 
10% is the maximum degree of functionalisation which allows to preserve the biological 
properties of native hyaluronan.  
The carboxylic acid groups of the HA were activated with DMTMM (4 eq. respect to the desired 
degree of functionalisation), at pH 7.4 and then reacted with N-(2-aminoethyl)acrylamide 
hydrochloride (1.2 eq. respect to the desired degree of functionalisation) at room temperature 
for 24 hours (Scheme 2). 
 
Scheme 2: Synthesis of amidated HA featuring an acrylamide  
 
The product was recovery after precipitation, effecting by adding ethanol, dialysis and 
lyophilisation. The precipitation of the product as the first purification process, sensibly reduces 
the dialysis time. 
Pure products have been obtained both dialysing the samples against distilled water or against 
a 1 mM solution of NaCl first, and then against distilled water. Furthermore, the conductivity of 
the dialysis water compartment was monitored in order to gain a clear indication of the time 
required for the completion of the process. 
1H NMR confirmed the reaction between HA and N-(2-aminoethyl)acrylamide and the peaks of 
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the protons on the double bond were clearly recognised at 6.20 and 5.80 ppm (Figure 21). 
Thanks to a Diffusion-ordered spectroscopy (DOSY) experiment, we could confirm that the 
signals were really belonging to a molecule having the same HA’s diffusion coefficient, thus 
amidation product (Figure 21). 
 
 
 
Figure 21: DOSY spectrum of HA-Acr 
DOSY spectrum of the HA-Acr (the one relative to the derivative with Mw: 305 kDa and degree of functionalisation: 
10% is depicted) was recorded in D2O using a 400 MHz spectrometer. NMR diffusion experiments provide a way to 
separate the different compounds in a mixture based on the differing translation diffusion coefficients (and 
therefore differences in the size and shape of the molecule, as well as physical properties of the surrounding 
environment such as viscosity, temperature, etc) of each chemical species in solution. 
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By the way, 1H NMR was not found a method sensitive enough to establish the loading of 
double bonds on the HA scaffold. Hence we performed in parallel a fluorescent assay which 
could ensure high sensitivity and extremely low detection limits: the fluorescamine assay.  
So, first of all, a calibration curve relating emission (at 460 nm) and concentration was plotted. 
Hence, subsequent dilution of small aliquots of the reaction mixtures at time zero (at known 
concentration of N-(2-aminoethyl)acrylamide) provided solutions at different known 
concentrations (ranging from 10-8 to 10-4 M); these samples were then reacted with an excess 
of fluorescamine (See 2.2.2.2.2). Six calibration curves were calculated, one for each batch, to 
ensure the highest possible accuracy; in fact we found that the molecular weight and the 
concentration of HA greatly influence the fluorescence; moreover, the linear range showed to 
be quite narrow. 
The fluorescence of the final reaction solutions was measured again to give a precise indication 
of the degree of functionalisation (Figure 23). 
 
 
 
Figure 22: Reaction of primary amine with fluorescamine 
Fluorescamine assay is well known for protein quantitation and has been developed in an attempt to alleviate the 
difficulties presented when using absorbance based assays.
31
 It is based on the rapid reaction of fluorescamine, a 
non-fluorescent compound, with primary amines to form highly fluorescent moieties emitting at 460 nm after 
excitation at 400 nm. 
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Functionalisation of low molecular weight HA (35 kDa) showed to be more efficient than the 
one of high molecular weight HA (305 kDa). In addition, as expected, the yield of the reaction 
decreased ondecreasing the concentration of the reactants; hence, the yields were excellent 
when the desired degree of modification was of the 10%, good for the 5% and moderate for the 
1%. 
These results suggested that a very good control on degree of functionalisation could be 
obtained by tuning the excess of regents. A screening is in course of study to determine the 
best experimental conditions. 
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Figure 23: Obtained degree of functionalisation measured by fluorescamine assay 
The functionalisation yield indicates the ratio between the obtained and the desired degree of functionalisation. 
Error bars represent standard deviation over three spectrophotometric measurements.  
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2.2.4 CONCLUSION 
Two different strategies have been investigated to promote the activation of the carboxylic acid 
function of the hyaluronan and its reaction with amines via acylic nucleophilic substitution. 
Specifically, a carbodiimide-based reagent (EDCI) was used with different primary amines. This 
reagent is known to be active, in water, in acidid environment (around pH 4.75); the only 
drawback is related to the fact that only a small percentage of amine remains not protonated, 
and thus nucleophilic, at this pH value. In fact, we found EDCI totally ineffective in promoting 
HA amidation even in the presence of a large excess of reagents. Moreover the purification of 
the reaction mixtures resulted particularly complex and challenging. 
Recent literature suggested that triazolol-based compounds could be suitable candidates for 
the activation of carboxylic acid functionalised polysaccharides for the preparation of 
conjugates.16,17 Hence, we envisaged the DMTMM as good candidate to promote HA amidation. 
By using this reagent in an aqueous environment, at pH 7.4, six different HA conjugates have 
been synthesised: in detail, two different molecular weight polymers have been used (i.e. 35 
and 305 kDa) and three degrees of functionalisation (nominally 1, 5 and 10%). In particular the 
use of N-(2-aminoethyl)acrylamide as nucleophile allowed the decoration of the HA scaffold 
with an α,β-unsaturated compound suitable for further reaction via Michael-type addition 
reaction (See Chapter 3). 
The formation of the desired products and their purity have been confirmed by DOSY NMR 
experiment. Moreover a protocol for the application of fluorescamine assay to measure the 
yields of the reaction was successfully set up. 
In conclusion experimental conditions to perform the reaction of HA with primary amines to 
form amides using DMTMM as activating agent have been realised. Moreover the purification 
process to obtain a pure adduct has been optimised. Particular attention was also given as well 
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to the analytical techniques required for the identification of the conjugate and the evaluation 
of its purity and of the functionalisation degree. 
Future development will concern de identification of the best excess of reagents to ensure the 
desired degree of functionalisation. Moreover, HA functionalised with acryloyl moieties will be 
used for the bioconjugation of cysteine containing peptides, like RGD containing peptides, wich 
are important ligands to promote specific biological processes.  
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2.3 DIISIOCYANATES AS CROSS-LINKER AGENTS FOR HA 
2.3.1 INTRODUCTION 
Biomaterials deserve a central role in the field of tissue engineering by directing cellular 
processes based on the structural and biochemical properties of the scaffold. Hydrogels, based 
both on synthetic and biopolymers, find numerous applications in biomedical devices, due to 
their high water content and tissue like physical, biochemical and mechanical properties.32 The 
advantages of hydrogels based on synthetic polymers rely on the ability to determine their 
properties through tailored polymer synthesis and choice of cross-linking mechanism. This 
allows to have a fine control over the degree of swelling, stability and biodegradability, 
mechanical strength and enables the generation of responsiveness to external stimuli. 
Biopolymers on the other hand offer the advantage of inherent functionalities for example for 
the reversible binding of growth factors, the creation of a microenvironment close to the 
natural situation and the degradation through specific enzymatic processes. 
Hyaluronan has a combination of unique physicochemical properties and biological functions 
that enable it to serve as an important starting material for the preparation of new 
biocompatible and biodegradable polymers. Soluble HA has been used in clinical applications 
including ocular surgery, visco-supplementation for arthritis and wound healing; however, due 
to the poor mechanical properties, rapid degradation and clearance in vivo of uncross-linked 
soluble HA limit many direct clinical applications. To improve the mechanical properties, 
degradation rate, and clearance, HA can be chemically modified or cross-linked to form 
hydrogel materials.12  
HA can be modified in many ways to tune the properties of the resulting materials. Chemical 
modifications of HA target three functional groups: the glucuronic acid carboxylic acid, the 
hydroxyl groups, and the N-acetyl group (following deamidation). Similar reaction have been 
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applied both for bioconjugation and cross-linking (See 2.1); nonetheless cautions are required 
to ensure biological compatibility of the cross-linking chemistry, as well as to establish whether 
that the reagents and by-products are benign in both short- and long-term applications. There 
are different types of cross-linking procedures: direct cross-linking, cross-linking of HA 
derivatives or cross-linking of different HA derivatives. Among them the use of diisocyanates as 
cross-linkers has never been reported in literature, and we envisaged as an attracting strategy 
to use these cheap and highly reactive bifunctional molecules to introduce chemical bonds 
between non terminal units of different macromolecules creating reticulated networks. This 
approach could represent a simple and modular methodology to prepare a series of hyaluronan 
derivatives, assuring an efficient control of the properties of the hydrogel by varying both the 
type of diisocyanate and its relative amount. 
The reactivity of isocyanates has been studied with HA only in multi-component reactions.18 
Specifically HA derivatives have been prepared via three- and four-component reactions known 
as the Passerini reaction and Ugi reactions.11 In the Passerini reaction, an aqueous solution of 
hyaluronan is mixed with aqueous glutaraldehyde (or another water-soluble dialdehyde) and 
added to a known amount of a highly reactive isocyanide, usually cyclohexylisocyanide. In the 
Ugi four-component reaction, a diamine is added to this three-component mixture. This 
methodology has been used both for conjugation29 or to cross-link native hyaluronan;19 in this 
case the degree of cross-linking is controlled by the amount of aldehyde and diamine.  
We decided to test the reactivity of HA as nucleophile with diisocyanates: our plan was to 
introduce new  non conventional urethane bridges between different chains.  
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2.3.2 EXPERIMENTAL PROCEDURES   
2.3.2.1 Materials 
Sodium Hyaluronate (HA) RESILEN-200 (average molecular weight 235 kDa) was kindly supplied 
by Kyowa Italiana Farmaceutici s.r.l. (Milan, Italy). 
Spectrum Spectra/Por 6 RC Dialysis Membrane Tubing (50 KDa MWCO) was used to dialyse the 
samples. 
All reagents and solvents, if not otherwise specified, were purchased from Sigma-Aldrich 
(Milan, Italy) used as received. Dry solvents were used as received and stored under inert gas.  
For thin-layer chromatography (TLC) analysis, Macherey-Nagel Alugram® sil G/UV 254 pre-
coated plates were used. 
2.3.2.2 General methods 
2.3.2.2.1 Molecular characterization 
1H NMR and 13C NMR were measured on a BRUKER AC300, BRUKER AC200 or BRUKER AV400 
spectrometers.  
Infrared spectra were recorded on a Jasco FT/IR 4100. 
UV spectra were recorded on a Jasco FT V-630 spectrophotometer. 
2.3.2.2.2 Swelling measurement 
The swelling capacity, Sw, is defined as the ratio between the weight of swollen gels (Ws) after 
extensive dialysis against distilled water and the weight of the dry networks (Wd): 
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 w   s  d
  Equation 1 
10 mg (Wd) of cross-linked samples in 0.5 mL of water were dialysed, in a 5 cm of dialysis tube, 
against distilled water at 40 °C for four hours. The outside of the tube was then carefully dried 
with paper, and the material recovered from the tube weighted (Ws) to calculate Sw. 
2.3.2.2.3 Rheological measurement 
The rheological characterisation of hydrogels was performed with a Rheometrics Scientifics 
SR200 controlled stress rheometer with parallel plates (25 mm) geometry, 1 mm gap and 30 °C 
temperature. Dynamic experiments were carried out, under isothermal frequency sweep (10-1-
101 Hz) in an autostress-adjustment mode. Solutions 12 mg/mL of samples were used. The 
experiment allowed the monitoring of G', G'' versus ω trends. In order to make reliable 
measurements, the test was carried out within the linear viscoelastic region, that is, generally 
at small strain levels. In the present frequency sweep experiment the applied stress was 
progressively tuned in order to keep deformations below the 5%. 
2.3.2.3 Synthetic procedures 
2.3.2.3.1 Synthesis of cross-linked HA 
Synthesis of HA-TBA 
12,5 g of Dowex® 50WX-8-400 (hydrogen form) were washed with pure water (3 x 250 mL). 
Then 24.5 mL of 1.5 M TBA-OH were added and the mixture was shaked for 30 minutes. The 
resin was then filtered and added to 1 g of sodium hyaluronate (HA-Na). After 3 h, the 
supernatant layer was filtered and the solution obtained freeze-dried for 3 days to afford the 
product. Yield: 90% wt. 1H NMR (300 MHz, D2O): 4.60 (bs, 2H), 3.90-3.30 (m, 10H), 3.26 (t, J = 
8.4 Hz, 8H), 2.09 (s, 3H), 1.69 (m, 8H), 1.42 (m, 8H), 1.02 (t, J = 7.3 Hz, 12H). 
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Synthesis of cross-linked HA 
540 mg of HA-TBA were dissolved in 75 mL of dry DMSO under nitrogen atmosphere. After 
complete dissolution the cross-linker was added: 0.10 and 0.05 eq. for examethylene- and 
octamethylene-diisocyanate, respectively (15 and 8 mg of examethylene-diisocyanate for HA-
CL1; 17 and 9 mg of octamethylene-diisocyanate for HA-CL1) or 0.30, 0.20 and 0.10 eq. of TEG-
2IB (105, 70, 35 mg respectively for HA-CL3), while the reaction was vigorously stirred. The 
mixture was left under stirring overnight at room temperature and then poured into 400 mL of 
cold AcOEt to precipitate the HA-derivative. The product was filtered on a microfilter (pore size: 
0.45 µm) and washed with 200 mL of AcOEt to completely remove the unreacted cross-linker. 
The resulting white precipitate was then dissolved in 70 mL of distilled water and dialysed 
against 0.1 M NaCl for 1 day, then against pure water for 5 days and finally freeze-dried 
affording the pure product as a white solid. 
HA-CL1 10%: Yield: 80% wt. White solid. 
1H NMR (400 MHz, D2O): 4.46 (bs, 1H), 4.37 (bs, 1H), 
3.74-2.89 (m, 10H), 1.96 (s, 3H), 1.56-1.26 (m, 0.80H), 0.85 (m, 0.15H). 
HA-CL1 5%: Yield: 84% wt. White solid. 
1H NMR (400 MHz, D2O): 4.47 (bs, 1H), 4.37 (bs, 1H), 
3.76-2.90 (m, 10H), 1.98 (s, 3H), 1.56-1.20 (m, 0.35H), 0.85 (m, 0.10H). 
HA-CL2 10%: Yield: 78% wt. White solid. 
1H NMR (400 MHz, D2O): 4.48 (bs, 1H), 4.37 (bs, 1H), 
3.77-2.89 (m, 10H), 1.96 (s, 3H), 1.60-1.33 (m, 0.95H), 0.85 (m, 0.20H). 
HA-CL2 5%: Yield: 84% wt. White solid. 
1H NMR (400 MHz, D2O): 4.45 (bs, 1H), 4.36 (bs, 1H), 
3.77-2.88 (m, 10H), 1.96 (s, 3H), 1.61-1.29 (m, 0.45H), 0.85 (m, 0.10H). 
HA-CL3 10%: Yield: 81% wt. White solid. 
1H NMR (400 MHz, D2O): 4.40 (bs, 2H), 3.79-2.88 (m, 
10H), 2.00 (s, 3H). 
HA-CL3 5%: Yield: 85% wt. White solid. 
1H NMR (400 MHz, D2O): 4.39 (bs, 2H), 3.69-2.87 (m, 
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10H), 1.98 (s, 3H). 
2.3.2.3.2 Synthesis of [ethane-1,2-diylbis(oxy)]bis(ethane-2,1-diyl)]   
bis(2-isocyanato benzoate) (TEG-2IB): 
Synthesis of 2,2'-(2,5,8,11-tetraoxadodecane-1,12-dioyl)dibenzoic acid (TEG-2BA):33 
2.96 g (20 mmol, 1 eq.) of phtalic anhydride were dissolved in 100 mL of dry DCM under 
nitrogen atmosphere. The solution was cooled to 0 °C, then triethylene glycol (1.50 g, 10 mmol, 
1 eq.) and TEA (3.0 g, 30 mmol, 1.5 eq.) were added, under stirring. The reaction mixture was 
maintained at 0 °C for 4 h and then at room temperature for 5h (the progress of the reaction 
was monitored by TLC, and the reaction stopped when the anhydride was completely reacted). 
The solvent was evaporated, the residue cooled to 0 °C and 200 mL of a saturated NaHCO3 
added. The mixture was extracted with diethyl ether (3 x 50 mL); the aqueous layer was cooled 
to 0 °C and acidified with 1 M hydrochloric acid followed by extraction with DCM (4x 100 mL). 
The combuned organic layers, dried over MgSO4 and the solvent removed under reduced 
pressure to afford the pure product. Yield: 96% wt. Yellow oil. 1H NMR (300 MHz, CDCl3): 9.80 
(bs, 2H), 7.76 (m, 4H), 7.55 (m, 4H), 4.48 (t, J = 4.3 Hz, 4H), 3.85 (t,  J = 4.3 Hz, 4H), 3.77 (m, 4H). 
Synthesis of [ethane-1,2-diylbis(oxy)]bis(ethane-2,1-diyl) bis(2-isocyanatobenzoate) (TEG-
2IB): 
The diacylchloride was prepared by refluxing 3.90 g (9.5 mmol, 1 eq.) of TEG-2BA in neat 
thionyl chloride (6.5 mL, 62 mmol, 6.5 eq.) for 3 h. The thionyl chloride excess was removed 
under reduced pressure to afford the diacylchloride which was used for the next step without 
further purification as a residue.  
The residue was dissolved in 100 mL of dry THF and the solution added dropwise to solution of 
NaN3 (4.5 g, 66 mmol, 6.9 eq. dissolved in 60 mL of water), under cooling in an ice bath. The 
reaction mixture was allowed to warm up at room temperature and stirred overnight, then 150 
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mL of toluene and 150 mL of a saturated solution of NaHCO3 were added. The aqueous layer 
was extracted with toluene (2 x 150 mL). The collected organic phases were dried over MgSO4, 
filtered and the solvent removed under reduced pressure at 40 °C promoting the Curtius 
rearrangement and affording the corresponding diisocyanate. Yield: 72% wt. Orange oil. 1H 
NMR (200 MHz, CDCl3):  8.03 (m, 2H), 7.51 (m, 2H), 7.20 (m, 4H), 4.50 (t, J = 4.7 Hz, 4H), 3.85 (t,  
J = 4.7 Hz, 4H), 3.71 (m, 4H); FT-IR (cm-1): 3257, 2874, 2257, 2143, 1714, 1592, 1528, 1452, 
1299, 1261, 1213, 1143, 1075, 955, 756, 697. 
1H NMR study on the reactivity of the diisocyanate TEG-2IB:  
To check the reactivity of the diisocyanate TEG-2IB, 10 µL of MeOH were added to 1 mL of a 10 
mM solution of TEG-2IB in CDCl3. The 
1H NMR of the solution, recorded after 1 day at room 
temperature, showed only the signal relative to the MeOH (3.49 ppm) and the ones 
corresponding to the methyluretane of compound TEG-2IB [1H NMR (200 MHz, CDCl3):  8.42 (m, 
2H), 8.02 (m, 2H), 7.55 (m, 2H), 7.00 (m, 2H), 4.45 (t, J = 4.9 Hz, 4H), 3.83 (t,  J = 4.9 Hz, 4H), 3.77 
(m, 4H)]. 
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2.3.3 RESULTS AND DISCUSSION 
2.3.3.1 Synthesis of new cross-linked derivatives of the hyaluronic acid 
On account of the observation that HA is endowed with rather poor mechanical properties, 
chemical modifications of the hyaluronan are essential to reach stiffer hydrogels, with an 
increased stability in front of in vitro degradation. The use of diisocyanates as cross-linkers has 
never been reported, and we focused our attention on the use these cheap and highly reactive 
homo-bifunctional molecules to reticulate the different HA chains in a simple and modular way; 
a series of hyaluronan derivatives has been prepared by varying both the type of diisocyanate 
and its relative amount. 
By using an ion exchange resin, commercial HA (purchased as sodium salt) was first converted 
into its tetrabutylammonium salt, which is soluble in polar aprotic solvents like DMF and DMSO. 
The aim was to avoid water for the cross-linking reaction to ensure the absence of others 
nucleophiles which could compete with the primary hydroxy group of HA, which is supposed to 
be the most reactive function with electrophiles (Scheme 4). 
 
 
Chemical Modification of the Hyaluronic Acid 
 
 
______________________________________________________________________________ 
63 
 
 
Scheme 3: Synthesis of diisocyanate TEG-2IB via Curtius rearrangement 
Diisocyanate TEG-2IB featuring two terminal aromatic isocyanate groups was synthesised by reacting triethylene 
glycol with phtalic anhydride. The resulting dicarboxylic acid was then converted into its dichloride which was 
treated in situ with sodium azide to provide the diacylazide. The latter undergoes Curtius rearrangement to TEG-
2IB even at 40 °C. 
 
The cross-linking reaction was then carried out in dry DMSO solution with commercially 
available hexamethylene- and octamethylene-diisocyanate, and with the diisocyanate TEG-2IB, 
synthesized by Curtius rearrangement (Scheme 3) affording products characterized by urethane 
bridges between different chains (Scheme 4). 
Two different cross-linking ratios (defined as the ratio between the number of moles of 
cross-linker employed and the total number of repeating units of HA) were used with 
hexamethylene- and octamethylene-diisocyanate, i.e. 5% and 10%, while with diisocyanate 
TEG-2IB, three kinds of adducts were synthesised characterised by adding 10%, 20% and 30% 
equivalents of cross-linker. 
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Scheme 4: Synthesis of cross-linked HA-derivative 
 
Precipitation of the product with ethyl acetate facilitated the removal of the unreacted 
cross-linker. Purification was performed by dialysis, first against a 0.1M NaCl solution to restore 
the sodium as counterion, and then against distilled water to remove impurities.  
1H NMR analysis of the cross-linked HA confirmed the presence of the aliphatic chains and the 
total restoration of the sodium as counterion for the materials resulting from the reaction 
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derivative with the two commercially available diisocyanates HA-CL1 and HA-CL2 at both the 
cross-linking degrees (5% and 10%) (Figure 24).  
 
 
Figure 24: 1H NMR spectra of HA-CL1 (cross-linking degree 10%) 
1
H NMR spectrum of HA-CL1 (D2O, 400 MHz) showing the signals relative to the hyaluronan (two signals at 4.45 and 
4.35 ppm due to the methylene groups adjacent to the primary alcohol, broad signals from 3.89 to 3.10 
attributable to the protons on the glucosaminic and glucuronic rings and a singlet at 1.90 ppm, related to the 
acetamide moiety) and new small peaks (1.60-0.80 ppm) confirming the presence of the aliphatic chains. 
 
HA-CL3 
1H NMR analysis could not be performed, since the HA-derivatives were not completely 
soluble in water and only the signals of the native hyaluronan were observed. The samples have 
been then analised by UV spectroscopy and the increasing of a peak of absorbance at 220 nm 
was observed for increasing degrees of cross-linkage. For the sake of comparison, we recorded 
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also the spectrum of the methyl urethane resulting from TEG-2IB and we observed a peak at 
220 nm.  
 
Figure 25: UV spectra of HA-CL3 
UV spectra of HA-CL3  were recorded on 1 mM aqueous solution of samples. The red line corresponds to the 
nominal degree of cross-linking of the 30%, the blue of 20% and the green of 10%.  
 
2.3.3.2 Swelling measurement 
The swelling is defined as the ratio between the weight of the swollen gel (Ws) and the weight 
of the corresponding dry polymer (Wd). The value is usually an indication to compare the cross-
linking densities of HA with different cross-linking agents. As a general rule, the higher is the 
cross-linking degree, the lower is the swelling.11  
As already mentioned, HA-CL3 was not analysed by 
1H NMR because of its poor solubility in 
water; hence we did not performe any swelling measurement on these samples. 
We measured Sw for the HA-derivative with examethylene- and octamethylene-diisocyanates 
and we found results in accordance with the theoretical cross-linking degree. Specifically, it was 
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found that the Sw showed an inverse proportionality to the cross-linking degree; moreover, the 
samples obtained by reaction with 5% equivalents of diisocyanate do not differ significantly 
from native HA, while remarkable differences were found in the materials resulting from the 
reaction with the 10% of cross-linker. However, the data obtained for the materials obtained by 
using examethylene- and octamethylene-diisocyanate are quite similar. 
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Figure 26: Swelling measurement (Sw) for cross-linked HA 
Sw, is the ratio between the weight of swollen gel (Ws) and the weight of the dry network (Wd). Ws was measured 
after extensive dialysis against distilled water at 40 °C. Error bars represent standard deviation (n = 3).  
 
2.3.3.3 Rheological measurement 
Dynamic shear experiments were carried out in order to investigate the viscoelastic mechanical 
behaviour of gels. Viscoelasticity is a concept that draws from theories describing ideal 
materials and their behaviour in front of applied forces; Hook’s law defines the behaviour of 
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ideal solids, whereas Newton’s theory defines the behaviour of ideal liquids: 
Hook’s law:        Equation 2 
Newton’s law         Equation 3 
Where   = shear stress (N/m2 = Pa),   = shear strain (unitless),   = shear modulus (Pa),    = 
shear rate or strain rate (s-1) and   = coefficient of viscosity (Pa·s). 
Equation 2 and Equation 3 fully describe the linear stress-strain and the stress-strain rate 
relationship. However, real materials exhibit a combination of elastic and viscous properties 
(i.e. they are viscoelastic) and therefore, other, more complex equations are necessary to 
quantitatively describe those material properties. 
Rheological tests for the characterisation of the viscoelastic properties of a material are usually 
dynamic shear oscillatory tests. Specifically, an oscillatory (sinusoidal) deformation (stress or 
strain) is applied to a sample and theresponce of the material as well as the phase angle, or 
phase shift, between the deformation and response, are measured. The sinusoidally varying 
shear stress and the resulting shear strain are illustrated in Figure 27 and can be described 
mathematically as: 
                  
    Equation 4 
                      
          Equation 5 
Where    = stress amplitude (Pa),   = strain amplitude,   = oscillatory frequency (rad.s
-1), t = 
time (s),   = phase angle (⁰). 
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Figure 27: Illustration of the sinusoidally varying stress and strain in dynamic oscillatory test  
Specifically:    = stress amplitude (Pa),   = strain amplitude and   = phase angle (⁰). 
 
The phase angle (δ) is the phase difference between stress and strain in the oscillatory test and 
has a value between 0⁰ and 90⁰. It can be used as a measure of the viscous and elastic ratio of a 
material; it will be 0⁰ for an ideal solid and 90⁰ for an ideal fluid. In the case of viscoelastic 
materials, such as a polymer or a polymer-based hydrogel, the mechanical response is 
somehow intermediate between an ideal elastic solid and an ideal viscous liquid and the phase 
difference has a value between 0° and 90°. 
The ratio between stress and strain is called complex modulus (G*) and can be described as: 
    
  
  
        
  
  
                Equation 6 
Where G' = shear storage or elastic modulus (Pa) and G'' = shear loss or viscous modulus (Pa). G' 
provides information about the energy elastically stored in the material during deformation, 
whereas G'' describes the viscous character or the energy dissipated as heat. It is important to 
note that the terminology “hydrogel” is often applied to materials where the storage shear 
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modulus is higher than the loss one (G' > G''), although strictly speaking one should consider 
the independence of G' on frequency as a criterion. 
We used dynamic frequency sweep experiments in which the material response to increasing 
frequency (rate of deformation) to a material that is placed between a defined geometry (most 
commonly parallel plate or cone and plate geometry) is monitored at a constant amplitude 
(stress or strain) and temperature. The experiment allowed the monitoring of G', G'' versus ω 
trends.  
 
Figure 28: Rheological measurement on HA-CL1 
Dynamic experiments were carried out on solutions (12 mg/mL) of the sample at 30 °C, with a frequency sweep 
range from 10
-1
 to 10
1
 Hz in the autostress-adjustment mode. The tests were carried out within the linear 
viscoelastic region. A: two measurements were performed for HA-CL1 5% (red and green), only G'' was recorded 
(). B: three measurements were performed for HA-CL1 10% (,,), G' values are in blue while G'' ones are in 
green. As a reference, the linear range relative to the G'' of HA 235 kDa is reported (orange dash line). 
 
Basically the studies on the rheological behavior of the products let us ascertain that there 
were no significant differences between the cross-linked polymer and the linear one. In fact G'' 
is the predominant component influencing the viscoelastic properties of the samples (Figure 
28) while hydrogels feature for definition G' > G''. A possible explanation is that local 
precipitation occurred in the areas where the cross-linker is present; the reason could be 
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related either to the hydrophobicity of the aliphatic core of the reticulating agent or to the 
impossibility of the polymer to change conformation, passing from DMSO to water, because of 
the presence of new covalent bonds. 
 
  
 
Chemical Modification of the Hyaluronic Acid 
 
 
______________________________________________________________________________ 
72 
2.3.4 CONCLUSION 
The development of new strategies to improve the mechanical properties of HA and reducing 
its clearance maintaining its biocompatibility is a very important task in tissue engineering. 
Usually, the cross-linking of the linear chains of HA creating a reticulated network helps for the 
creation of new materials suitable for cells culture and implantation.  
An unconventional methodology to cross-link HA has been developed. Specifically the reactivity 
of the primary hydroxyl group as a nucleophile with isocyanates has been demonstrated.  
Diisocyanates are cheap molecules never used as cross-linker agents with HA; in order to 
control their high reactivity, reactions were carried out in DMSO instead of in water. The 
complete solubility of hyaluronan in this solvent was ensured by changing its counterion and 
using, hence, its TBA salt. 
In particular two commercially available diisocyanates have been used (hexamethylene- and 
octamethylene-diisocyanate) providing water soluble products in which the presence of 
aliphatic bridges was confirmed by 1H NMR analysis and swelling measurements. 
Another aryl diisocyanate, characterised by a triethylene glycol chain, was prepared by Curtius 
rearrangement; in this case, the cross-linked products were found was slightly soluble and we 
could prove the formation of the adducts by UV analysis only. 
Subsequent studies on the rheological behavior of the products let us ascertain that there were 
no significant differences between the cross-linked polymer and the linear one. A possible 
explanation is that hydrophobic and short-chain reticulating agents were responsible for local 
precipitation of the substrat in the areas where the cross-linker is present. 
Anyway this strategy opens applicative perspectives to be applied for the formation of mixed 
hydrogels, e.g. HA and PEG or collagen, or with different diisocyanates. 
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Furthermore, the use of the substrates to coat petri dishes on which mesoangioblasts were 
cultured showed the complete atoxicity of the materials and a cellular proliferation very similar 
to that observed for the standard conditions (See 2.5). 
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2.4 HA MODIFICATION VIA CuI CATALYSED 
1,3-CYCLOADDITION 
 
2.4.1 INTRODUCTION 
The demand for new chemical materials and biologically active molecules is continuously 
growing today; an emerging class of reactions is the one named as “click chemistry,” identifying 
a set of powerful, simple and selective reactions that generate links based on heteroatoms, 
offering a unique approach to this problem.34 All the reactions that require only benign 
conditions, simple workup and purification procedures and can rapidly create molecular 
diversity through the use of reactive modular building blocks can be defined as “click”. 
Sharpless and co-workers have identified a number of reactions meeting these criteria;35 
according to their definition, a “click reaction” is chracterized by a gain in thermodynamic 
enthalpy of at least 20 kcal·mol-1. Common features of these transformations are related to 
their orthogonality, regioselectivity and highly efficiency; moreover, click reactions can be 
performed in aqueous solutions at room or physiological temperature and generally display 
outstanding functional group tolerance; not surprisingly, these characteristics make them 
compelling reactions within the bioengineering toolkit for polymer synthesis and 
bioconjugation.36 
In particular, tissue engineering has the aim of delivering biomolecules, cells, and supporting 
structures to the body promoting self-healing.  To accomplish this task, biocompatible materials 
are required to serve either as structural supports for tissue regeneration or as delivery vehicles 
for cells and drugs transplantation. To make relevant progresses in this field, the development 
of synthetic organic techniques aiming to facilitate the chemoselective cross-linking and the 
functionalisation with bioactive molecules of synthetic and natural polymer, is a key point. 
 
Chemical Modification of the Hyaluronic Acid 
 
 
______________________________________________________________________________ 
75 
Recently, the click chemistry has been widely used within regenerative medicine both for 
forming new cross-linked hydrogels and for implementing bioconjugation techniques involving 
the decoration of 2D cell substrates or even the immobilisation of bioactive factors within 3D 
scaffolds. Common reactions for this purpose are the Diels−Alder reactions and other highly 
efficient reactions, such as nucleophilic substitutions, radical additions, Michael additions (in 
particular when thiol-nucleophiles are involved), but one of the most powerful transformations 
discovered to date is the CuI catalyzed variant of the Huisgen 1,3-dipolar cycloaddition of azides 
to alkynes to afford 1,2,3-triazoles.This reaction is very similar to the classic Huisgen 
cycloaddition where an organic azide reacts with an alkyne to form a triazole ring (Figure 29).37  
 
 
 
Figure 29: Huisgen thermal 1,3-cycloaddition 
The final product of thermal 1,3-cicloaddition, proposed by Huisgen in 1968, is an almost 1:1 mixture of the two 
regioisomers depicted in the Figure. 
 
In 2002, Sharpless demonstrated that the Huisgen cycloaddition reaction can proceed at low 
temperatures with high rates, high efficiency and regiospecificity (only the 1,4-adduct is 
formed) by using a CuI catalyst; the in situ-generated catalyst, deriving by the use of copper(II) 
sulfate and ascorbic acid as the reducing agent, showed to be efficient as well.38 Moreover, a 
nearly perfect conversion is obtainable both in aqueous and organic solvents. 
The advantages of this reaction in biomedical applications are related to the fact that the 
starting materials, azides and terminal alkynes, are remarkably stable within biological systems, 
enabling a facile introduction of these reactive groups into a wide range of biomolecules. 
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Furthermore these reactive groups are basically absent in nature and this fact greatly limits the 
formation of by-products. 
The mechanism proposed for this reaction explains the experimental evidences that make this 
transformation so unique: it tolerates very many organic functional groups and shows a wide 
scope with respect to both alkyne and azide reactants; in addition it proceeds in a great variety 
of solvents, tolerates a wide range of pH values and performs efficiently over a broad 
temperature range. 
Researchers proposed that the stepwise catalytic cycle begins with the formation of a CuI 
acetylide species formed via a π complex (Figure 30). Even if alkyne π complexation requires 
ligand dissociation, hence a slightly endothermic reaction, in aqueous solution, however, the 
next step involving the formation of the copper species is remarkably exothermic. Copper 
coordination reduces the pKa of the alkyne C-H by up to 9.8 pH units, thus promoting 
deprotonation. Probably, a dynamically changing family of different CuI acetylide species may 
exist in solution, depending on the reaction conditions; in fact, kinetic studies indicate that the 
rate of the catalytic process is second order in copper, but that, by increasing copper 
concentrations, less reactive species, such as metal aggregates, are formed. The role of the 
second copper atom seems to be the activation of the azide functionality, but the π 
complexation of a terminal acetylide function bound to a neighboring copper atom may also 
occur. This complexation increases acetylide activity toward cyclization by reducing the alkyne 
electron density. The formation of the active copper acetylide species is followed by azide 
displacement of one ligand generating a copper acetylide-azide complex. At this point 
cyclization occurs: complexation of the azide activates it toward the nucleophilic attack of 
acetylide carbon C(4) at N(3) of the azide (numbers based on the traditional triazole 
nomenclature), generating a metallacycle. Subsequent ring contraction, protonation of the 
triazole-copper derivative and dissociation of the resulting product close the reaction and 
regenerates the catalyst. 
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Figure 30: Proposed catalytic cycle for 1,3-cycloaddition catalysed by CuI 
 
2.4.1.1 HA-based hydrogels crosslinked by CuI-catalysed azide-alkyne cycloaddition   
The dipolar cycloaddition between an azido group and a terminal alkyne group presents 
numerous advantages that make it very appealing for application in the case of HA. In 
particular, it occurs at physiological pH and temperature, ensuring a complete biocompatibility 
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during cell encapsulation or incorporation of biologically active molecules. Furthermore, the 
use of CuI catalyst accelerates the process, preserving the inertness of both azides and alkynes 
toward the vast majority of functional groups that are typical of the biological environment.  
Only few examples regarding the chemical modification of HA by Sharpless cycloaddition are 
present in the literature, all focused on the in situ gel formation of systems that might act as 
vehicles for sustained drug delivery and tissue engineering applications. 
The first person who exploited this route was Crescenzi who synthesized hydrogels of HA using 
a novel procedure for the rapid chemical gelation of aqueous solutions of previously modified 
hyaluronan.39 Specifically, new derivatives bearing azido and alkyne groups linked by short arms 
to the polysaccharide main chains were prepared by amidation mediated by EDCI. Once the 
two types of derivatives are mixed in aqueous medium, they give rise to the dipolar 1,3-
cycloaddition, after the addition of CuCl in a catalytic amount (Figure 31). The formed gel has 
been characterized (rheology, IR spectroscopy, swelling properties and, in particular, NMR 
spectral features) and employed in drug delivery studies. In fact, carrying out the gelation 
process in aqueous solutions containing benzidamine and doxorubicin, respectively, the 
polysaccharide networks acted as drug reservoirs and the drug release resulted well 
controllable by acting on the degree of cross-linking. Furthermore, encouraging results were 
obtained when the click-gels were formed using aqueous suspensions of Saccharomices 
cerevisiae yeast cells; in this case, a scaffold inside which the cells were homogeneously 
distributed and smoothly adhered to the inner pores surfaces was observed. Moreover, after 
24 h about 60% of the entrapped cells were still exhibiting some proliferating activity. 
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Figure 31: Representation of the Formation of HA-based click-gels 
 
Two years later, the same research group published the use of the same azido derivative 
(Figure 31) in combination with a series of dialkyne reagents differing in the length of the 
bridge. In this case the catalyst was generated in situ combining copper sulfate and ascorbic 
acid.40 The aim of the investigation was to evaluate the influence of the typology of the cross-
linker; they found that the degree of cross-linking was in an inverse relationship with the 
flexibility of the bridging unit: longer spacer arm gave rise to higher cross-linking densities. Both 
the kinetic of gelation and the the elastic moduli value determined of by rheology, as well as 
the swelling ratios were in good agreement with the experimental findings. 
In similar a study published in 2011,41 hyaluronic acid-based hydrogels with tunable mechanical 
properties were prepared by exploiting the copper-catalysed azide-alkyne cycloaddition of 
alkyne-functionalized hyaluronic acid crosslinked with linkers carrying two terminal azide 
functionalities. The cross-linker density as well as the length and the rigidity of the linker 
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molecules were varied (Figure 32). 
 
 
 
Figure 32: Formation of hydrogels from modified-HA by the use of click chemistry with different cross-
linkers 
 
The target of the last example present in literature regarding the use of an HA-derivative in the 
Sharpless cycloaddition reaction specifically was to mimic the natural cartilage extracellular 
matrix: a biological hydrogel was synthesized from the HA biopolymers, chondroitin sulfate and 
gelatin.42 HA and chondroitin sulfate were modified with 11-azido-3,6,9-trioxaundecan-1-amine 
to insert an azide function, and gelatin was modified with propiolic acid in order to have a 
terminal alkyne. The azide groups of HA and chondroitin sulfate were reacted with the 
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acetylene groups of gelatin, catalyzed by CuI, to form triazole rings, thereby forming a cross-
linked hydrogel. As expected, the gelation time decreased with increasing the catalyst 
concentration. The hydrogel obtained in this way was used as a substrate for in vitro cell culture 
and the results confirmed that chondrocytes could adhere and proliferate on it. 
In conclusion, the use of the copper catalysed cycloaddition seems to be a promising strategy to 
provide biocompatible hydrogels with tailored and tunable mechanical properties, but the 
examples found in literature on its application on HA were directed to cross-link the polymer. 
On these bases, we decided to try to fill the gap on the knowledge about the applicability of 
1,3-dipolar cycloaddition in bioconjugation reactions. Specifically we tried to develop a strategy 
to covalently link bioactive molecules, or poorly soluble precursors, to the HA scaffold and then 
to proceed with further modifications to provide a versatile tool for the design of a 
multifunctionalised HA bearing different molecules capable of developingv synergic biological 
effects. 
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2.4.2 EXPERIMENTAL PROCEDURES   
2.4.2.1 Materials 
Sodium Hyaluronate (HA) RESILEN-200 (average molecular weight 235 kDa) was gently supplied 
by Kyowa Italiana Farmaceutici s.r.l. (Milan, Italy). 
Spectrum Spectra/Por 6 RC Dialysis Membrane Tubing (50 KDa MWCO) was used to dialyse the 
samples. 
All reagents and solvents, if not otherwise specified, were purchased from Sigma-Aldrich 
(Milan, Italy) and used as received. Dry solvents were used as received and stored under inert 
gas. All the amino acids derivatives employed displayed the natural stereochemical 
configuration. 
For thin-layer chromatography (TLC) analysis, Macherey-Nagel Alugram® sil G/UV 254 pre-
coated plates were used. Column chromatography was performed on Macherey-Nagel MN 
Kieselgel silica gel.  
2.4.2.2 General methods 
2.4.2.2.1 Molecular characterization 
Melting point (mp) determinations were performed by using a Buchi B-540 instrument.  
1H NMR and 13C NMR were measured on a BRUKER AC300, BRUKER AC200 or BRUKER AV400 
spectrometers.  
Optical rotations ([α]D
25) were measured on a JASCO P-1030 polarimeter with a 1 dm cell at the 
sodium D line (λ = 589 nm).  
Mass analyses were performed using a VG 7070 EQ-HF instrument.  
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Infrared spectra were recorded on a Jasco FT/IR 4100. 
2.4.2.3 Synthetic procedures 
2.4.2.3.1  Synthesis of HA derivatives 
Synthesis of bromoacetate derivatised Hyaluronan (HABA):26 
2.0 g of HA (5 mmol) were dissolved in 200 mL of distilled water. The pH of the solution was 
adjusted to 9.0 by adding 1 M NaOH. Bromoacetic anhydride (13 g, 50 mmol, 10 eq.) was then 
added dropwise to the solution at 0 °C. The reaction was stirred for 24 h at 4 C, then the 
reaction mixture was dialyzed (MWCO 50000) for 7 days against distilled water. The sample 
was then freeze-dried and analysed. Yield: 65% wt. White solid. 1H NMR (400 MHz, D2O) (δ = 
ppm): 4.88 (bs, 2H, CH2OC=O), 3.97 (s, 0.1 H, COCH2Br), 3.86-3.40 (m, 10H), 2.03 (s, 3H, 
NHCOCH3). 
Synthesis of azidoacetate derivatised Hyaluronan (HAAA): 
1.0 g of HABA (2.5 mmol of monomeric unit of HA) was dissolved in 100 mL of distilled water to 
which 200 mg of NaN3 (2.5 mmol, 1 eq.) were added. The reaction was stirred for 24 h at room 
temperature. The reaction mixture was then dialyzed (MWCO 50000) for 7 days against distilled 
water. The sample was then freeze-dried and analysed. Yield: 75% wt. White solid. 1H NMR 
(400 MHz, D2O) (δ = ppm): 4.59 (bs, 1H), 4.51 (bs, 1H), 3.87-3.38 (m, 10H), 2.05 (s, 3H, 
NHCOCH3); FT-IR (cm
-1): 3382, 2921, 2153 (N3), 1651, 1417, 1206, 1155, 947, 894, 447. 
Synthesis of click-HA conjugates: 
If not specified, this general procedure was followed for the synthesis of HA-based conjugates 
via copper catalysed Huisgen cycloaddition; the triple bond-containing compound (2 eq. respect 
to the monomeric unit of HA) was added to a 1% w/v solution of HAAA in distilled water. Then, 
an aqueous solution 5% w/v of sodium ascorbate (0.5 eq. respect to the monomeric unit of HA) 
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was added, followed by the addition of a 5% w/v solution of CuSO4·5H2O in distilled water (0.1 
eq. respect to the monomeric unit of HA). The mixture was stirred for 24 h at room 
temperature. The reaction mixture was then dialyzed (MWCO 50000) against EDTA solution (10 
mM) for 24 h and finally against distilled water for 7 days. The sample was then freeze-dried 
and analysed. 
Synthesis of the propargyl alcohol-HA conjugate (HA-TR1): 
For this synthesis the general procedure was followed using, respectively, 100 mg of HAAA 
(0.25 mmol of monomeric unit of HA), 30 mg of propargyl alcohol (0.5 mmol, 2eq.), 20 mg of 
sodium ascorbate (0.125 mmol, 0.5 eq.) and 6 mg of CuSO4·5H2O (0.025 mmol, 0.1 eq.). Yield: 
60% wt. White solid. 1H NMR (400 MHz, D2O) (δ = ppm): 7.36 (s, 0.04 H, aromatic H on the 
triazole ring), 4.51 (bs, 2H, CH2OC=O), 3.94-3.37 (m, 10H), 2.06 (s, 3H, NHCOCH3); FT-IR (cm
-1): 
3417, 2920, 1633, 1416, 1379, 1205, 1152, 1076, 947, 895. 
Synthesis of the propargyl benzoate-HA conjugate (HA-TR2): 
For this synthesis the general procedure was followed using, respectively, 200 mg of HAAA (0.5 
mmol of monomeric unit of HA), 160 mg of propargyl benzoate (1.0 mmol, 2 eq.), 45 mg of 
sodium ascorbate (0.25 mmol, 0.5 eq.) and 13 mg of CuSO4·5H2O (0.05 mmol, 0.1 eq.). Yield: 
70% wt. White solid. 1H NMR (300 MHz, D2O) (δ = ppm): 7.29 (s, 0.02H aromatic H), 4.49 (d, J = 
7 Hz, 1H), 4.42 (d, J = 7 Hz, 1H), 3.98-3.40 (m, 10H), 1.93 (s, 3H); FT-IR (cm-1): 3397, 2926, 1728, 
1628, 1413, 1377, 1312, 1241, 1154, 1047, 945, 893. 
Synthesis of [3Z-Arg-Gly-Asp(OBn)-NHProp]-HA conjugate: 
3Z-Arg-Gly-Asp(OBn)-NHProp (44 mg, 0.05 mmol, 0.2 eq.) was added to 1% w/v a solution of 
HAAA (100 mg, 0.25 mmol of monomeric unit of HA)  in distilled water. Then, a 5% w/v 
aqueous solution of sodium ascorbate (45 mg, 0.25 mmol, 1 eq.) was added followed by 
CuSO4·5H2O 5% w/v in distilled water (13 mg, 0.05 mmol, 0.2 eq.). The mixture was stirred for 
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48 h at room temperature. The reaction mixture was then dialyzed (MWCO 50000) against an 
EDTA solution (10 mM) for 24 h and finally against distilled water for 7 days. The sample was 
then freeze-dried and analysed. No traces of the product were detected. 
Synthesis of (H2N-Arg-Gly-OProp)-HA conjugate (HA-TR3): 
To a solution of 250 mg of HAAA (0.6 mmol of monomeric unit of HA) in 50 mL of distilled 
water, 2 g of Dowex-TBA resin (See 0) were added and the mixture was gently shaked for 3 
hours. The supernatant liquid was removed by filtration and the solution concentrated to a final 
volume of 10 mL. Additional 15 mL of DMSO were added to the flask, and the addition followed 
by a further addition of 20 mg (0.03 mmol, 0.2 eq.) of 3Z-Arg-Gly-OProp; as soon as the mixture 
resulted homogeneous, 1 mL of distilled water containing 50 mg (0.3 mmol, 0.5 eq.) of sodium 
ascorbate was added dropwise, followed by the further addition of 1 mL of an aqueous solution 
containing 15 mg (0.06 mmol, 0.1 eq.) of CuSO4·5H2O. The reaction was stirred at room 
temperature for 2 days; then 50 mg (0.9 mmol, 1.5 eq.) of propargyl alcohol were added to 
completely ensure the quenching of all the azido groups on the HAAA; the reaction was stirred 
for further 12 h and then dialysed against a solution containing EDTA (10 mM) and 
tetrabutylammonium hydroxide (10 mM) for 24 h and then against pure water for 24 h. 
The aqueous solution of the product was submitted to heterogeneous hydrogenation without 
further characterization. Specifically, the solution was concentrated at reduced pressure to a 
final volume of 10 mL, then an equal volume of MeOH was added. 25 mg of Palladium (5% on 
activated charcoal catalyst) were added and the reaction was vigorously stirred under hydrogen 
pressure (6 bar) in a closed autoclave, overnight. The crude mixture was then filtered over a 
plug of celite, the solvent removed under reduced pressure, and the film obtained dissolved 
again in 20 mL of distilled water, then dyalised for 24 h against EDTA (10 mM), against NaCl (10 
mM) for 48 h and finally against pure water for 72 h. The product was analysed after frieze-
drying. Yield: 40% wt. White solid. 1H NMR (400 MHz, D2O) (δ = ppm): 8.59-7.48 (m, 0.02H), 
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6.10-5.10 (m, 0.10H), 4.58 (d, J = 8 Hz, 1H),  4.49 (d, J = 8 Hz, 1H), 3.94 (d, J = 8 Hz), 3.87-3.35 
(m, 10H), 1.95 (s, 3H); FT-IR (cm-1): 3287, 2909, 1615, 1406, 1373, 1315, 1151, 1024, 891. 
Synthesis of [Boc-Arg(Z)2-OTEG-OProp]-HA conjugate (HA-TR4): 
A slightly modified version of the general procedure was used in this case; specifically: to a 1% 
w/v solution of 280 mg of HAAA (0.7 mmol of monomeric unit of HA) in distilled water, a 
solution of 90 mg (0.13 mmol, 0.19 eq.) of (3Z)-Arg-OProp in 2 mL of MeOH was added 
dropwise. Then, sodium ascorbate and CuSO4·5H2O were added to the reaction mixture, as 
already described, using the following quantities, respectively: 60 mg (0.35 mmol, 0.5 eq.) of 
sodium ascorbate and 20 mg (0.07 mmol, 0.1 eq.) of CuSO4·5H2O. After 48 h stirring, the 
product was purified and recovered as mentioned above. Yield: 75% wt. White solid. 1H NMR 
(300 MHz, D2O) (δ = ppm): 8.39 (s, 0.04H, aromatic H on the triazole heterocycle), 7.39 (s, 
0.20H, aromatic H on phenyl rings), 4.58 (d, J = 6 Hz, 1H), 4.49 (d, J = 6 Hz, 1H), 3.95-3.37 (m, 
10H), 2.04 (s, 3H, NHCOCH3); FT-IR (cm
-1): 3407, 2918, 1633, 1416, 1379, 1153, 1048. 
Synthesis of the (Boc-Arg(Z)2-OTEG-OProp)-HA conjugate (HA-TR5): 
A suspension of 200 mg (0.5 mmol) of HA-TR4 in 50 mL of distilled water was stirred overnight 
under hydrogen pressure (6 bar), at room temperature, with 20 mg of Palladium catalyst 
(5% on activated charcoal). The mixture was then filtered over a plug of celite and then over a 
regenerate cellulose microfilter (pore size 0.2 µm) and freeze-dried. Yield: 85% wt. White solid. 
1H NMR (300 MHz, D2O) (δ = ppm): 8.50 (s, 0.04H, aromatic H on the triazole heterocycle), 4.59 
(d, J = 6 Hz, 1H), 4.49 (d, J = 6 Hz, 1H), 3.96-3.35 (m, 10.2H), 2.05 (s, 3H, NHCOCH3); FT-IR (cm
-1): 
3375, 2918, 1613, 1416, 1377, 1321, 1149, 1079, 1046, 950, 899. 
2.4.2.3.2 Synthesis of bromoacetic anhydride:43 
6.4 g of 1,3-diisopropylcarbodiimide (DIC, 50 mmol, 0.5 eq.) dissolved in 20 mL of dry DCM 
were added dropwise to a solution of 13.9 g (100 mmol, 1 eq.) of bromoacetic acid in 50 mL of 
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dry DCM, under nitrogen atmosphere, at -15 °C. After stirring the mixture at room temperature 
for 1 h, the solution was cooled and left at -20 °C for 5 hours, then filtered to remove the solid 
urea formed from DIC. Evaporation of the solvent under reduced pressure gave the product 
that was used without further purification. Yield: 99% wt. Yellow oil. 1H NMR (200 MHz, CDCl3) 
(δ = ppm): 3.99 (s, 4H). 
2.4.2.3.3 Synthesis prop-2-yn-1-yl benzoate:44 
To a stirred solution of benzoic acid (2.0 g, 16 mmol, 1 eq.), propargyl alcohol (1.0 g, 18 mmol, 
1.1 eq.) and 4-dimethylaminopyridine (DMAP, 250 mg, 2 mmol, 0.1 eq.) in 30 mL of dry DCM, 
under nitrogen atmosphere, N,N′-dicyclohexylcarbodiimide (DCC, 3.7 g, 18 mmol) was added in 
small portions at room temperature. The mixture was stirred and monitored by TLC analysis 
until complete disappearance of benzoic acid (2 h). The crude mixture was then filtered and the 
product purified by column chromatography on silica gel (70-230 mesh) using a mixture 7:3 v/v 
of hexane and AcOEt as eluant. Yield: 79% wt. Yellow oil. 1H NMR (200 MHz, CDCl3) (δ = ppm): 
8.07 (m, 2H), 7.58 (m, 1H), 7.45 (m, 2H), 4.93 (d, J = 2.5 Hz, 2H), 2.52 (t, J = 2.5 Hz, 1H). 
2.4.2.3.4 Synthesis of 3Z-Arg-Gly-Asp(OBn)-NHProp: 
Synthesis of H2N-Gly-OtBu: 
Method A: 
Synthesis of Z-Gly-OH: 
3.00 g (75 mmol, 1.1 eq.) of NaOH were dissolved in 50 mL of distilled water, then 50 mL of 
acetone were added and 5.00 g (67 mmol, 1 eq.) of glycine were added to the mixture. The 
solution was cooled down to 0 °C and a 1:1 v/v mixture of water and benzyl chloroformate  
(12.6 g, 74 mmol, 1.1 eq.) was added dropwise. After stirring at room temperature overnight, 
the acetone was removed under reduced pressure. The mixture was acidified with a 1M 
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hydrochloric acid solution and the resulting bilayered system was separated; to the lower layer 
5 mL of DCM were added and the white precipitate formed filtered affording the pure product, 
which was dried under reduced pressure. Yield: 71% wt. White solid. 1H NMR (300 MHz, CDCl3) 
(δ = ppm): 7.36 (m, 5H), 5.23 (bs, 1H), 5.14 (s, 2H), 4.04 (d, J = 5.4 Hz, 2H). 
Synthesis of Z-Gly-OtBu: 
To a stirred solution of Z-Gly-OH (2.5 g, 12 mmol, 1 eq.), t-butyl alcohol (1.3 g, 18 mmol, 1.5 eq.) 
and DMAP (25 mg, 0.2 mmol, 0.02 eq.) in 30 mL of dry DCM under nitrogen atmosphere, DIC 
(1.6 g, 13 mmol, 1.1 eq.) was added in small portions, at 0 °C. The reaction was stirred for 3 h 
and left under stirring overnight at -12 °C in order to promote the complete precipitation of the 
solid urea formed from the DIC. The crude mixture was then filtered and the product purified 
by flash chromatography over a silica gel column (230-400 mesh) using a 4:6 v/v mixture of 
hexane and AcOEt as eluant. Yield: 27% wt. Yellow oil. 1H NMR (200 MHz, CDCl3) (δ = ppm): 7.37 
(m, 5H), 5.23 (bs, 1H), 5.13 (s, 2H), 3.88 (d, J = 5.3 Hz, 2H), 1.47 (s, 9H). 
Synthesis of H2N-Gly-OtBu: 
0.65 g (2.5 mmol) of Z-Gly-OtBu were dissolved in 5 mL of MeOH, then 10 mg of Palladium 
catalyst (5% on activated charcoal) were added and the reaction vigorously stirred overnight at 
room temperature, under hydrogen atmosphere. The crudemixture was then filtered on a plug 
of celite, then the evaporation of the solvent afforded the pure product. Yield: 88% wt. Yellow 
oil. 1H NMR (200 MHz, CDCl3) (δ = ppm): 3.48 (s, 2H), 1.47 (s, 9H). 
Method B:45 
Synthesis of t-butyl bromoacetate: 
To a stirred solution of dimethyl aniline (5.0 g, 40 mmol, 1 eq.), t-butyl alcohol (3.0 g, 40 mmol, 
1 eq.) in 10 mL of dry Et2O, under nitrogen atmosphere, 8.0 g (40 mmol, 1 eq.) of bromoacetyl 
bromide were slowly added at 0 °C. The reaction was then stirred at room temperature for 4 h. 
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The separated dimethylaniline hydrobromide was dissolved by adding 10 mL of water and the 
organic layer was washed with 1M HCl solution(10 mL), with a saturated solution of NaHCO3 (10 
mL) and finally with water (10 mL). The organic extracts were dried over Na2SO4 and the solvent 
removed to afford the product. Yield: 73% wt. Yellow oil. 1H NMR (200 MHz, CDCl3) (δ = ppm): 
3.75 (s, 2H), 1.48 (s, 9H).  
Synthesis of t-butyl azidoacetate: 
2.85 g (44 mmol, 1.5 eq.) sodium azide and 5.70 g (29 mmol, 1 eq.) of t-butyl bromoacetate 
were dissolved in a 60:40 v/v mixture of acetone and water. The mixture was refluxed on a 
steam bath for 14 h. The acetone was then removed under reduced pressure and the aqueous 
phase exhaustively extracted with Et2O (15 mL x 3); the combined organic layers were dried 
over Na2SO4 and filtered. Removal of the solvent afforded the product. Yield: 95% wt. Orange 
oil. 1H NMR (300 MHz, CDCl3) (δ = ppm): 3.74 (s, 2H), 1.50 (s, 9H). 
Synthesis of H2N-Gly-OtBu: 
To a solution of 2.60 g (26 mmol) of t-butyl azidoacetate in 15 mL of MeOH 50 mg of Palladium 
catalyst (5% on activated charcoal) were added and the mixture was vigorously stirred 
overnight, at room temperature, under hydrogen atmosphere (5 bar). The crude mixture was 
filtered on a plug of celite and the evaporation of the solvent afforded the pure product. Yield: 
95% wt. Yellow oil. 1H NMR (200 MHz, CDCl3) (δ = ppm): 3.48 (s, 2H), 1.47 (s, 9H). 
Synthesis of 3Z-Arg-OH:46 
Boc-Arg(Z)2-OH (1.80 g, 2.3 mmol, 1 eq.) was treated at 0°C with 60 mL of a 1:1 v/v solution of 
DCM and trifluoroacetic acid. After 1 h, the solvent was removed under reduced pressure. The 
residue was dissolved in DCM (50mL) and the solution concentrated under reduced pressure 
repeating this treatment for three times (3 x 50 mL). The residue was the trifluoroacetic acid 
salt. This material was dissolved in dioxane (60 mL) at 0 °C and a 1 M solution of Na2CO3 (40 mL) 
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was added. After stirring the mixture for 10 minutes, a white precipitate was formed. Benzyl 
chloroformate (432 mg, 2.5 mmol, 1.1 eq.) was added and the solution stirred and allowed to 
warm up at room temperature over 12 h. Water (150 mL) was added and the aqueous layer 
acidified with citric acid and then extracted with DCM (3 x 100 mL) to afford the crude product, 
which was purified by cristallisation (1:1 v/v hexane and AcOEt, 15 mL as eluant). Yield: 75% wt. 
White solid. 1H NMR (200 MHz, CDCl3) (δ = ppm): 7.30 (m, 15H), 5.21 (s, 2H), 5.10 (s, 2H), 5.02 
(s, 2H), 4.35 (m, 1H), 3.96 (m, 2H), 1.69 (m, 4H). 
Synthesis of 3Z-Arg-Gly-OtBu: 
To a stirred solution of 3Z-Arg-OH (1.27 g, 1.7 mmol, 1 eq.), HBTU (1.04 g, 2.75 mmol, 1.6 eq.), 
TEA (870 mg, 6.8 mmol, 4 eq.), DMAP (24 mg, 0.2 mmol, 0.1 eq.) in 10 mL of a 9:1 v/v mixture 
of DCM and DMF, H2N-Gly-OtBu (287 mg, 1.2 mmol, 1 eq.) was added in 20 min. The mixture 
was stirred overnight at room temperature and then treated with water (10 mL), with a 
saturated solution of citric acid (10 mL), with an aqueous 0.1 M solution of NaOH (10 mL) and 
finally with water (10mL). The product was obtained in a pure state after column 
chromatography on silica gel (mesh 70-230), eluting with a 9/1 v/v mixture of DCM/AcOEt. 
Yield: 72% wt. White solid. 1H NMR (300 MHz, CDCl3) (δ = ppm): 9.45 (bs, 1H), 9.31 (bs, 1H), 
7.30 (m, 15H), 6.90 (bs, 1H), 6.10 (bd, J = 8.1 Hz, 1H), 5.22 (s, 2H), 5.09 (m, 4H), 4.34 (bt, J = 7.8 
Hz, 1H), 4.10 (m, 2H), 3.73 (dd, J = 4.9, 18.6 Hz, 1H), 3.40 (dd, J = 4.9, 17.8 Hz, 1H), 1.71 (m, 4H), 
1.41 (s, 9H). 
 Synthesis of 3Z-Arg-Gly-OH: 
550 mg (0.8 mmol, 1 eq.) of 3Z-Arg-Gly-OtBu were dissolved in 10 ml of DCM and 550 µL (8 
mmol, 10 eq.) of H3PO4 85% were added dropwise at room temperature. The mixture was 
stirred for 4 h, monitoring the complete disappearance of the reagent in the organic phase, 
then, 10 mL of water were added. A white solid precipitated which was filtered, collected and 
dried at reduce pressure affording 230 mg (0.4 mmol) of the title product. The organic phase 
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was washed again with water (10 mL), dried over MgSO4 and filtered. Evaporation of the 
solvent gave further 200 mg (0.3 mmol) of product. Yield: 85% wt. White solid. 1H NMR (300 
MHz, DMSO) (δ = ppm): 9.13 (bs, 2H), 8.16 (t, J = 5.6 Hz, 1H), 7.35 (m, 15H), 5.21 (s, 2H), 5.04 (s, 
2H), 4.99 (s, 2H), 4.02 (bt, J = 6.5 Hz, 1H), 3.83 (m, 2H), 3.68 (dd, J = 5.6, 17.5 Hz, 2H), 1.55 (m, 
4H). 
Synthesis of Boc-Asp(OBn)-NHProp: 
To a stirred solution of Boc-Asp(OBn)-OH (2.00 g, 6.2 mmol, 1 eq.), propargylamine (510 mg, 6.8 
mmol, 1.1 eq.), TEA (2.50 g, 25.0 mmol, 4 eq.) and DMAP (76 mg, 0.62 mmol, 0.1 eq.) in 100 mL 
of a 95:5 v/v mixture of DCM and DMF, under a nitrogen atmosphere, 2.82 g (7.4 mmol, 1.2 eq.) 
of HBTU were added and the mixture stirred at room temperature overnight. The mixture was 
treated with a saturated solution of citric acid (100 mL), with a 0.1 M aqueous solution of NaOH 
(100 mL) and finally with water (100 mL). The product was obtained in a pure state after flash 
column cromatography on silica gel (mesh 230-400), eluting with a 97:3 v/v mixture of DCM 
and EtOH. Yield: 62% wt. Yellow oil. 1H NMR (200 MHz, CDCl3) (δ = ppm): 7.35 (m, 5H), 6.72 (bs, 
1H), 5.66 (bs, 1H), 5.14 (s, 2H), 4.53 (m, 1H), 4.02 (dd, J = 2.5, 5.3 Hz, 2H), 3.07 (dd, J = 4.5, 17.2 
Hz, 1H), 2.73 (dd, J = 6.2, 17.1 Hz, 1H), 2.22 (t, J = 2.5, 1H), 1.46 (s, 9H); FAB-MS 361 (M+H)
+. 
Synthesis of H2N-Asp(OBn)-NHProp: 
1.30 g (3.6 mmol, 1eq.) of Boc-Asp(OBn)-NHProp were dissolved in 50 mL of DCM and 7 mL (36 
mmol, 10 eq.) of H3PO4 85% were slowly added. After stirring the mixture for 4 h, it was diluted 
with 50 mL of water and the aqueous phase neutralized first with a saturated NaHCO3 solution. 
then the pH was brought to 8.5 by addition of 1M NaOH. The aqueous layer was then extracted 
with DCM (3 x 50 mL) and the combined organic layers were dried over MgSO4 and filtered. 
Removal of the solvent afforded the pure product. Yield: 99% wt. Yellow oil. 1H NMR (300 MHz, 
CDCl3) (δ = ppm): 7.60 (bs, 1H), 7.34 (m, 5H), 5.14 (d, J = 2.3 Hz, 2H), 4.03 (m, 2H), 3.72 (dd, J = 
3.0, 8.1 Hz, 2H), 3.00 (dd, J = 3.9, 16.9 Hz, 1H), 2.71 (dd, J = 8.1, 16.9 Hz, 1H), 2.21 (t, J = 2.6, 1H). 
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Synthesis of 3Z-Arg-Gly-Asp(OBn)-NHProp: 
3Z-Arg-Gly-OH (200 mg, 0.32 mmol, 1 eq.) was dissolved in 10 mL of DMF under nitrogen 
atmosphere, then in a sequence TEA (130 mg, 1.28 mmol, 4 eq.), DMAP (4 mg, 0.03 mmol, 0.1 
eq.) and HBTU (133 mg, 0.35 mmol, 1.1 eq.) were added; after 15 minutes stirring, H2N-Asp-NH-
Prop (97 mg, 0.35 mmol, 1.1 eq.) was added and the reaction was stirred overnight at room 
temperature. The crude mixture was concentrated to a final volume of 1 mL, then 25 mL of 
DCM were added and the organic phase washed with a saturated solution of citric acid (10 mL), 
with a saturated solution of NaHCO3 (10 mL) and with water (10 mL). The organic layer was 
dried over MgSO4, filtered and the solvent removed under reduce pressure. The product was 
purified by flash cromatography on silica gel (mesh 230-400), eluting with a 97/3 v/v mixture of 
DCM/EtOH. Crystallisation from DCM afforded the pure title compound. Yield: 18% wt. White 
solid. 1H NMR (300 MHz, DMSO) (δ = ppm): 9.13 (bs, 1H), 7.35 (m, 20H), 5.21 (s, 2H), 5.06 (s, 
2H), 5.03 (s,2H), 4.99 (s, 2H), 4.68 (m, 1H), 4.01 (m, 1H), 3.83 (m, 2H), 3.82 (d,  J = 2.3 Hz, 2H), 
3.70 (m, 2H), 3.07 (t, J = 2.3 Hz, 1H), 2.81 (dd, J = 7.7, 16.1 Hz, 1H), 2.58 (dd, J = 7.8, 16.1 Hz, 1H), 
1.56 (m, 4H); FAB-MS 877 (M+H)+. 
2.4.2.3.5 Synthesis of 3Z-Arg-Gly-OProp: 
To a stirred solution of 3Z-Arg-Gly-OH (200 mg, 0.25 mmol, 1 eq.) and propargyl alcohol (30 mg, 
0.50 mmol, 2 eq.) in 8 mL of dry DMF, under nitrogen atmosphere, HBTU (105 mg, 0.28 mmol, 
1.1 eq.), DMAP (3 mg, 0.025 mmol, 0.1 eq.) and TEA (100 mg, 1.0 mmol, 4 eq.) were added. The 
reaction was stirred overnight at room temperature, then the solvent removed and the crude 
residue suspended in 20 mL of a saturated solution of citric acid and extracted with DCM (15 
mL x 3). The combined organic layers were dried over MgSO4 and filtered, the solvent removed 
and the resulting oil purified by cromatographyc on a silica gel column (70-230 mesh), eluting 
with a 97:3 v/v mixture of DCM and EtOH. Yield: 32% wt. White solid. 1H NMR (400 MHz, CDCl3) 
(δ = ppm): 9.40 (bd, 1H), 7.31 (m, 15H), 5.23 (s, 2H), 5.10 (m, 4H), 4.70 (d, J = 2.3 Hz, 0.7H), 4.62 
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(d, J = 2.3 Hz, 1.3H), 4.39 (m, 1H), 4.26 (t, J = 4.8 Hz, 1H), 4.10 (m, 1H), 3.81 (m, 1H),  3.70 (t, J = 
4.8 Hz, 1H), 2.48 (t, J = 2.3 Hz, 0.4H), 2.42 (t, J = 2.3 Hz, 0.6H), 1.69 (m, 4H); ESI-MS 694 (M+Na)+. 
2.4.2.3.6 Synthesis of Boc-Arg(Z)2-OTEG-OProp: 
Synthesis of TEG-OTs:47 
To a stirred solution of 6.01 g (40 mmol, 4 eq.) of triethylene glicole (TEG) and 2.00 g of TEA (20 
mmol, 2 eq.) in 50 ml of DCM, 1.91 g (10 mmol, 1 eq.) of tosyl chloride (TsCl) were added in a 
single portion and Tte mixture stirred at room temperature for 6 h. The mixture was treated 
with a 1M HCl solution (3 x 50mL), then with a saturated NaHCO3solution (1 x 50 mL). The 
organic layer was dried over Na2SO4, filtered and the solvent removed under reduced pressure. 
The product was purified by chromatography on a silica gel column using a 95:5 v/v mixture of 
DCM and MeOH as eluant. Yield: 50% wt. Yellow oil. 1H NMR (300 MHz, CDCl3) (δ = ppm): 7.80 
(d, J = 8.2 Hz, 2H), 7.30 (d, J = 8.2 Hz, 2H), 4.17 (t, J = 4.6 Hz, 2H), 3.70 (m, 4H), 3.62 (m, 4H), 3.59 
(t, J = 4.9 Hz, 2H), 2.44 (s, 3H), 2.00 ( bs, 1H);  13C NMR (300 MHz; CDCl3) (δ = ppm): 144.78, 
132.80, 129.73, 127.79, 72.39, 70.59, 69.07, 68.52, 61.51, 21.46; FT-IR (cm-1): 3423, 2921, 2874, 
1598, 1453, 1355, 1189, 1176, 1122, 1097, 1068, 1017, 923, 818, 776, 664, 554; EI-MS 305 
(M+H)+. 
Synthesis of TEG-OProp:48 
A solution of 90 mg (1.6 mmol, 1 eq.) of propargyl alcohol in 5 mL of dry THF was cooled to –78 
°C under nitrogen atmosphere. Then, 1 mL (1.6 mmol, 1 eq.) of buthyllitium (1.6 M in hexane) 
was slowly added, keeping the temperature below -70 °C. After 5 minutes, 500 mg (1.6 mmol, 1 
eq.) of TEG-OTs dissolved in 1 mL of dry DMF were added. The mixture was left to warm up to 
room temperature and stirred overnight. The reaction was quenched with 1 ml of distilled 
water, then the mixture was dried over Na2SO4, filtered and the solvent removed under 
reduced pressure. The pure product was obtained after flash cromatography over a silica gel 
 
Chemical Modification of the Hyaluronic Acid 
 
 
______________________________________________________________________________ 
94 
column (230-400 mesh), using a 98:2 v/v mixture of DCM and MeOH as eluant. Yield: 37% wt. 
Yellow oil . 1H NMR (200 MHz, CDCl3) (δ = ppm): 4.20 (d, J = 2.4 Hz, 2H), 3.67 (m, 10H), 3.62 (t, J 
= 5.2 Hz, 2H), 2.44 (t, J = 5.2 Hz, 1H);  13C NMR (300 MHz; CDCl3) (δ = ppm): 79.58, 74.81, 72.66, 
70.60, 70.30, 69.08, 61.64, 28.40; FT-IR (δ = cm-1): 3282, 2873, 2114, 1941, 1642, 1459, 1351, 
1290, 1249, 1176, 1095, 1033, 925, 886, 839, 665; FAB-MS 189 (M+H)+. 
Synthesis of Boc-Arg(Z)2-TEG-OProp: 
To a stirred solution of TEG-OProp (50 mg, 0.27 mmol, 1 eq.), Boc-Arg(Z)2-OH (144 mg, 0.27 
mmol, 1 eq.) and DMAP (3 mg, 0.03 mmol, 0.1 eq.) in 5 mL of AcOEt at 0 °C a solution of 61 mg 
(0.30 mmol, 1.1 eq.) of DCC in 3 mL of ethyl acetate was added dropwise. The reaction mixture 
was left to warm up to room temperature and stirred for 3 hours and kept overnight at -20 °C. 
The precipitated urea formed from the DCC was filtered and the solvent removed under 
reduced pressure. The residue afforded the title compound which was obtained in a pure state 
after column chromatography on silica gel (70-230 mesh) using a 6:4 v/v mixture of hexane and 
AcOEt as eluant. Yield: 57% wt. Yellow oil. [α]D (c = 0.1 w/v; CHCl3): + 7.165; 
1H NMR (300 MHz, 
CDCl3) (δ = ppm): 7.38 (m, 10H), 5.24 (s, 2H), 5.14 (s, 2H), 4.28 (m, 1H), 4.19 (m, 2H), 4.18 (d, J = 
2.4 Hz, 2H), 3.99 (t, J = 6.7 Hz, 2H), 3.29 (m, 10H), 2.42 (t, J = 2.4 Hz, 1H), 1.54 (m, 4H), 1.41 (s, 
9H); 13C NMR (300 MHz; CDCl3) (δ = ppm): 172.44, 163.82, 160.46, 155.78, 155.36, 136.92, 
134.65, 128.37, 128.31, 127.88, 127.77, 79.71, 79.62, 74.56, 70.53, 70.47, 70.36, 69.04, 68.88, 
68.82, 66.93, 64.18, 58.33, 53.24, 44.15, 29.43, 28.28, 24.28; FT-IR (cm-1): 3390, 3285, 3034, 
2930, 1717, 1644, 1610, 1510, 1455, 1404, 1379, 1367, 1350, 1254, 1167, 1098; FAB-MS 713 
(M)+. 
2.4.2.3.7 Synthesis of Ac-Arg(Z)2-Gly-Asp(OBn)-TEG-OProp:  
Synthesis of N-acetyl-Arg(Z)2-OH:49 
A solution of Boc-Arg(Z)2-OH (900 mg, 1.65 mmol, 1 eq.) in 20 mL of DCM was treated at 0 °C 
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with 20 mL of trifluoroacetic acid (TFA) for 1 h, then the solvent was removed under reduced 
pressure. 5 mL of DCM were added, followed by a further addition of 425 mg (3.3 mmol, 2 eq.) 
of N,N-diisopropylethylamine (DIPEA). The mixture was then treated with acetic anhydride (173 
mg, 1.65 mmol. 1 eq.). After evaporation of the solvent, the residue was purified by column 
chromatography on silica gel (70-230 mesh) using a mixture of DCM/methanol 9/1 v/v as 
eluant. Yield: 31% wt. Colorless oil . [α]D (c = 0.6 w/v; CHCl3): + 5.088; 
1H NMR (300 MHz, CDCl3) 
(δ = ppm): 7.32 (m, 10H), 5.23 (s, 2H), 5.11 (s, 2H), 4.55 (m, 1H), 4.05 (m,1H), 3.80 (m, 1H), 1.80 
(s, 3H), 1.70 (m, 4H); 13C NMR (300 MHz; CDCl3) (δ = ppm): 175.17, 171.69, 163.19, 160.62, 
155.71, 136.31, 134.52, 128.96, 128.88, 128.53, 128.37, 128.22, 69.19, 67.38, 52.88, 44.35, 
26.99, 25.00, 22.56; FT-IR (cm-1): 3387, 2605, 2498, 1714, 1652, 1255, 1097, 1009, 807, 777, 
735, 696; FAB-MS 485 (M)+. 
Synthesis of N-acetyl-Arg(Z)2-Gly-OtBu:  
To a 10 mL solution of N-acetyl-Arg(Z)2-OH (170 mg, 0.36 mmol, 1 eq.) in DCM, TEA (144 mg, 
1.20 mmol, 3.3 eq.) and hydroxybenzotriazole (HOBt, 73 mg, 0.54 mmol, 1.5 eq.) were added 
followed by  the addition of 83 mg (0.43 mmol, 1.2 eq.) of EDCI. After 15 minutes stirring, the 
mixture was treated with 57 mg (0.43 mmol, 1.2 eq.) of H2N-Gly-OtBu. After stirring overnight 
at room temperature, the mixture was washed first with a saturated solution of NaHCO3 (10 
mL), then with a saturated solution of citric acid (10 mL) and finally with brine (10 mL). The 
organic layer was dried over MgSO4, filtered and the solvent evaporated to dryness; the residue 
was purified by chromatography on a silica gel column (70-230 mesh) using AcOEt as eluent. 
Yield: 48% wt. White solid (mp 125-128 °C). [α]D (c = 1.4 w/v; CHCl3): + 16.040; 
1H NMR (300 
MHz, CDCl3) (δ = ppm): 9.51 (bs, 1H), 9.41 (bs (1H), 7.36 (m, 10H), 7.07 (d, J = 7.8 Hz, 1H), 6.97 
(t, J = 5.3 Hz, 1H), 5.23 (s, 2H), 5.13 (d, J = 1.9 Hz, 2H), 4.56 (m, 1H), 4.08 (m, 1H), 3.90 (m, 1H), 
3.79 (dd, J = 17.9, 6.1 Hz, 1H), 3.49 (dd, J = 17.9, 5.0 Hz, 1H), 1.88 (s, 3H), 1.74 (m, 4H), 1.42 (s, 
9H); 13C NMR (300 MHz; CDCl3) (δ = ppm): 171.70, 170.21, 168.47, 163.26, 160.98, 155.78, 
136.34, 135.54, 128.85, 128.62, 128.31, 81.83, 69.11, 67.23, 52.49, 44.24, 41.84, 28.22, 28.03, 
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24.64, 23.03; FT-IR (cm-1): 3371, 3287, 1758, 1725, 1647, 1598, 1548, 1403, 1265, 1251, 1192, 
1152, 1100, 1035, 1010, 981, 938, 910, 848, 822, 811, 776, 697, 666, 639; FAB-MS 598 (M)+. 
Synthesis of N-acetyl-Arg(Z)2-Gly-OH:  
50 mg (0.08 mmol, 1 eq.) of  N-acetyl-Arg(Z)2-Gly-OtBu were dissolved in 10 mL of DCM, then 
85 µL of H3PO4 85% (0.8 mmol, 10 eq.) were added and the reaction was stirred at room 
temperature for 6 h. The mixture was then washed with 15 mL of water. The layers were 
separated and the aqueous one was washed with DCM (3 x 10 mL); the collected organic layers 
were dried over MgSO4 and filtered. Removal of the solvent afforded the pure product. Yield: 
88% wt. White solid. [α]D
25
 (c = 0.5 w/v; MeOH): - 2.228; 
1H NMR (300 MHz, MeOD) (δ = ppm): 
8.10 (t, J = 5.6 Hz, 1H), 7.36 (m, 10H), 5.28 (s, 2H), 5.13 (s, 2H), 4.34 (t, J = 7.8 Hz, 1H), 3.85 (m, 
4H), 1.91 (s, 3H), 1.73 (m, 4H); 13C NMR (300 MHz; MeOD) (δ = ppm): 174.42, 173.28, 172.75, 
164.89, 162.05, 157.00, 138.40, 136.62, 130.21, 129.76, 129.68, 129.49, 129.06, 128.99, 128.22, 
69.81, 68.28, 54.33, 45.62, 41.85, 29.96, 26.11, 22.51; FT-IR (cm-1): 3400, 3281, 1747, 1723, 
1628, 1549, 1507, 1459, 1405, 1555, 1216, 1191, 1177, 1147, 1106, 1092, 1030, 10003, 978, 
931, 907, 807, 781, 6970; FAB-MS 542 (M)+. 
Synthesis of Boc-Asp(OBn)-OTEG-OProp:  
Boc-Asp(OBn)-OH (171 mg, 0.53 mmol, 1 eq.), TEA (162 mg, 1.59 mmol, 3 eq.) and HBTU (241 
mg, 0.64 mmol, 1.2 eq.) were dissolved in 10 mL of a 9/1 v/v mixture of DCM/DMF, under 
nitrogen atmosphere. After 15 minutes, 100 mg (0.53 mmol, 1 eq.) of TEG-OProp were added 
and the reaction was stirred at room temperature overnight. The solvent was removed under 
reduced pressure and the product purified by flash chromatography on a silica gel column (230-
400 mesh) using a 6:4 v/v mixture of hexane and AcOEt as eluant. Yield: 61% wt. Yellow oil. 
[α]D
25
 (c = 1.0 w/v; CHCl3): - 0.030; 
1H NMR (300 MHz, CDCl3): 7.32 (m, 5H), 5.48 (d, J = 7.9 Hz, 
1H), 5.10 (d, J = 1.3 Hz, 2H), 4.58 (m, 1H), 4.24 (td, J = 4.5, 1.9 Hz, 2H), 4.16 (d, J = 2.4 Hz, 2H), 
3.64 (m, 10H), 3.01 (dd, J = 4.8, 16.9 Hz, 1H), 2.87 (dd, J = 4.8, 16.8 Hz, 1H), 2.41 (t, J = 2.4 Hz, 
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1H), 1.42 (s, 9H); 13C NMR (300 MHz; MeOD) (δ = ppm): 171.03, 170.83, 170.52, 135.38, 128.49, 
128.28, 128.18, 79.97, 47.47, 70.47, 70.33, 69.00, 68.69, 66.65, 64.61, 58.27, 50.00, 36.84, 
28.20; FT-IR (cm-1): 3369, 3286, 3065, 3033, 2975, 2873, 2115, 1714, 1499, 1456, 1390, 1366, 
1286, 1249, 1165, 1102, 1048, 1031, 921, 861, 780, 753, 699; FAB-MS 394 (M+H-Boc)+. 
Synthesis of H2N-Asp(OBn)-OTEG-OProp:  
To a stirred solution of Boc-Asp(OBn)-OTEG-OProp (115 mg, 0.29 mmol, 1 eq.) in 2 mL of DCM, 
cooled at 0 °C, 2 mL of TFA were added dropwise. The reaction was allowed to warm up at 
room temperature and stirred for 1.5 h. The pure product was obtained as a trifluoroacetic acid 
salt after removal of the solvent at reduced pressure. Yield: 99% wt. Yellow oil. [α]D (c = 1.0 w/v; 
CHCl3): - 0.166; 
1H NMR (300 MHz, CDCl3): 7.34 (m, 5H), 5.15 (s, 2H), 4.45 (m, 1H), 4.35 (m, 2H), 
4.15 (d, J = 2.3 Hz, 2H), 3.63 (m, 10H), 3.19 (d, J = 4.5 Hz, 2H), 2.46 (t, J = 2.3 Hz, 1H); 13C NMR 
(300 MHz; CDCl3) (δ = ppm): 170.46, 167.37, 160.74 (q, J = 156 Hz), 134.70, 128.69, 128.47, 
115.46 (q, J = 1332 Hz), 78.90, 76.62, 75.30, 70.173, 70.06, 69.87, 68.93, 68.38, 67.85, 65.55, 
58.32, 49.95, 33.40; FT-IR (cm-1): 3448, 3285, 2918, 1752, 1675, 1525, 1456, 1397, 1359, 1306, 
1174, 1029, 949, 839, 798, 753, 723, 702; EI-MS 394 (M+H)+. 
Synthesis of Ac-Arg(Z)2-Gly-Asp(OBn)-OProp:  
To a stirred solution of Ac-Arg(Z)2-Gly-OH (40 mg, 0.074 mmol, 1 eq.) in 2 mL of DMF, under 
nitrogen atmosphere, 70 µg of TEA (0.3 mmol, 4 eq.) and 34 mg of HBTU (0.09 mmol, 1.2 eq.) 
were added. After 20 minutes a solution of H2N-Asp(OBn)-OProp (70 mg, 0.18 mmol, 2.41 eq.) 
in 1 mL of a 1:1 v/v mixture of DCM and DMF was added dropwise. The reaction was stirred at 
room temperature overnight. Yield: 24% wt. Yellow oil. 1H NMR (300 MHz, CDCl3): 7.36 (s, 15H), 
6.56 (d, J = 8.8 Hz, 1H), 5.26 (s, 2H), 5.14 (m, 4H), 4.95 (m, 1H), 4.88 (m, 1H), 4.20 (d,  J = 2.4 Hz, 
2H), 4.16 (m, 1H), 4.01 (m, 1H), 3.65 (m, 16H), 2.43 (t, J = 2.4 Hz, 1H), 1.88 (s, 3H), 1.75 (m, 4H); 
FAB-MS 920 (M+H)+.  
 
Chemical Modification of the Hyaluronic Acid 
 
 
______________________________________________________________________________ 
98 
2.4.3 RESULTS AND DISCUSSION 
As discussed before (See 2.1), chemical modification of HA can be performed at two different 
sites: the carboxylic acid group and the hydroxy group; in the second case it is reasonable to 
assume that reaction occurs on the primary hydroxy of the N-acetylglucosamine moiety, 
because of its better chemical accessibility. Few examples of modification of the HA with 
electrophiles reacting with the primary hydroxy group have been reported.11 In particular, this 
nucleophilic centre is selected as the reacting centre with anhydrides; the synthesis and the 
characterization of two novel haloacetate derivatives of HA in aqueous media has been 
previously reported.26 Specifically, a bromoacetate-derivatised HA was obtained by treating HA 
with bromoacetic anhydride under basic reaction conditions. The reaction procedure is 
characterised by a strict control of the pH, which must be maintained at the value of 9 to 
promote the deprotonation of the primary alcohol (which has a lower pKa respect to the other 
ones), favoring the nucleophilic attack. Furthermore a high reactant (bromoacetic anhydride) 
molar excess is necessary because of the expected side reaction involving the formation of the 
mixed anhydride between bromoacetic anhydride and HA, followed by its hydrolysis to restore 
the HA glucuronic acid carboxy acid group. Hence, the consumption of the anhydride reagent 
reduces the overall possibility of modification of the primary hydroxyl groups.  
We started our work by repeating the reaction described in literature to obtain the 
bromoacetate (HABA) derivative on the HA with the average molecular weight of 235 kDa  
(Scheme 5). 
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Scheme 5: Synthesis of HA-bromoacetate (HABA) 
 
We slightly changed the experimental settings (mainly due to the technical equipment 
required); in fact, while Prestwich et al. maintained the reaction mixture at constant 
temperature of 4 °C all over the course of the reaction, we added freshly prepared bromoacetic 
anhydride at 0 °C and allowed the temperature slowly to rise up to 20 °C. The same changes in 
the 1H NMR spectrum (D2O) as the ones reported in literature were observed. Compared to the 
spectrum of the starting material (Figure 33 A and B), a new broad resonance at 3.97 ppm 
appeared, corresponding to the methylene protons of the bromoacetate group; furthermore, 
the specific pattern of the signal related to the two protons of the methylene group on the 
N-acetylglucosamine moiety was modified. 
The displacement of the bromine is reported in literature with sodium iodide, affording the 
corresponding iodoacetic derivative (HAIA). HABA and HAIA display different reactivities with 
thiols as nucleophiles and both polymers have already been investigated in biological assays. 
We decided to take advantage of the good reactivity of HABA towards nucleophiles, to insert an 
azido group by reaction with sodium azide via an SN2  nucleophilic substitution (Scheme 6).  
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Scheme 6: Synthesis of HA-azidoacetate (HAAA) 
 
Thanks to the complete solubility of HABA in water, we could perform the substitution reaction 
without the addition of other salts, simplifying the purification process. We used a large molar 
excess of sodium azide to ensure the complete conversion in 24 hours. The final product could 
be recovered in a pure state after dialysis followed by freeze-drying. The progress of the 
reaction could be confirmed by IR analysis, by monitoring the appearance of the typical azide 
band at 2150 cm-1 (Figure 33 D). Else more the 1H NMR of the sample, compared with the 
spectrum of the precursor, (Figure 33 B and C) showed that the peak corresponding to the 
methylene protons of the haloacetate group (at 3.97 ppm) completely disappeared. To the best 
of our knowledge this is the first example of insertion of an azide onto the HA backbone by a 
SN2 reaction; previous examples, in fact, reported the use of bifunctional molecules featuring 
both an azide and an amino group suitable for condensation with the HA through the usual 
coupling reagents, e.g. carbodiimides.39,50 Thus, our strategy did not require the use of both 
sophisticated molecules, such as the namino-azides, and the excess of expensive reagents, such 
as the carboxy-activating agents, with remarkable advantage for atom economy.51 
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Figure 33: 1H NMR spectra of HA, HABA, HAAA and FT-IR spectrum of HAAA 
A: 
1
H NMR spectrum of HA (D2O, 400 MHz) showing two signals at 4.60 and 4.50 ppm due to the methylene close 
to the primary alcohol, broad signals from 3.89 to 3.39 of the protons on the glucosaminic and glucuronic rings and 
a singlet at 2.07 ppm relative to the acetamide moiety. B: 
1
H NMR spectrum of HABA (D2O, 400 MHz) where a new 
peak of the methylene protons of the bromoacetate group appeared at 3.97 ppm. C: 
1
H NMR spectrum of HAAA 
(D2O, 400 MHz) showing no more traces of the peak at 3.97 ppm. D: FT-IR spectrum of HAAA, the broad spectrum 
relative to the polymer features a new band at 2150 cm
-1
 relative to the stretching vibrations of the azide. 
 
The presence of the azide group on the HA skeleton allowed us to perform the Sharpless 
cycloaddition reaction, initially tested with propargyl alcohol, which is the model reagent for 
this transformation (Scheme 7).  
FT-IR spectrum confirmed the absence of the azido group in the product, meaning that it had 
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completely reacted, affording the triazole heterocycle. In addition, thanks to the use of this 
small and hydrophilic alkyne, we ensured the water-solubility of the product, which was then 
analysed by 1H NMR in D2O (Figure 34). In the NMR spectrum, the signal related to the aromatic 
proton of the triazole ring could be easily individuated and, from its integration, it was possible 
to calculate the degree of substitution, defined as modified groups per 100 disaccharide units. 
Specifically, both the ratio between the integral of the aromatic proton and the signal of the 
methyl group and the area of the peaks between 4.10 and 3.30 ppm were found in agreement 
with a substitution level of the 4%, which is an optimal value considering that the modification 
of more than the 10% of monomeric units of HA , invariably produces undesired effects on the 
biocompatibility of the substrate. 
Furthermore we tested the biological effects promoted by the insertion of this new functional 
group on the HA in vitro, on human pericyte-derived cells (See 2.5). 
 
 
 
Scheme 7: Sharpless cycloaddition with HAAA and propargyl alcohol 
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Figure 34: 1H NMR spectrum of HA-TR1 
1
H NMR spectrum of HA-TR1 (D2O, 400 MHz) showing a new aromatic signal at 7.36 ppm relative to the proton on 
the triazole ring.  
 
We repeated the copper catalysed cycloaddition with the benzoate of the propargyl alcohol 
described before (Scheme 8). The aim was, on the one hand, to have an even more precise 
indication of the degree of substitution and, on the other hand, to extend the scope of the 
reaction to more hydrophobic alkyne-containing compounds by using the same protocol.  
Again, we have been able to confirm the reactivity of the azide group in click reactions 
following the disappearance of the peak at 2150 cm-1 in the IR spectrum. After purification by 
dialysis, the product was found not completely soluble in water; hence, we did not observe two 
distinct 1H NMR signals for the different aromatic protons, as we were expecting for a better 
determination of the degree of substitution. The addition of 10% v/v deuterated DMSO did not 
help to complete solubilised the product.   
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Scheme 8: Synthesis of propargyl benzoate and its use in the Sharpless cycloaddition with HAAA 
 
We then directed our attention to the reactions of bioconjugation between HA and precursors 
of aminoacidic sequences, in order to investigate the versatility of this strategy and to extend 
its use to a plethora of compounds capable to be further modified directly on the HA scaffold. 
Our idea was to provide a versatile tool to be used with different bioactive compounds such as 
peptides, fatty acids, steroids, drugs. Furthermore the in situ modification could open the way 
to the design of a multifunctionalised HA, bearing different molecules as pendants in order to 
produce a synergic biological effect. 
The synthesis of a fully protected tripeptide was accomplished as shown in Scheme 9.  
We selected the tripeptide composed by Arginine-Glycine-Aspartate (RGD) because of it 
biological importance in mediating and regulating processes like cell adhesion, angiogenesis, 
apoptosis and cell migration.52-54  
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Furthermore, our aim was that to investigate whether it were possible to carry out some benzyl 
group deprotection reactions by heterogeneous hydrogenation directly on the HA derivative; 
hence, we designed a molecule featuring protecting groups labile in front of reductive cleavage.   
For the synthesis or the RGD precursor, we first prepared three properly functionalised amino 
acids. Then, we formed the new amidic bonds using one of the most popular in situ activation 
reagents in solid and solution phase peptide synthesis, that is the HBTU. In addition to the high 
reactivity, HBTU has also been shown to limit epimerization during condensation and during 
DMAP catalyzed functionalisation. 
We tried also to synthesise a RGD sequence that could be selectively deprotected at the 
N-terminus of the arginine to undergo further functionalisation with an alkyne. Unfortunately, 
the coupling reaction between the arginine unit and the fragment containing the glycine and 
the aspartate moiety failed (See Supporting Information 2.8.1.1).  
Trying to graft the RGD-alkyne containing sequence on the HAAA, we changed the commonly 
used protocols, to avoid the necessity of using a large excess of reagent; thus, in order to 
balance the kinetic of the reaction, we used twice the amount of catalyst present in the 
reaction medium, i.e. respectively 0.2 eq. of CuII and 1.0 eq. of ascorbate respect to the 
monomeric unit of HA. We found, however, that even after two days the formation of the 
desired product did not occour: the click-reaction probably failed because of the poor solubility 
of the peptide in water. 
 To overcome this problem, we investigated two different strategies.  
The first one contemplated the transformation of the HAAA into its tetrabutylammonium salt, 
replacing the sodium cation, in order to promote its solubility in organic solvents (e.g. dimethyl 
sulfoxide or dimethylformamide) in which the peptide exhibits a good solubility; at this point 
the cycloaddition could be performed in a mixture of water and organic solvent. 
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The second strategy was based on the assumption that a water-soluble linker could promote 
the accessibility of the alkyne and then the development of the conjugation reaction.  
 
Scheme 9: Synthesis of a protected precurson of the RGD sequence featuring a terminal alkyne 
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To examine the feasibility of the first pathway, we started with the synthesis of a fully 
protected dipeptide bearing a terminal propargyl ester (Scheme 10). Specifically derivatives of 
arginine and glycine were used to prepared a compound carrying protecting groups removable 
by heterogenous hydrogenation, and with solubility not very different from that of the 
tripeptide presented in Scheme 9, but synthesised through a reduced number of steps.   
Conversion of the sodium salt of the HAAA into its tetrabutylammoniu salt was accomplished 
using a sulphonic ion-exchange polystyrenic resin (Dowex® 50WX-8-40). The procedure used for 
this purpose has already been reported for HA9 and allows the synthesis of a polymer soluble in 
organic solvents (i.e. DMF and DMSO) in high yields, in short times and under mild conditions. 
We were then able to perform the Sharpless cycloaddition reaction in a mixture of water and 
DMSO (1:1.5 v/v): we maintained the amount of catalyst and antioxidant used at the beginning 
(i.e. 0.5 eq. of CuII and 1.0 eq. of sodium ascorbate respect to the monomeric unit of HA) and 
0.2 eq. of the alkyne. After two days, we added a large excess of propargyl alcohol to ensure 
that all the azido groups on the polymer had been transformed. We checked the sample by IR, 
by drying a small sample under vacuum. As we were expecting, the peak relative to the azide 
progressively disappeared. Then, we removed the catalyst by dialysis; hence, we decided to 
directly submit the sample to heterogenous hydrogenation in order to avoid manipulations of 
the poorly soluble sample. Specifically, deprotection was accomplished with Palladium on 
activated charcoal as catalyst, with a 1:1 mixture of water and methanol as solvent and a 
positive pressure of hydrogen (6 bar) to ensure the complete deprotection. To the best of our 
knowledge, this is the first example of a successful heterogenous hydrogenation on HA 
derivatives. The product was purified by filtration to remove the solid catalyst and then by 
dialysis, which allowed also the reconversion of the product into the sodium salt (Scheme 10). 
The aqueous solution of the final adduct resulted completely clear and could be analysed by 1H 
NMR (Figure 35); the spectrum confirmed the presence of the arginine residue: in fact, a 
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multiplet related to the two methylene groups in β and γ position clearly appeared between 
1.75 and 1.60 ppm. We could observe, however, also several peaks in the aromatic and benzylic 
region, indicating that the deprotection was probably not complete, or some impurities were 
still present in the sample. Furthermore, we could recover only the 40% of the initial weight; 
this was probably an indication that or the hydrolysis leading to smaller polymeric fragments 
(lost during dialysis) occurred, or part of the product was not soluble and was consequently lost 
during the filtration over celite, necessary to remove the Palladium catalyst. 
We concluded that, even if this method could offer new hints, demonstrating that the Sharpless 
cycloaddition on HA can be performed in mixed (aqueous/organic) solvents in the presence of 
scarsely soluble reagents, the experimental set needs to be more deeply studied and improved, 
since deprotection and sample recovery was found lacking in efficiency. 
Thus, we focused our attention on the second pathway presented before, in order to see if 
those conditions are more favourable for chemically modifying the HA.          
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Scheme 10: Synthesis of HA-TR3 
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Figure 35: 1HNMR spectrum of HA-TR3 
1
H NMR (D2O, 400 MHz, solvent peak suppression) showing a multiplet between 1.75 and 1.60 ppm, related to the 
two methylenes in β and γ position of the arginine, and several aromatic and benzylic signals. 
 
The second strategy devised to overcome the problems caused by the poor solubility in water 
of the protected aminoacids and of their HA-conjugates, contemplated the use of a fragment of 
triethylene glycol as water-soluble linker between the triple bond and the peptide. Our aim was 
to promote the accessibility of the terminal alkyne in aqueous media. For this purpose, a 
bifunctional linker featuring a terminal alkyne and an alcoholic function suitable for further 
functionalisations, e.g. esterification with carboxylic acids, was synthesised as shown in Scheme 
11.  
The core constituted by the triethylene glycol was mono-activated as tosylate and the 
nucleophilic substitution effected with tha anion of propargyl alcohol afforded the desired 
product. We tried both NaH and nBuLi to generate the alcoxyde and the use of the alchyllitium 
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as the base gave better yields,  the 37%, while the 25% yield was obtained with NaH.  
 
 
 
Scheme 11: Synthesis of the water soluble linker featuring a terminal alkyne 
   
The linker was coupled with a protected arginine residue by esterification mediated by DCC as 
activating agent, in order to provide a simple compound characterised by two fragments with 
different solubility in water (Scheme 12).  
HA was successfully conjugated with a unit of the protected arginine through a copper(I) 
catalyzed reaction; in this case the reaction was carried out in water solution effected by 
maintaining the sodium as the counter ion of the biopolymer. After dialysis, carried out to 
remove the salts from the solution, it was possible to verify from the 1H NMR spectrum the 
success of the reaction by recognizing and estimating two aromatic signals, one related to the Z 
protecting groups (7.39 ppm) and the other to the triazole unit (8.40 ppm) (Figure 36).  
Deprotection from the Z protecting groups was effected by heterogeneous hydrogenation using 
water as solvent (Scheme 12). In this case the mass recovery of the product was excellent (85% 
wt) and the purity of the product, extimated by 1H NMR, satisfactory as well; in fact, only one 
signal was still present at 8.50 ppm, indicating that the Z protecting groups had been 
completely cleaved and, moreover, that removal of the residues was successfully accomplished. 
Furthermore, the complete solubility in water of the final product allowed us to perform the 
purification of the product from the catalyst through a simple filtration. 
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Interestingly we did not observe any signal for the Boc protecting group neither in HA-TR4 nor 
in HA-TR5; hence, we concluded that the reaction medium was acid enough, due to the 
presence of ascorbic acid and HA, to promote its hydrolysis.   
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Scheme 12: Synthesis of protected arginine functionalised with the water-soluble linker and a 
terminal alkyne and of the HA conjugates HA-TR4 and HA-TR5 
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Figure 36: 1HNMR of HA-TR4 
1
H NMR (D2O, 300 MHz, solvent peak suppression) showing two well different aromatic signals: one at 8.40 ppm 
(hydrogen atom on the triazole ring) and one at 7.39 ppm (protons on the phenyl groups of the Z protecting 
groups). 
 
Once proven the feasibility of the synthetic pathway, a new more complete scheme, affording 
the RGD peptide decorated with the previously reported linker was optimized and the best 
experimental conditions are reported in Scheme 13. 
In detail, the N-terminus of the arginine was protected as acetyl derivative in order to have a 
stable moiety mimicking a peptidic bond. All the new amidic bond have been formed by using 
HBTU as the coupling reagent and TEA as the organic base. The last reaction between the two 
fragments, one containing the arginine and the glycine and the other one containing the 
aspartate and the linker, showed to be particularly challenging; different coupling reagent, i.e. 
HBTU, DCC, EDCI used in combination with HOBt, and solvents, i.e. DCM and DMF and their 
 
Chemical Modification of the Hyaluronic Acid 
 
 
______________________________________________________________________________ 
115 
mixture, were used, but the best yield we could attain was the 24% wt, after careful purification 
by column chromatography.  
The final product featured protecting groups labile in front of the heterogenous hydrogenation. 
In conclusion, we found a reliable synthetic pathway affording, with yields ranging from 
moderate to good, the protected tripeptide composed by arginine, glycine and aspartic acid, 
functionalised with a chain of triethylene glycol bearing a terminal triple bond as useful 
precursor to be linked to the HA scaffold via a classical click cycloaddition catalysed by CuI.  
 
Scheme 13: Synthesis of the protected RGD sequence bearing a water soluble linker with a terminal 
alkyne functionality 
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2.4.4 CONCLUSION 
Bioconjugation between HA and bioactive compounds is a key point in the development of 
hydrogels for tissue engineering. We explored the versatility of the 1,3-dipolar cycloaddition 
reaction catalysed by CuI to “click” on the HA scaffold different terminal alkynes, both 
hydrophilic and hydrophobic, tryng to develope a methodology applicable to a wide variety of 
compounds. We were interested as well in the modification of these active molecules directly 
on the conjugate derivative, in order to allow the design of a strategy contemplating the 
insertion of different peptides, fatty acid, grown factors… with a specific architecture. 
A new strategy toward the functionalization of the HA with an azido group has been devised. 
Specifically, the primary hydroxyl group in the HA repeating unit was selected as the reacting 
centre with electrophilic species like anhydrides. The synthesis and the characterization of the 
HA bromoacetate derivative (HABA) had been previously reported.26 We took advantage from 
this derivative to insert an azido group by reaction with sodium azide via an SN2  nucleophilic 
substitution. The progress of the reaction could be monitored by IR analysis through the growth 
of the typical azide band at 2150 cm-1.  
The presence of this group in HA allowed us to perform a Sharpless cycloaddition reaction, 
initially tested with propargyl alcohol, which is the classical model reagent for this 
transformation. The substitution degree was initially estimated by examining the 1H NMR 
spectra: the ratio between the integral of the aromatic proton of the triazole ring and the signal 
of the methyl group were indicative of a 4% substitution level.  
In order to have an even more precise indication, a derivate bearing more aromatic signals was 
prepared by reaction of the azido derivative with the benzoate of the propargyl alcohol; in this 
case, however, we found that the adducts with hydrophobic molecules display a poor solubility 
in water.  
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Our attention has been focused on the introduction of the RGD (Arginine-Glycine-Aspartate) 
motif in order to promote cells adhesion on the hydrogel. Hence the precursor of this sequence 
bearing a terminal alkyne has been synthesised, but the click-reaction failed probably because 
in aqueous environment the peptide was not completely soluble. 
Even using the tetrabutylammonium salt of the HA and a mixture of DMSO and water we were 
not able to isolate the pure desired product in a pure state. 
To overcome this problem, a water soluble linker based on a triethylene glycol core bearing a 
terminal alkyne was synthesized. 
HA was successfully conjugated with a unit of protected arginine through a CuI catalysed 
reaction; deprotection from the Z protecting groups was completed by heterogeneous 
hydrogenation. From the 1H NMR spectra it was possible to verify the success of the reaction by 
recognizing and estimating the two aromatic signals, one relative to the Z protecting groups 
and the other to the triazole unit. 
Once proven the feasibility of the synthetic pathway, a new more complete scheme affording 
the RGD peptide decorated with the water-soluble linker was optimized. 
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2.5 PROLIFERATION AND DIFFERENTIATION OF 
MESOANGIOBLASTS ON HYALURONAN DERIVATIVES 
2.5.1 INTRODUCTION 
Regenerative medicine is the process of creating living, functional tissues to repair or replace 
tissue or organ functions lost due to age, disease, damage, or congenital defects. This field 
holds the promise of regenerating damaged tissues and organs in the body by stimulating 
previously irreparable organs to heal themselves. Regenerative medicine also empowers 
scientists to grow tissues and organs in the laboratory and safely implant them when the body 
cannot cure itself. Importantly, regenerative medicine has the potential to solve the problem of 
the shortage of organs available for donation compared to the number of patients that require 
life-saving organ transplantation. Regenerative medicine is essentially focused on human cells. 
These may be somatic, adult stem or embryo-derived cells.55 
Related to regenerative medicine, the field of tissue engineering has developed to meet the 
tremendous need for organs and tissues. Numerous strategies currently used to engineer 
tissues depend on employing a specific, both organic and inorganic, material. These scaffolds 
serve as a synthetic extra cellular matrix (ECM) to organize cells into a three-dimensional 
architecture and to present stimuli, which direct the growth and the formation of a desired 
tissue. Depending on the tissue of interest and on the specific application, the required material 
used as the scaffold and its properties are quite different.32,56 
Recent work has suggested application of mesoangioblasts for stem cell therapies for muscular 
dystrophy. Experiments in dystrophic mice have shown that mesoangioblasts transplantation 
can restore muscle function.57,58 More recently, mesoangioblast transplantion was used to 
ameliorate the effects of muscular dystrophy in golden retrievers with a congenital muscular 
dystrophy.59 
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Mesoangioblasts are multipotent progenitors of mesodermal tissues, and are physically 
associated with the embryonic dorsal aorta in avian and mammalian species. They have in 
common the anatomical location, the expression of endothelial and/or pericyte markers, the 
ability to proliferate in culture and the ability to undergo differentiation into various types of 
mesoderm cells upon proper culture conditions. Their ability to extensively self-renew in vitro, 
while retaining multipotency, qualiﬁes mesoangioblasts as a novel class of stem cells. When 
transplanted in vivo, they give rise to multiple differentiated mesodermal phenotypes.60 Since 
the corresponding human cells, more precisely defined as “pericyte-derived cells”, have been 
recently isolated and characterised, a clinical trial with these cells is planned in the near 
future.61 
Anyway, the possibility of using this novel strategy for the cell therapy in genetic diseases is 
strictly related to the capacity to expand mesoangioblasts in culture in a reproducible and 
efficient way. That is why our aim is to investigate the ability of the HA to act as a basement for 
cells culture; cells are in fact very sensitive to their environment and  the contact with 
something mimicking the ECM could, in theory, assure a better proliferation and 
differentiation. 
Hyaluronic acid (HA) which is the simplest glycosaminolglycan (GAG) is found in nearly every 
mammalian tissue and fluid. Its presence is especially prevalent during wound healing and in 
the synovial fluid of joints. HA is a linear polysaccharide characterized by a repeating unit 
constituted by the disaccharide of (1-3) and (1-4)-linked β-D-glucuronic acid and N-acetyl-β-
glucosamine units.6  
A variety of chemical modifications of native hyaluronan have already been devised to provide 
new materials. The resulting hyaluronan derivatives have physicochemical properties that may 
significantly differ from the native polymer, but most derivatives retain the biocompatibility 
and biodegradability and, in some cases, the pharmacological properties of native 
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hyaluronan.11  
We have taken advantage of this attractive building block for preparing new polymers; hence 
several different methods to provide modified HA have been performed in order to develop 
robust protocols to be used either to introduce drugs, ligands or other bioactive molecules 
retained to play an important role in cells proliferation and differentiation, or to cross-link the 
linear chains affording reticulated networks with defined mechanical properties and increased 
resistance to clearance (See 2.2, 2.3, 2.4).     
Human pericyte-derived cells were cultured using HA and its derivatives as substrates to 
evaluate their biological influence on in vitro proliferation and differentiation. 
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2.5.2 EXPERIMENTAL PROCEDURES   
2.5.2.1 Materials 
Sodium Hyaluronate (HA) RESILEN-200 (average molecular weight 235 kDa) was gently supplied 
by Kyowa Italiana Farmaceutici s.r.l. (Milan, Italy). HA derivatives were synthesised as 
previously reported (See 2.2.2, 2.3.2, 2.4.2). 
Megacell DMEM, fetal bovine serum, glutamine, non-essential amino acids, trypan blue, 
penicillin and streptomycin were purchased from Sigma (Milan, Italy). Human basic fibroblast 
growth was purchased from Peprotech (Milan, Italy). β-Mercaptoethanol was purchased from 
GIBCO (Milan, Italy).  Reduced growth factors Matrigel was purchased from BD Biosciences 
(Milan, Italy) and prepared as previously reported.61 
2.5.2.2 Proliferation and differentiation of pericyte-derived cells on HA derivatives 
2.5.2.2.1 Isolation and culture of human adult pericyte-derived cells 
Cells were isolated from non-dystrophic patients undergoing diagnostic biopsy as previously 
reported.61 Briefly, tissue fragments were cultured for 7-8 days. After the initial outgrowth of 
fibroblast-like cells, small round and refractile cells were observed. Because of their poor 
adhesion (many of these cells were floating), this cell population was easily collected by gently 
pipetting the original culture and was plated on petri dishes at a density of 5·104 cells per 30-
mm dish. The medium consisted of MegaCell DMEM supplemented with 5% fetal bovine serum, 
5 ng ml-1 basic fibroblast growth factor, 2 mM glutamine, 0.1 mM β-mercaptoethanol, 1% non 
essential aminoacids, 100 IU ml-1 penicillin and 100 mg ml-1 streptomycin. 
2.5.2.2.2 Analysis of cell proliferation 
Cells were plated at a density of 5·103 cells per cm2 on different substrates, and passed on 
average every three days. At each passage, the number of cells was counted in triplicate: cells 
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isolated from enzymatic digestion were stained with Trypan blue, and living cells were counted 
in a haemocytometer.  
2.5.2.2.3 Differentiation assays  
Cells undergoes differentiation following previously reported protocols.61 Specifically, 
differentiation into skeletal muscle cells was induced by coculturing human adult pericyte-
derived cells with C2C12 mouse myoblasts at 1:5 ratio on the proliferation substrates. 
Alternatively, spontaneous skeletal myogenic differentiation of human pericyte-derived cells 
was induced by plating cells onto matrigel-coated dishes in differentiation medium. After 7 
days, cultures were fixed and stained with antibodies against striated myosin (MF20) and MyoD.  
2.5.2.2.4 Immunofluorescence microscopy 
Cells were fixed with 4% paraformaldehyde for 10 minutes on the differentiation substrates. 
Cells were processed for immunofluorescence microscopy as previously described.62  
2.5.2.2.5 Matrigel coating of tissue culture surfaces 
Matrigel coated petri dishes have to be freshly prepared and cannot be stored. Reduced 
Matrigel stock solution was diluted 1:80 in cold DMEM and then carefully applied on petri 
dishes covering the all surface. After 30 minutes incubation at 37 °C (5% CO2 incubator), the 
Matrigel leaving the surface wet was gently removed. Finally the surface was rinsed with the 
appropriate culture medium before planting cells. 
2.5.2.2.6 HA coating of tissue culture surfaces 
Natural hyaluronan and its derivatives were dissolved in pure water with a final concentration 
of 12.5 mg/mL and filtered over a sterile microfilter (pore size 2.0 µm). The solutions were then 
carefully applied on petri dishes covering the all surface and removing the excess of liquid. After 
8 hours of incubation at 37 °C (5% CO2 incubator under UV lamp) covered with their lead, cells 
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were planted with the appropriate culture medium. 
2.5.2.3 Images Analysis 
For each sample four different regions were acquired. The analysis was performed on an 
average number of 50 cells per sample using ImageJ software.  
Segmentation of phase contrast images: in order to segment the phase contrast images, the 
contrast of the original image was increased. After this first step the image was thresholded 
and using the “find edges” ImageJ plugin the edges of the cell were identified. The last 
operation was done using the “Analyse Particle” plugin which quantitatively characterise the 
cell morphology providing  values of parameters such as the area and the circularity of the cell 
which is equal to 1 for a perfect circle while approaching zero for very elongated shapes 
(circularity = 4π x area/perimetre2).  
Segmentation of fluorescence images: fluorescence images were used to quantify the number 
of differentiated cells (sarcomeric myosin positive cells) and the red region representing the 
myotubes which characterise the differentiated cells. The blue and red channels (blue: nuclei 
stained with DAPI; red: myotubes stained with anti-sarcomeric myosin antibody) of the original 
image were separated, thresholded and converted into binary images. The difference between 
these two images (performed with the “Image Calculator” plugin) provided the image with all 
the nuclei outside the red region (undifferentiated cells). Using the “Analyse Particle” plugin the 
following values were measured: total number of cells, total number of undifferentiated cells 
(the difference between these two values represents the number of differentiated cells) and 
area of the red region.  
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2.5.3 RESULTS AND DISCUSSION 
We based our study on different methodologies that can be used for the chemical modification 
of the HA, key building block for producing advanced biomaterials. The synthesised HA-based 
compounds must retain complete biocompatibility when used as substrates in cell cultures. 
Natural or modified HA has never been used in human pericyte derived cell cultures. 
Considering that all the different strategies presented (See 2.2, 2.3, 2.4) afforded polymers that 
could be dissolved in water giving viscous solutions, the general method used to test their 
biocompatibility has been that to coat petri dishes with a solution of the desired compound, 
remove the excess of liquid and plant cells on it. 
As first point, solutions at different concentration of sodium hyaluronate (HA-Na) with average 
molecular weight 235 kDa were tried as substrates during human pericyte derived cells 
proliferation in order to identify the more suitable one. As discriminating factor the population 
doubling was considered. 
The best result was obtained by using 12.5 mg/mL of HA-Na, hence this concentration was 
maintained constant with all the HA-derivatives used because they have been synthesised using 
a polymer of average molecular weight 235 kDa as starting material.    
A set of compounds was tested to investigate cells proliferation and differentiation (Figure 37). 
Specifically HA-coated petri dishes were used during the proliferation while differentiation was 
carried out using two different protocols; indeed mesoangioblast differentiation into skeletal 
muscle in vitro can be induced by coculturing human adult pericyte-derived cells with mouse 
myoblasts (hence on the same substrate present during the proliferation) or by plating cells 
onto matrigel-coated dishes in differentiation medium.  
The aim of the investigation was that to provide data about the biological properties displayed 
by the hyaluronan, to see whether the cation could exhibit an effect, to check the 
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biocompatibility of the new functional groups grafted on the HA, i.e. a triazole moiety, 
urethanic bridges and aliphatic chains. Furthermore we were interested as well in checking if 
differences occurred in the behaviour of the azide derivative respect to its click-product.   
 
 
Figure 37: HA-derivatives tested as substrates for stem cell cultures 
The structures of the compounds tested as substrates in pericyte-derived stem cells are reported. HA-Na (average 
molecular weight 235 kDa) is commercially available and has been used as starting material for the synthesis of all 
the other HA-derivatives depicted. 
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Since the very first trials, the azido derivative (HAAA) and all the ammonium salts, except the 
lysinium one (HA-Lys), displayed very high toxicity towards stem cells. These results could be 
easily rationalised for the ammonium salts, considering that the free amines found are toxic; on 
the contrary organic azides have no intrinsic toxicity unless they are unstable.63 
 Proliferation on the sodium and lysinium hyaluronate (HA-Na and HA-Lys), the triazole-
derivative (HA-TR1) and the cross-linked polymers (HA-CL1 10%) of human pericyte derived 
cells occurred with good results. For some of the substrates the population doubling was 
measured (Figure 38). The data demonstrated that, after 6 days cells, have a proliferation rate 
of approximately 7 population doublings in the standard conditions while on the other samples 
the value ranges approximately between 5.5 and 6 hence just slightly lower.  
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Figure 38: Population doubling of human pericyte derived cells on HA coated petri dishes 
 
Proliferation was also checked monitoring cells via contrast phase microscopy. For a precise 
 
Chemical Modification of the Hyaluronic Acid 
 
 
______________________________________________________________________________ 
127 
evaluation of cell morphology an algorithm was developed in order to perform a segmentation 
of phase contrast images and measure cell area and circularity that have been chosen as 
distinguishing parameters (Figure 39). 
 
 
 
Figure 39: Segmentation of phase contrast images 
Operation performed on the original image (A): enhancing the contrast (B), tresholding (C) and finding the edges of 
the cell (D) and identification and morphological characterisation of the cell (E). 
 
The data obtained from the segmentation of phase contrast images highlighted that in most 
cases there are no significant differences between the standard conditions and the HA-based 
substrates. Anyway a general trend was noticed: the more the hydrophilicy of the functional 
group inserted is the lower the area mean value of the cells is, the same could be said for the 
circularity but in this case differences are less marked. 
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Figure 40: Morphological analysis of human pericyte derived cells planted on HA-derivatives  
Area and Circularity of cells on different substrates. The area mean value of HA-TR1 and HA-CL1 10% showed a 
significant difference with the area mean values of the Control. Moreover the circularity mean value of the Control 
is significant different from the circularity mean value of the HA-CL1 10%.  
 
Our hypothesis is based on the assumption that, usually, on hydrophobic substrates such as 
tissue culture polystyrene, cell attachment is typically mediated through adsorbed matrix 
proteins, while on hydrophilic, non-ionic and non-protein adsorbing substrates, such as HA,64 
the negligible protein adsorption and the lack of strong polar adhesion forces frustrate cell 
adhesion. Thus the introduction of less hydrophilic groups, e.g. the alkyl chain of HA-CL1, could 
guarantee a minimum level of adsorption of matrix proteins to promote cells spreading. 
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The scale of hydrophobicity would then be: HA-TR1 < HA-Na < HA-Lys < HA-CL1 10%. 
If at a first sight HA-TR1 could hardly look less hydrophobic of HA-Na, looking at the simulated 
partition coefficient octanol/water (LogD) at physiological pH, i.e. 7.4, of the two corresponding 
residues it showed to be effectively more hydrophilic. 
 
 
Figure 41: Comparison of hydrophobicity between HA-Na and HA-TR1 
The partition coefficient of the two corresponding residues was simulated at physiological pH value (pH 7.4) with 
the simulator provided in ACD/Labs 6.00. 
 
Cells differentiation into skeletal muscle was induced following two protocols as already 
mentioned. As first point it is important to highlight that cells can undergo differentiation only if 
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they are in good condition. Indeed myotubes formation could be regarded as a proof of the 
biocompatibility of the substrates. 
Myogenic differentiation of human pericyte-derived cells could be appreciated by 
immunofluorescence microscopy (Figure 42-A). 
To have a quantitative idea about the efficiency of the differentiation process, images were 
analysed calculating two different parameters: the ratio between the total number of cells and 
the differentiated ones (DAPI stained nuclei inside the red region characterised by the 
expression of sarcomeric myosin) and the area of the sarcomeric myosin region (red). The first 
parameter gives an indication about how many cells differentiate (no differentiaon = 0, total 
differentiation = 1 respect to the control) while the second parameter indicates how good is the 
differentiation (higher values of the red region indicate more sarcomeric myosin produced by 
differentiated cells). The combination of these two parameters gives an indication of the 
efficiency of the overall differentiation process. (Figure 42) 
All the cells cultured on the HA-derivatives retained the capacity to differentiate proving the 
biocompatibility of the substrates. As already explained the area of the myotubes will be 
regarded as the main parameter indicating the goodness of the substrate to promote skeletal 
muscle formation. The data analysed showed as matrigel significantly overcomes HA-based 
substrates. Moreover only little differences were observed for pericyte-derived cells cultured in 
the same conditions but with different substrates. In particular very promising results were 
obtained by using HA-Lys. HA-TR1 behaved as the native HA demonstrating that the moiety 
inserted does not modify the biocompatibility of the polymer. The insertion of urethane groups 
and aliphatic bridges has been completely tolerated as well. (Figure 43) 
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Figure 42: Analisys of images recorded by immunofluorescence microscopy 
Immunofluorescence microscopy allows to recognize myotubes (stained red by anti-sarcomeric myosin antibody) 
and all nuclei (stained blue by DAPI). The original fluorescence image (A) was separated into the red and blue 
channels (B-C) and thresholded (D-E). The difference between image D and F provides the nuclei outside the red 
region (F). Through the “Analise Particle” plugin applied on image D, E and F it is possible to calculate the area of 
the red region (G), the number of all cells (H) and the number of the undifferentiated cells and hence to 
back-calculate the number of differentiated cells. 
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Figure 43: Analysis on the differentiation of human pericyte derived cells planted on HA-derivatives 
The two parameters chosen as indicators of the ability of cells to differentiate are reported. Specifically 
Differentiation indicates the ratio between the number of nuclei inside the red region and the total number of 
nuclei; each value obtained has been normalised to the control. Only cells differentiated on the substrate of 
proliferation were analysed in this way. The red area indicates the area of myosin positive myotubes and has been 
measured for all the experiments performed. 
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2.5.4 CONCLUSION 
Mesoangioblasts are multipotent progenitors of mesodermal tissues, able to proliferate in 
culture and to undergo differentiation into various types of mesoderm cells upon proper 
culture conditions, hence they are qualiﬁed as a novel class of stem cells. The corresponding 
human cells, more precisely defined as “pericyte-derived cells”, have been recently isolated and 
characterised, a clinical trial with these cells is planned in the near future.61 Indeed recently the 
application of mesoangioblasts for stem cell therapies has been looked as attractive issue to 
provide symptoms amelioration in the case of muscular dystrophy.65  
The capacity to expand and differentiate mesoangioblasts in vitro is a key point for the 
possibility of using this novel strategy for the cell therapy in genetic diseases. Thus new HA has 
been chemically modified to explore different reactions that might be applied on this 
biopolymer both for its bioconjugation and cross-linking.  
A variety of chemical modifications of native hyaluronan have already been devised to provide 
new materials. The resulting hyaluronan derivatives have physicochemical properties that may 
significantly differ from the native polymer. Hence to check whether the strategy investigated 
brought to the synthesis of derivatives retaining the biocompatibility and biodegradability and 
the pharmacological properties of native hyaluronan, they have been used as substrates for 
human pericyte derived cell proliferation and differentiation.  
The results obtained highlighted that two of the strategies reported for the chemical 
modification of the HA, i.e. Sharpless cycloaddition and reaction with diisocyanates, add on the 
polymeric scaffold moieties completely atoxic and that ensure the biocompatibility of the 
native polymer. Moreover the biological effect of the counterion was investigated and different 
HA-ammonium salts have been tested showing that the biological effect expressed can be 
related to the one which is exhibited by the amine itself. 
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2.8 SUPPORTING INFORMATION 
2.8.1.1 Trial for the synthesis of RGD sequence with unprotected N-terminus   
As cited in 2.4.3, the synthesis of a RGD sequence that could be selectively deprotected at the 
N-terminus of the arginine was attempted. The aim was that to functionalise this tripeptide in a 
different position, in order to be able to study the differences observed during the HA 
functionalisation and, eventually, the differences in the biological response. We started from 
the protection and coupling of glycine and aspartate as shown in Scheme S 1. Unfortunately we 
did not success in the synthesis of the tripeptide using HBTU as coupling reagent, but only the 
starting materials were recovered. 
 
Scheme S 1: Pathway followed for the synthesis of Boc-Arg(Z)2-Gly-Asp(OBn)-OMe 
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2.8.1.1.1 Synthetic procedures 
Synthesis of Boc-Gly-OH: 
To a stirred solution of glycine (5.0 g, 67 mmol, 1 eq.) in 35 mL of water, 2.7 g of NaOH (67 
mmol, 1 eq.) in 20 mL of water were added. The mixture was cooled at 0 °C, then a solution of 
Boc anhydride (14.5 g, 67 mmol, 1 eq.) in 25 mL of acetone was slowly added dropwise over 30 
minutes. The reaction was allowed to warm at room temperature and stirred overnight. The 
acetone was removed under reduced pressure, the solution was acidified with a saturated 
solution of citric acid and extracted with DCM (3 x 15 mL). The organic layer was dried over 
MgSO4, filtered and the solvent removed affording the pure product. Yield: 45% wt. White 
solid. 1H NMR (200 MHz, CDCl3) (δ = ppm): 5.05 (bs, 1H), 3.98 (d, J = 5.4 Hz, 2H), 1.46 (s, 9H).  
Synthesis of Boc-Asp(OBn)-OMe: 
To a stirred solution of Boc-Asp(OBn)-OH (2.4 g, 7.1 mmol, 1 eq.) in 17 mL of dry DMF 1.5 g of 
K2CO3 (10.9 mmol, 1.5 eq.) was added and the suspension cooled at 0 °C; after 10 minutes, 1.0 
g of MeI (7.1 mmol, 1 eq.) were added. The reaction mixture was allowed to warm at room 
temperature and stirred for 3 h. The mixture was then diluted with 25 mL of water and 
extracted with AcOEt (3 x 25 mL); the combined organic layers were washed with a saturated 
solution of NaHCO3 (25 mL) and brine (3 x 25 mL). The organic phase was dried over Na2SO4 and 
filtered over a plug of silica gel. Evaporation of the solvent afforded the pure product. Yield: 
88% wt. White solid. 1H NMR (300 MHz, CDCl3) (δ = ppm): 7.34 (m, 5H), 5.47 (d, J = 9.3 Hz, 1H), 
5.12 (s, 2H), 4.58 (m, 1H), 3.70 (s, 3H), 3.04 (dd, J = 4.4, 16.9 Hz, 1H), 2.86 (dd, J = 4.8, 16.8 Hz, 
1H), 1.44 (s, 9H). 
Synthesis of H2N-Asp(OBn)-OMe: 
4.36 g of Boc-Asp(OBn)-OMe (13.0 mmol, 1 eq.) were dissolved in 50 mL of a 1:3 v/v solution of 
TFA and DCM and the mixture was stirred for 5 h. 50 mL of DCM were added and the solution 
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was then extracted with 0.1 M HClaq.  (3 x 30 mL); the pH of the combined organic phases was 
adjusted to 9 with 1 M NaOH. The aqueous layer was then extracted with DCM (3 x 25 mL); 
evaporation of the solvent afforded the pure product. Yield: 84% wt. Yellow oil. 1H NMR (200 
MHz, CDCl3) (δ = ppm): 7.36 (m, 5H), 5.15 (s, 2H), 3.58 (dd, J = 2.1, 5.0 Hz, 1H), 3.70 (s, 3H), 2.82 
(dd, J = 5.0, 6.7 Hz, 2H), 1.75 (bs, 2H); FT-IR (cm-1): 3311, 3064, 3034, 2954, 1738, 1686, 1660, 
1536, 1520, 1453, 1406, 1317, 1277, 1247, 1216, 1166, 997, 852, 755, 699. 
Synthesis of Boc-Gly-Asp(OBn)-OMe: 
To a stirred solution of Boc-Gly-OH (0.63 g, 3.6 mmol, 1 eq.), DMAP (90 mg, 0.7 mmol, 0.2 eq.) 
and TEA (1.2 g, 10.8 mmol, 3 eq.) in 7.5 mL of DCM cooled at 0 °C a solution of EDCI (820 mg, 
4.3 mmol, 1.2 eq.) in 20 mL of DCM was added dropwise. The reaction temperature was 
allowed to progressively raise to room temperature in 30 minutes, then the reaction was stirred 
at room temperature overnight. The mixture was washed with a saturated solution of NaHCO3 
(50 mL), a saturated solution of citric acid (50 mL) and brine (50 mL), the organic phase was 
dried over Na2SO4 and filtered. Evaporation of the solvent afforded the pure product. Yield: 50% 
wt. Yellow oil. [α]D
25 (c = 0.1 w/v; CHCl3): + 26.741; 
1H NMR (300 MHz, CDCl3) (δ = ppm): 7.35 
(m, 5H), 5.12 (s, 2H), 4.87 (m, 1H), 3.79 (d, J = 5.7 Hz, 2H), 3.70 (s, 3H), 3.08 (dd, J = 4.3, 17.1 Hz, 
1H), 2.89 (dd, J = 4.5, 17.1 Hz, 1H), 1.46 (s, 9H); 13C NMR (200 MHz; CDCl3) (δ = ppm): 170.97, 
170.59, 169.56, 156.03, 135.38, 128.51, 128.32, 128.24, 79.81, 66.70, 52.61, 48.47, 43.97, 
36.24, 28.22; FT-IR (cm-1): 3339, 3065, 3034, 2978, 1737, 1683, 1719, 1455, 1438, 1390, 1366, 
1280, 1250, 1217, 1171, 1051, 1029, 995, 944, 864, 752, 699; FAB-MS 395 (M+H)+. 
Synthesis of H2N-Gly-Asp(OBn)-OMe: 
1.3 g of Boc-Gly-Asp(OBn)-OMe (3.3 mmol, 1 eq.) were dissolved in 50 mL of a 1:3 v/v solution 
of TFA and DCM and the mixture was stirred for 3 h. Then, the same work-up described in 0 
was applied affording the pure product. Yield: 87% wt. White solid (m.p. 207-209 °C). [α]D
25
 (c = 
0.1 w/v; DMSO): + 12.723; 1H NMR (200 MHz, CDCl3) (δ = ppm): 7.35 (m, 5H), 5.14 (s, 2H), 4.91 
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(m, 1H), 3.71 (s, 3H), 3.36 (s, 2H), 3.08 (dd, J = 4.70, 16.8 Hz, 1H), 2.89 (dd, J = 4.5, 16.8 Hz, 1H); 
FT-IR (cm-1): 3192, 1741, 1686, 1661, 1497, 1358, 1331, 1310, 1270, 1219, 1172, 1145, 1097, 
988, 822. 
Synthesis of Boc-Arg(Z)2-Gly-Asp(OBn)-OMe: 
To a solution of 70 mg of Boc-Arg(Z)2-OH (0.13 mmol, 1 eq.), TEA (53 mg, 0.52 mmol, 4 eq.), 
DMAP (2 mg, 0.01 mmol, 0.1 eq.) in 2 mL of dry DCM, HBTU (60 mg, 0.16 mmol, 1.2 eq.) was 
added, under nitrogen atmosphere. After 30 minutes, a solution of H2N-Gly-Asp(OBn)-OMe (38 
mg, 0.13 mmol, 1 eq.) in 3 mL of dry DMF was added. The reaction was monitored by TLC and 
1H NMR, but the no new products were detected.  
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3 EFFECTS OF ENVIRONMENTAL FACTORS AND 
REACTANT ARCHITECTURE ON THE OUTCOME OF THE 
MICHAEL-TYPE ADDITION USED FOR 
BIOCONJUGATION 
 
3.1 INTRODUCTION 
3.1.1 The Michael reaction 
The Michael reaction refers to the addition of a nucleophile (Michael donor) to an activated 
α,β-unsaturated carbonyl compound (Michael acceptor) and it is typically base-catalyzed 
(Figure 44).1  
 
 
 
Figure 44: Schematic depiction of the Michael addition reaction. 
 
T. Komnenos published in 1883 the first example of  the addition of a carbon nucleophile to an 
electron-deficient double bond; in particular he reported the reaction between the anion of 
diethyl malonate and ethylidene malonate. After this first report, in 1887, A. Michael 
systematically investigated the reaction of stabilized anions with α,β-unsaturated systems; 
during this study he synthesized a substituted pentanedioic acid diester  through the addition 
of diethyl malonate to the double bond of ethyl cinnamate in the presence of sodium ethoxide. 
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In 1894, he enlarged the scope of the reaction to triple bonds, acting as electrophiles (Figure 
45).  This method of forming new carbon-carbon bonds became exceedingly popular by the 
early 1900s and today all the reactions involving the addition of stabilized carbon nucleophiles 
to activated π-systems are called Michael additions and the products are named Michael 
adducts.2  
 
 
Figure 45: Classical examples of Michael addition 
 
Nowadays, however, it is current use to refer to Michael-type addition to include a wide variety 
of molecules that show reactivity in 1,4-conjugate addition reactions: virtually, any electron-
withdrawing group can be used. Furthermore, a broad range of acceptors and of non-carbon 
donors and both inter- and intramolecular versions have been reported, such as reactions 
involving non-enolate nucleophiles such as amines, thiols, and phosphanes.3 In this thesis 
particular attention will be given to thiol-containing nucleophiles and examples of their use in 
Michael-type addition reactions will be discussed.  
As a general feature, Michael donors derived from the deprotonation of CH-activated 
compounds such as aldehydes, ketones, nitriles, β-dicarbonyl compounds, etc. as well as from 
deprotonation of heteroatoms; the broad diversity of different donor-acting nucleophiles often 
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allows the use of relatively weak bases (e.g. triethylamine) in catalytic amounts, since the 
product of Michael addition is itself an anion that can further react with various electrophiles. 
The choice of the base catalyst has a tremendous effect on reaction kinetics and suitable bases 
are required to promote the deprotonation and so the activation of the donor depending on 
the pKa of the nucleophile.  
Another important feature characterising this reaction is that it is so versatile that it can be 
performed both in protic and aprotic solvents. This reaction, in fact, works even in aqueous 
media; the conjugated carbon centre, in α,β-unsaturated carbonyl compounds, is considerably 
“softer” if compared to the non-conjugated site, while water is a “hard” solvent. Consequently, 
one of the implications deriving from this property of water, is that such reactions can tolerate 
water since the nucleophiles and the electrophiles are soft whereas water is hard; in other 
words water will not significantly compete with other nucleophiles in such reactions. Hence, 
various conjugate additions have been successfully carried out in aqueous media, most of all 
using soft heteroatom-based nucleophiles such as amines, thiols, phosphanes, and some 
halides.  
Concerning the selectivity of the reaction, it can be highly diastereoselective when both the 
Michael donor and the acceptor display a defined stereochemistry; moreover, during the last 
decade, great efforts have been made to develop asymmetric versions providing an important 
tool for total synthesis of complex molecules.4  
3.1.2 Reaction mechanism and kinetics 
The generally accepted mechanism2,5 is illustrated in Figure 46, where the addition of a 
malonate anion across the double bond of ethyl cinnamate is taken as the benchmark reaction. 
First of all, an enolate is generated via deprotonation by the base. The enolate anion then 
reacts in a 1,4-conjugate addition to the olefin of the acrylate system. Until proton transfer 
occurs, the resulting anion is stabilized by the carbonyl ester group and this intermediate is 
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itself a base indeed. The reaction is reversible in protic solvents and the thermodynamically 
most stable product usually predominates. The overall driving force for the conjugate addition 
is the enthalpic change that accompanies the replacement of a π-bond with a σ-bond. Thus, 
there is the preference for 1,4-addition over 1,2-addition. 
In some cases, however, kinetically controlled reaction conditions can afford attack at the α-
carbon rather than at the β-carbon of the olefin, but the careful choice of the reaction medium 
and the use of additives can suppress these undesired reactions. 
 
 
 
Figure 46: Mechanism of Michael addition 
 
The kinetics of the addition obey a second order rate law (See Equation 1, where Nu = 
nucleophile and El = electrophile):  
               Equation 7 
If the nucleophile derives from a deprotonation process, its concentration is a function of the 
base strength and of the equilibrium constant of the deprotonation process (Ka).  
In conclusion, the most important factors affecting the reaction rate are the reactants 
architecture and the reaction medium (solvent, buffer system, base strength).  
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3.1.2.1 Michael-type acceptor effect 
Typical acceptors in the Michael-type addition are olefins activated for nucleophilic attack. 
Actually, for allowing the reaction to occur, the anion resulting from the nucleophilic attack by 
the donor must be stabilized as well. Thus, the electronic availability and the steric hindrance at 
the double bond play a key role. A class of compounds that meets these requirements is that of 
the α,β-unsaturated carbonyl compounds.  
The reactivity of the acceptor will decrease if electron rich substituents are present, such as in 
the case of alkyl, aryl or alkoxy substituted olefins such as styrene derivatives or vinyl ethers. 
Moreover, the larger the groups located in the α and β positions, the slower the reaction rate, 
although this effect can be offset by stronger polar contributions. For example, alkyl 
methacrylates are relatively poor Michael acceptors compared to the corresponding acrylates. 
Surely, differences in reactivity between acceptors can be overtaken by tuning the 
nucleophilicity of the Michael donors. For instance, with poor Michael acceptors, stronger 
nucleophiles, such as carbanions, are necessary to successfully achieve the Michael addition. 
On the other hand, better acceptors readily accept weaker nucleophiles such as amines and 
thiols. 
Aptula et al reported in 20076 an exhaustive study where the reactivity of a set of α,β-
unsaturated compounds was evaluated towards the sulfhydryl group of the cysteine residue of 
the tripeptide glutathione (GSH) as a thiol-containing model nucleophile. The comparison was 
focused on polarized α,β-unsaturated compounds featuring double or triple bonds and included 
the ones containing an aldehyde, ketone, ester, sulfoxide, sulfone, sulfonate, nitro, or cyano 
moiety, as well as ortho- and para-pyridyl compounds and ortho- and para-quinones (Figure 
47). Specifically, they calculated the RC50 value for each compound; the reactive end point 
(RC50) represents the required concentration of electrophile so that half the available free thiol 
would be bound at the fixed time of 2 h. It was observed that acetylenic derivatives are more 
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reactive than their corresponding olefinic analogues; methyl substitution on a vinyl carbon 
atom reduces the reactivity, but the methyl substitution on the α-carbon atom produces a 
larger rate reduction; an additional unsaturated group increases the reactivity. 
A further study developed by Schw bel,7 where a broader set of Michael-type acceptors was 
used in order to develop a model to predict the kinetic rate constants of such compounds 
towards glutathione (GSH), under the same experimental conditions (i.e. phosphate buffer at 
pH 7.4 and 25°C), gave evidence of the same trend observed before; in short, they fixed as a 
general reactivity scale the sequence propiolate > acrylate > crotonate >> methacrylate. 
A direct comparison of the reactivity between acrylate and methacrylate8 confirms that methyl 
substitution on the α-carbon atom of the vinyl group reduces the reactivity. This decrease in 
reactivity is perceived to be due to a combination of steric and electronic aspects: first, 
α-methylation sterically hinders the thiol attack and secondly and more importantly, the 
electron-donating α-methyl moiety decreases the partial positive charge on the β-carbon atom, 
making it less electrophilic. 
Moreover, the rather small variability in reaction rate within different methacrylates and 
acrylates, indicates that the electronic effect of the ester group is less important than the effect 
of the substitution pattern on the α carbon. 
Other studies9 including the amide group as electron withdrawing moiety revealed that its 
ability to activate the double bond is comparable to that exhibited by the ciano group, that is 
the kinetic rate constant is one order of magnitude lower than the one measured for the 
corresponding ester.  
Another well known Michael acceptor that showed to react very quickly in Michael-type 
addition is maleimide. Kinetic investigations10 revealed that its derivatives react with thiols (2-
mercaptoethanol, free cysteine and the cysteine residues present at the N-terminus of 
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peptides) faster than with bromoacetylderivatives in aqueous media, even at pH 6.5. The use of 
maleimide containing compounds involves, however, substantial drawbacks which cannot be 
neglected (See 3.1.3 for a detailed discussion).  
 
Figure 47 : Reactivity towards GSH of selected Michael-type acceptors 
Michael acceptors considered by Aptula
6
 for the determination of a scale of reactivity; specifically, the kinetics of 
the Michael-addition reaction between the reported electrophiles and GSH as thiol-containing model nucleophile 
were followed (phosphate buffer at pH 7.4, room temperature) with a spectrophotometric assay to determine the 
reactive end point (RC50, expressed in mM), that indicates the concentration of electrophile required to react with 
half of the available free thiol in 2 h; the values obtained are reported below the relative compound. 
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3.1.2.2 Michael-type donor effect 
As mentioned before, Michael reaction initially referred to the 1,4-addition between an 
activated-methylene function and a conjugated double bond, leading to the formation of a new 
carbon-carbon bond; the initial step of the carbon-Michael addition is the deprotonation of the 
donor. In order to increase the acidity of the hydrogen to be removed, the donors must be able 
to stabilize the resulting negative charge. Stabilized carbanions usually result from ketones, 
aldehydes, nitriles, amides, nitrones, sulfones, malonates and acetoacetates. To know in 
advance the pKa of the Michael-type donor results particularly useful for the choice of the 
proper base; stronger bases than required, in fact, may promote side reactions, such us ester or 
amide hydrolysis. 
Since when the scope of the reaction has been thoroughly investigated, the use of 
heteroatomic nucleophiles became very popular and donors featuring nitrogen, sulfur, oxygen 
and phosphorus as nucleophilic centres have been widely used. 
Specifically, when a nitrogen-donor is involved in the Michael addition, the reaction is often 
called aza-Michael reaction. Since amines can act both as nucleophiles and bases, no additional 
bases are generally required in these reactions. The reaction tends to follow second-order 
kinetics based on the concentration of the olefin acceptor and the donor amine. As drawback, it 
must be taken into account that primary amines can react with two equivalents of acceptor to 
form tertiary amines. The aza-Michael version of the conjugated addition indeed represents 
one of the most attractive procedures for the asymmetric synthesis of β-amino carbonyl 
compounds and related derivatives. This class of compounds is extremely important because of 
their ubiquitous occurrence as constituents of a plethora of biologically important natural and 
synthetic products and, moreover, they have been shown to be very versatile intermediates to 
them. In conclusion, the aza-Michael reaction tremendously increased in importance in recent 
years as an excellent synthetic tool for forming new carbon-nitrogen bonds.  
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The first enantioselective conjugate amine additions reported in the literature11 was carried out 
with the TiCl2-BINOL complex as Lewis acid catalyst to promote the coordination with the 
N-acyloxazolidinone, creating a chiral environment in which the primary amine preferentially 
attacks one face of the complex, resulting in the formation of one prevailing diastereomer. The 
oxazolidinone ring can then be removed to afford β-amino acids (Figure 48). Although, the 
enantioselectivity was modest (maximum enantiomeric excess: 42%), this first attempt opened 
a new field in asymmetryc synthesis using the aza-Michael addition to generate β-amino acids. 
 
 
 
Figure 48 : The first example of a stereoselective aza-Michael addition 
 
Another important class of heteroatomic donors used in combination with Michael-type 
acceptors are thiol-containing compounds. The importance of thiol-containing donors is due to 
the presence of cysteine residues in proteins and, by consequence, in biological systems.  
Thiols have the advantage of being, in general, more nucleophilic than amines12, but, 
considering that thiolates are even more reactive, bases are often used to deprotonate them. 
The deprotonation of marcaptans needs mild bases because of their relatively high acidity. 
Kinetic studies proved that the thiolate anion is often the active species in Michael additions 
involving thiols. Hence, it is well known that the thiol Michael addition reaction rate increases 
with increasing the pH value, due to the higher concentration of the thiolate anion in solution.13 
A recent paper14 presented a quantitative structure-reactivity relationship for the Michael-type 
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addition of thiols onto acrylates; specifically a homologous series of peptides with charged 
amino acids flanking a cysteine, was reacted with PEG-diacrylate in order to elaborate the 
dependence between the Michael-type reactivity and the structure of the reaction partners. 
Peptides featuring different primary structures showed different behaviors in the Micael-type 
addition: it was found that charged amino acids located close to the SH groups considerably 
altered the pKa of the cysteine residue (single titrations were performed in order to determine 
each pKa). The conclusion was that a linear correlation between the thiolate concentration, 
hence its pKa, and the second order reaction kinetics could be made, and is a key point in 
tailoring the reaction kinetics to the needs of an application. 
A further issue to take into account is that thiols undergo oxidation leading to the formation of 
disulfides, and that this reaction becomes faster as more basic is the reaction medium. 
3.1.2.3 Reaction medium effect 
Based on the frontier orbital theory, a two-terms equation can be used to explain the 
differences in reactivity of a series of electrophiles toward a specific nucleophile. The two terms 
are a coulombic attraction/repulsion term and a term related to the overlap of the frontier 
orbitals: the highest occupied orbital [HOMO] of the nucleophile and the lowest unoccupied 
orbital [LUMO] of the electrophile. Surely both of them are influenced by the interaction with 
the solvent and the eventual additives. Looking at the increasing importance of Michael-type 
addition as a tool for bioconjugation, water as solvent must be considered with particular 
attention. The consequences of water “hardness” have already been discussed in 3.1.1. Usually, 
buffered systems with controlled pH are used, hence the actual behavior of the water as 
solvent can be tuned by carefully selecting salts featuring cation-anion bonds with different 
percentages of ionic/covalent character. In fact, the interaction between the ions in solution 
and the charged intermediates might amplify steric or electronic factors, thus influencing the 
outcome of the reaction.   
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Even if we were particularly interested in the use of Michael-type addition as a tool for 
effecting bioconjugation processes, we will, nevertheless, report some general considerations 
about the variables affecting the reaction (i.e. base catalyst and solvent system). 
Considering that the Michael donors often derive from the deprotonation of a conjugate 
acid-precursor, the choice of the base catalyst has a tremendous effect on the reaction kinetics. 
As previously noted, the concentration of the Michael donor species is highly dependent upon 
the relative base strength. In the case of strong bases the concentration of the enolate anion 
approximately corresponds to the concentration of the base, even though the main drawback 
with using strong bases, such as hydroxide and methoxide anions, is that they may promote 
side reactions such as ester hydrolysis. In this light, non-nucleophilic bases are often desirable 
and the careful choice of the base remains a key point.  
Other factors affecting the reaction kinetics are the stabilization of the charges assisted by the 
solvent. Basically, any kind of solvent, if capable to dissolve catalyst, donor and acceptor, can be 
used (e.g. methanol, ethanol, diethyl ether, tetrahydrofuran, benzene, xylene, dioxane and 
mixtures of these solvents). Initially, protic solvents were considered as highly desirable in the 
carbon-Michael reaction as particularly efficient to promote a rapid proton transfer and to 
stabilize charged intermediates.  
The stabilisation of the charges effected by the solvent greatly affects the base strength as well; 
for example, N-methylimidazole was proven to act as basic catalyst in the Michael addition of 
malonodinitrile to chalcone (Figure 49)   both in the common organic solvents and in ionic 
liquids (ILs)15 {i.e. [emim]SO4Et (1-ethyl-3-methylimidazolium ethylsulfate), [bmim]PF6 (1-butyl-
3-methylimidazolium hexafluorophosphate) and [bmmim]PF6 (1-butyl-2,3-dimethylimidazolium 
hexafluorophosphate)}, and its basicity is higher in ILs than in conventional solvents. For 
reactions studied in ILs, residual amounts of N-methylimidazole or the acidity of the IL itself can 
have strong effects on the outcome of the reaction.     
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Figure 49: Solvent effect on the reaction rate of the Michael addition of malonodinitrile to chalcone 
catalyzed by 5% mol of N-methylimidazole 
The Michael addition of malonodinitrile to chalcone in various ILs as well as in conventional organic solvents was 
studied in the following conditions: chalcone (1.0 mmol), malonodinitrile (10.0 mmol) and the catalyst (5% mol) 
were stirred for 4 h at room temperature. Samples of the reaction mixture were taken at different times in order 
to spectrophotometrically determine the values of the rate constants of the reaction (t1/2 is the half-life time of the 
Michael addition). 
 
3.1.3 Reversibility of Michael-type reaction  
As already mentioned in the description of the reaction mechanism (See 3.1.2), the Michael 
addition is a reversible reaction in protic solvents. The relative concentration of the reactants 
depends on the thermodynamic balance; this means that the thermodynamically most stable 
product usually predominates. A general consideration from the kinetic point of view is that the 
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higher the reaction rate of the Michael addition reaction, the higher is the kinetics of the retro-
Michael reaction as well: this means that the factors affecting the rate constant are the same 
already discussed before. 
Recently this reversibility was regarded with particular attention in the design of controlled 
drug delivery systems, an issue particularly important in the field of biomaterials. Controlling 
the rate and the extent of the retro-type reaction might indeed be a tool to reach this goal. 
Michael-type addition reactions have recently emerged as a widely employed strategy for the 
covalent conjugation of proteins, peptides, and drugs to various polymers and other molecules 
by the reaction of free cysteine or thiols with acrylamides, acrylates, vinyl sulfones, and 
maleimides.  
The retro-Michael reaction in the case of thiol-adducts has been observed in reducing 
environments, indicating that, in the presence of other thiol-based nucleophiles, the Michael-
adduct deriving from a given thiol can undergo the exchange of the thiol moiety. Sulfide 
exchange is regarded with particular interest for designing new strategies of drug delivery 
systems due to the weak reducing capacity of blood (ca. 2-20 μM glutathione) compared to that 
of reductive cellular compartments, or highly reductive and hypoxic tumor tissues (ca. 0.5-10 
mM glutathione).  
Ploemen reported in 199416 a study about the reversibility of the conjugation reaction of the 
diuretic drug ethacrynic acid (Figure 50) with glutathione. Ethacrynic acid and its glutathione-
adduct are known to be potent inhibitors of glutathione S-transferase family members, which 
are enzymes involved in xenobiotic metabolism. They observed a time-dependent transfer of 
ethacrynic acic to N-acetyI-L-cysteine or glutathione (GSH) S-transferase P1-1 (featuring a 
cysteine residue in position 47) when the glutathione conjugate was incubated with a 5-fold 
molar excess of one of two other thiol containing nucleophiles. With increasing pH values, the 
pseudo first order rate constant of transfer increased from 0.010 h-1 (pH 6.4) to 0.040 h-1 (pH 
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7.4) and 0.076 h-1 (pH 8.4). 
 
 
 
Figure 50: Reversible Michael-type addition reaction between ethacrynic acid and glutathione 
Ethacrynic acid, trade name Edecrin, is a diuretic drug used to treat high blood pressure and the swelling caused by 
diseases like congestive heart failure, liver failure, and kidney failure. Glutathione (GSH) is a tripeptide cysteine 
with important function as antioxidant. The Michael-type adduct of these two compounds is an inhibitor 
of glutathione S-transferase family members, which are enzymes involved in xenobiotic metabolism. 
 
The conclusion is that, under normal physiological conditions, the inhibition of glutathione 
S-transferase P1-1 by covalent binding of ethacrynyc acic would be reversed by glutathione; 
moreover this inhibition mediated by the glutathione is reversible itself depending on the in 
vivo concentration of glutathione.  
More recently the stability of Michael-type adducts between different thiols and maleimide 
was studied.17 Maleimides have been commonly employed in disulfide-based drug conjugation 
and polymer network formation due to their specificity to thiols, fast aqueous reaction kinetics, 
lack of byproducts, and the stability of the thioether addition products. While the wide use of 
maleimide-thiol conjugation reactions have been motivated by the product stability, the study 
reports details on the reversibility of maleimide-thiol conjugation reactions and on the 
Effects of Environmental Factors and Reactant Architecture on the Outcome of the 
Michael-Type Addition Used for Bioconjugation  
 
 
______________________________________________________________________________ 
159 
hydrolytic stability of the conjugate itself. They have found that the rate and the extent of 
exchange, which is governed by the rate of the retro-addition, can be modulated by increasing 
or decreasing the Michael donor reactivity. 
 
 
 
Figure 51: Degradation of maleimide-thiol adducts in reducing environement 
Succinimide thioethers, formed by the Michael-type addition of thiols to N-ethylmaleimide, undergo retro and 
exchange reactions in the presence of other thiol compounds at physiological pH and temperature. Model studies 
(
1
H NMR, HPLC) of the conjugated adduct with 3-mercaptopropionic acid, incubated with glutathione, showed 
half-lives of conversion from 20 to 80 h, while extents of conversion from 20% to 90% were found for 4-
mercaptophenylacetic acid, N-acetylcysteine and N-acetylcysteine conjugates.  
 
If the reversibility of the Michael addition is on the one hand a tool to tune the stability of the 
adducts, on the other hand it does not often allow to have conjugates as stable as required. For 
example, a recent study about the development of new ways to synthesise antibody-drugs 
conjugates demonstrated that, for maximal intratumoral drug delivery, the linkers are required 
to be highly stable in the systemic circulation, in order to allow an efficient drug release at the 
target site. In this respect, maleimide-based conjugates showed half-lives in circulation of 1-2 
days, while amide linkers ensure much longer half-lives of about 7 days.18 The mechanism of 
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the drug release from maleimide-adducts likely involves, even in this case, a retro-Michael 
reaction that takes place in plasma; specifically, some of the released drug-maleimide 
derivatives became covalently bound to the cysteine-34 of serum albumin. 
 These studies led to the development of strategies of controlled drug-release taking advantage 
from the tunable reactivity of the thiol function in cysteine coupled with maleimide linkers in 
the generation of antibody conjugates. An impressive recent investigation19 reports on 
engineered antibodies featuring cysteines at three sites differing in solvent accessibility and 
local charge. This strategy allowed the control of the rate of the retro-Michael reaction, causing 
drug release and maleimide exchange with reactive thiols of the plasma (e.g. albumin, free 
cysteine and glutathione), or of hydrolysis of the succinimide ring in the linker, thereby 
preventing this exchange reaction (Figure 52). Thus, the chemical and structural dynamics of 
the conjugation site can influence antibody conjugate performances by modulating the stability 
of the antibody-linker interface. 
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Figure 52: Proposed mechanism for the influence of the conjugation site on linker stability and 
therapeutic activity of antibody conjugates. 
The maleimide exchange from the antibody conjugate and hydrolysis of succinimide ring in the linker are key steps 
that influence conjugate stability and therapeutic activity. Specifically, if the thiol belongs to a solvent accessible 
site, this brings to retro-Michael reaction with other plasmatic thiols and the reaction outcome depends on the 
relative concentration of the different nucleophiles; hence, reactive thiols cause low stability of the antibody 
conjugate decreasing the therapeutic activity. On the contrary, a partially accessible site with a positively charged 
environment promotes the hydrolysis of the succinimide ring in the linker, enhancing the linker stability and the 
conjugate therapeutic activity. 
 
3.1.4 Bioconjugates via Michael addition 
The technology of bioconjugation encompasses several disciplines in the life sciences fields. 
Bioconjugation recently increased in importance as a tool for providing materials useful for 
biomedical applications and fundamental studies. Bioconjugates consist in polymers covalently 
bound to biopolymers (proteins, polysaccharides, polynucleotides, antibodies) or bioactive 
species (pharmaceuticals). This goal can be reached by crosslinking and modifying the native 
state and functional goups of peptides and proteins, sugars and polysaccharides, nucleic acids 
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and oligonucleotides, lipids, and almost any other imaginable typology of molecules that can be 
chemically derivatised. This strategy is often used to improve the resistance to clearance from 
the bloodstream in terms of excretion from the liver or kidneys, thus increasing circulatory 
lifetimes of protein drugs. Furthermore, the linkage with particular peptidic fragments 
mediating the recognition process may be crucial to bind the bioactive fragment to proteins 
receptor. Recognition properties are important in artificial organs and implants as well as in 
biosensors. Moreover, through a careful modification or tailored conjugation strategies, the 
structure and the function of proteins can be investigated, the active site conformation 
elucidated, or the receptor-ligand interactions revealed. Polymer-protein and polymer-drug 
conjugates have been used also to improve the solubility of a suitable molecule within the 
body.  
Michael addition chemistry has been recently regarded with particular attention for linking 
biomolecules to different substrates. This reaction, in fact, benefits from mild reaction 
conditions and high functional group tolerance as well as from high conversions and favourable 
reaction rates. In biological applications, such as protein derivatisation, the mild Michael 
addition reaction conditions represent a highly favourable situation, since high temperatures, 
oxidizing environments, radicals and organic solvents are not compatible.  
In a recent application,20 a Michael-type addition was successfully used as a convenient tool for 
surface functionalization. As reaction partners, thiols and acrylates were used and the 
comparison of two strategies has been reported. In particular, the aim was to generate a 
PEGylated surface decorated with peptidic groups. 
A first attempt contemplated the generation of thiol functions on a poly(styrenic) surface, 
followed by reaction with an excess PEG-diacrylate (first Michael-type addition); the free 
acrylate functions  would be employed for conjugation with a thiol-containing peptide (second 
Michael-type addition). 
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The second route involved the initial acryloylation of a PEGylated particle, followed by 
conjugation with a thiol-containing peptide (Figure 53). 
The use of a Michael-type addition in heterogeneous conditions revealed that the localization 
of the reaction partners is crucial: the combination thiol on the surface/acrylate in solution 
showed that the thiol groups distributed on the surface lack in reactivity. Disulfide formation 
can be excluded, due to the reducing reaction environment; thus, the poor reactivity is likely to 
be ascribed to the hydrophobicity of the thiols and of the polymeric surface, which do not 
kinetically favor the reaction with products dissolved in water or in the very polar solvents 
employed. On the contrary, employing previously PEGylated materials functionalized with 
acrylates and soluble thiols the target was reached. 
 
 
Figure 53: Strategies for the Use of Michael-type for surfaces modification 
The two different strategies for the bionconjugation with peptides and macroparticles. As highlighted one the 
introduction of the Michael-type acceptor first, and then of soluble thiols successfully worked.  
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Another application of this method for attaching biological molecules to hydrogels is described, 
using a chemical scheme that can be performed in contact with proteins, cells, and tissues21. 
This was accomplished using a conjugate addition reaction on acrylamides which readily react 
with thiol groups; in particular peptides containing a single thiol group were coupled to the 
PEG-diacrylamide in aqueous solution at room temperature in about 2 h. Only a portion of the 
acrylamide groups were targeted for reaction with peptide, thus to leave a sufficient amount of 
PEG-diacrylamide to be polymerized by free-radical mechanisms via photoinitiation. The 
photopolymerization step can be performed in contact with cells, providing a means to produce 
bioactive scaffolds for tissue engineering. The presence of particular peptidic sequence is 
required so that cells will respond only to the incorporated ligand. PEG, in fact, is well known to 
possess low adhesion to proteins so the decoration of the substrates with lingands allowing 
cell-adhesion, such as RGD protein, is often a critical issue. Hence, currently, strong interest 
exists in functionalizing polymers with the RGD protein to promote cell adhesion for tissue 
scaffolds. The RGD protein selectively promotes cell adhesion, while avoiding non-specific 
adsorption of proteins. Furthermore, cell spreading, a change in the cellular morphology, occurs 
in the presence of the RGD coating, indicating cell signaling has occurred. 
3.1.4.1 Bioconjugates via Michael addition on Hyaluronic acid 
Bionconjugation on HA is often required to improve its possibility to reach the biological target, 
and this property is extremely related to its efficacy as carriers. Several strategies for modifying 
and functionalising HA have already been reported (See 2.1), but, focusing on the use of 
Michael-type addition, an example is the paper by Ouasti et al.22 who conjugated the cell 
adhesion peptide RGD onto the backbone of a HA-derivative to study the influence of the 
peptide on the cellular uptake of HA via the RGD-specific integrins and CD44 receptors present 
on cell surfaces. Specifically, they first synthesised methacrylated HA by conjugating 
N-(3-aminopropyl)-methacrylamide onto the HA carboxylic acid group via EDC-mediated 
amidation reaction. This was followed by a second conjugation reaction with a RGD-containing 
Effects of Environmental Factors and Reactant Architecture on the Outcome of the 
Michael-Type Addition Used for Bioconjugation  
 
 
______________________________________________________________________________ 
165 
peptide including a cysteine to feature a thiol nucleophile, via Michael-type addition (Figure 
54). 
Moreover the aza-version of the Michael-type addition was performed as well on the HA 
backbone23; the aim in this case was the synthesis of a poly(L-leucine) grafted HA that may have 
advantages for mimicking natural processes occurring in proteins and thus have potential use in 
biomedical applications. The combination of polysaccharide and polypeptide, in fact, should 
provide tailored biomaterials that can be used in tissue engineering as hydrogels and as drug 
carriers in delivery system. In particular, poly(L-leucine) was grafted on hyaluronan via a 
Michael addition reaction between primary amine terminated poly(L-leucine) and acrylate-
functionalized HA. The precursor hyaluronan, as tetrabutyl ammonium salt, form was first 
functionalized with acrylate groups by reaction with acryloyl chloride in the presence of 
triethylamine in N,N-dimethylformamide. Michael addition at high a molar grafting ratio gave 
only 0.20 degree of conversion with respect to the repeat unit of HA, even with high excess of 
peptide, indicating grafting limitation due to insolubility of the final product; soluble graft 
copolymers were obtained only for low grafting ratios (<0.039). 
In conclusion, due to its versatility even for the application on HA, Michael addition is a 
precious tool for bioconjugating specific bioactive molecule on it and hence a detailed study to 
investigate all the factors affecting the reaction outcome is really useful in order to be able to 
tune the reaction kinetics and the stability of the final adduct. Thus we deeply studied the 
effect of the reagents architecture (influence of the Michael donor and acceptor), their stability 
and that of the Michael adducts.    
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Figure 54: Bioconjugation on HA with a RGD-containing peptide via Michael-type addition 
HA (of 64, 234, or 1100 kDa) was functionalized with RGD-containing peptides through the EDC-mediated reaction 
with 3-aminopropyl methacrylamide which was then reacted with the peptidic thiol in a Michael-type addition. 
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3.2 EXPERIMENTAL PROCEDURES   
3.2.1 Materials 
5,5′-Dithiobis-(2-nitrobenzoic acid) (DTNB; Ellman’s reagent) was supplied by Invitrogen 
(Oregon, USA); all other reagents including 3-mercaptopropionic acid (3-MPA),  2-hydroxyethyl 
acrylate (1), 2-hydroxyethyl methacrylate (2), and Sephadex® G-10 were purchased from Sigma-
Aldrich (Gillingham, Dorset, UK) and used without further purification. All the other reagents 
were of analytical grade and used without further purification. 
3.2.2 General methods 
3.2.2.1 Molecular characterization 
Absorbance readings were recorded on a BIOTek® Synergy 2 multi-mode microplate reader 
(NorthStar Scientific Ltd., Leeds, UK). 1H NMR spectra were recorded using Bruker AC-300 MHz 
or AC-400 MHz spectrometers. FT-IR spectra were recorded in ATR mode (Golden gate) on a 
Tensor 27 Bruker spectrometer. Crude reactions were analyzed via reversed phase 
chromatography on a Agilent 1100 series HPLC equipped with analytical (5 μm particle size, 4.6 
x 150 mm) Zorbax Eclipse XDB-C18 column and a Laserchrom S3210 UV/VIS detector set at 220 
nm. 
3.2.2.2 Ellman’s test 
Monitoring the reaction kinetics of thiols and Michael-type acceptors was carried out by 
measuring the remnant thiol content of reaction samples (quenched at different time points) 
by Ellman’s test. Briefly, an aliquot of 50 μL of each quenched reaction mixture was pipetted 
into a 96-wells plate, followed by addition of 250 μL of a freshly-prepared 300 μM DTNB 
aqueous solution in Tris buffer (1 M, pH 7.0). The content in each well was gently mixed by 
repeatedly pipetting the solution in and out with the help of a multichannel micropipette, and 
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then by shaking the 96-wells plate inside the microplate reader for 1.5 minutes at 30 °C. The 
absorbance was then recorded at 412 nm. 
3.2.2.3 HPLC analysis 
An analytical linear gradient elution from 0% to 75% of solvent B and 100% to 25 % of solvent A, 
run over 20 min at 1 mL/min, was used, where solvent A is 0.1% trifluoroacetic acid (TFA) in 
water and solvent B is 0.1% TFA in acetonitrile. 
3.2.2.4 Statistics 
Spectrophotometric experiments were carried out in triplicate, and the mean and standard 
deviations calculated for each reaction condition. 
3.2.3 Synthetic procedures 
3.2.3.1  Synthesis of Michael-type acceptors 
3.2.3.1.1 General procedure for the synthesis of compounds 3-6: 
A solution of 710 mg of TEA (7.0 mmol, 1.2 eq.) and 725 mg of N-acetylethanolamine (7.0 
mmol, 1.2 eq., for compounds 3-4), or 715 mg of N-acetylethyldiamine (7.0 mmol, 1.2 eq., for 
compounds 5-6) in 10 mL of dry DCM was cooled down to 0 °C. Then, 525 mg of acryloyl 
chloride (5.8 mmol, 1.0 eq., for compounds 3-5) or 610 mg of methacryloyl chloride (5.8 mmol, 
1.0 eq., for compounds 4-6) dissolved in 10 mL of dry DCM were added dropwise under an 
argon atmosphere. The reaction mixture was allowed to reach room temperature and stirred 
overnight. In order to prevent radical condensation of the alkene groups, BHT (ca. 10 mg) was 
added before removal of the solvent in a rotary evaporator. The crude products were purified 
by flash column chromatography on silica gel (70-230 mesh) eluted with AcOEt/EtOH mixtures, 
and BHT was added before solvent evaporation (ca. 1% wt. BHT in the concentrate).  
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2-(Acetylamino)ethyl acrylate (3): Eluent: AcOEt/EtOH-98/2. Yield: 92% wt. Colourless oil. 1H 
NMR (300 MHz, CDCl3) (δ = ppm): δ 6.43 (d, J = 17.3 Hz, 1H), 6.12 (dd, J = 17.3, 10.4 Hz, 1H), 
5.95 (bs, 1H), 5.87 (d, J = 10.4 Hz, 1H), 4.24 (t, J = 5.3 Hz, 2H), 3.55 (m, 2H), 1.99 (s, 3H); FT-IR 
(cm-1): 3285, 3087, 1722, 1637, 1549, 1409, 1373, 1269, 1185, 1066, 1040, 984, 810, 669; HPLC 
retention time: 6.31 min (Supporting information Figure S 1). 
2-(Acetylamino)ethyl 2-methylacrylate (4): Eluent: AcOEt/EtOH-98/2. Yield: 57% wt. 
Colourless oil. 1H NMR (400 MHz, CDCl3) (δ = ppm): 6.12 (s, 1H), 5.80 (bs, 1H), 5.60 (s, 1H), 4.25 
(t, J = 5.5, 2H), 3.57 (m, 2H), 1.99 (s, 3H), 1.95 (s, 3H); FT-IR (cm-1): 3294, 3083, 2959, 1717, 
1652, 1548, 1452, 1373, 1320, 1293, 1159, 1040, 943, 815, 654; HPLC retention time: 8.25 min 
(Supporting information Figure S 2). 
N-[2-(acetylamino)ethyl]acrylamide (5): Eluent: AcOEt/EtOH-80/20. Yield: 53% wt. White 
solid. 1H NMR (300 MHz, CDCl3) (δ = ppm): 6.69 (bs, 1H), 6.47 (bs, 1H), 6.26 (d, J = 17.0 Hz, 1H), 
6.11 (dd, J = 17.0, 10.1 Hz, 1H), 5.65 (d, J = 10.1 Hz, 1H), 3.43 (m, 4H), 1.98 (s, 3H); FT-IR (cm-1): 
3278, 3087, 2945, 1648, 1626, 1551, 1446, 1408, 1369, 1327, 1291, 1244, 1104, 1061, 986, 953, 
807, 715; HPLC retention time: 4.52 min (Supporting information Figure S 3). 
N-[2-(acetylamino)ethyl]-2-methylacrylamide (6): Eluent: AcOEt/EtOH gradient from 90:10 to 
80:20. Yield: 86% wt. White solid. 1H NMR (300 MHz, CDCl3) (δ = ppm): 6.70 (bs, 1H), 6.24 (bs, 
1H), 5.75 (s, 1H), 5.35 (s, 1H), 3.44 (m, 4H), 1.99 (s, 3H), 1.96 (s, 3H); FT-IR (cm-1): 3300, 3090, 
2934, 1650, 1616, 1543, 1445, 1369, 1333, 1287, 1237, 1224, 1099, 1045, 998, 146, 919, 851, 
643; HPLC retention time: 5.63 min (Supporting information Figure S 4).  
3.2.3.1.2 Synthesis of N-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl]acetamide 
(7): 
686 mg of maleic anhydride (4.7 mmol, 1.0 eq.) were added to a stirred solution of 480 mg of 
N-acetylethyldiamine (450 µL, 4.7 mmol, 1.0 eq.) in dry DCM (10 mL). The reaction mixture was 
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stirred at room temperature overnight. Then, the solvent was evaporated, 10 mL of acetic acid 
were added, and the final solution was refluxed for 4 h. After removal of acetic acid under 
vacuum the obtained solid was purified by flash column chromatography on silica gel (70-230 
mesh) using AcOEt/EtOH (95/5) as eluent. Yield: 50% wt. White solid. 1H NMR (400 MHz, CDCl3) 
(δ = ppm): 6.73 (s, 2H), 5.78 (s, 1H), 3.70 (t, J = 5.2 Hz, 2H), 3.46 (m, 2H), 1.94 (s, 3H); FT-IR (δ = 
cm-1): 3284, 3107, 1693, 1652, 1556, 1449, 1417, 1378, 1366, 1336, 1292, 1172, 1111, 981, 913, 
839, 761, 697, 651, 632; HPLC retention time: 5.30 (Supporting information Figure S 5). 
3.2.3.2 Synthesis of Michael-adducts 
3.2.3.2.1 General procedure for the synthesis of Michael-type adducts MA1-4/NAC: 
Michael-type acceptor 1, 2, 3 or 4 (5.0 mmol, 1.0 eq., respectively 580, 650, 785 and 855 mg), 
816 mg of N-acetyl cysteine (NAC) (5.0 mmol, 1.0 eq.), and 555 mg of TEA (5.5 mmol, 1.1 eq.) 
were dissolved in 5 mL of degassed anhydrous MeOH under an inert atmosphere. The reaction 
mixture was stirred for 24 h (the complete consumption of the Michael-type acceptor was 
monitored by TLC analysis with potassium permanganate staining). Afterwards, Dowex® 50WX8 
hydrogen-form resin (2 g) was added in order to remove TEA. After the suspension was gently 
shaken for 30 min, the resin was removed, the filtrate concentrated in a rotary evaporator, and 
the product obtained finally purified by flash column chromatography on silica gel (230-400 
mesh). 
 N-acetyl-S-[3-(2-hydroxyethoxy)-3-oxopropyl]cysteine (MA1-NAC): Eluent: gradient from 
pure AcOEt to AcOEt/EtOH-90/10. Yield: 50% wt. Colourless oil. 1H NMR (300 MHz, MeOD) (δ = 
ppm): 4.57 (m, 1H), 4.16 (t, J = 4.8 Hz, 2H), 3.73 (t, J = 4.8 Hz, 2H), 3.06 (dd, J = 13.9, 4.6 Hz, 1H), 
2.84 (m, 3H), 2.67 (t, J = 7.0 Hz, 2H), 2.01 (s, 3H); FT-IR (cm-1): 3331, 2933, 1719, 1648, 1541, 
1416, 1376, 1345, 1185, 1078, 1039, 888, 836, 589; HPLC retention time: 6.25 (Supporting 
information Figure S 6). 
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N-acetyl-S-[3-(2-hydroxyethoxy)-2-methyl-3-oxopropyl]cysteine (MA2-NAC): Eluent: gradient 
from pure AcOEt to AcOEt/EtOH-90/10. Yield: 60% wt. Colourless oil. 1H NMR (300 MHz, MeOD) 
(δ = ppm): 4.65 – 4.52 (m, 1H), 4.16 (t, J = 4.8 Hz, 2H), 3.74 (t, J = 4.8 Hz, 2H), 3.05 (m, 1H), 2.88 
(m, 2H), 2.73 (m, 2H), 2.01 (s, 3H), 1.24 (d, J = 6.5 Hz, 3H); FT-IR (cm-1): 3336, 2937, 1719, 1650, 
1540, 1456, 1417, 1376, 1341, 1212, 1169, 1123, 1076, 943, 896, 847, 759; HPLC retention 
time: 7.35 (Supporting information Figure S 7). 
N-acetyl-S-{3-[2-(acetylamino)ethoxy]-3-oxopropyl}cysteine (MA3-NAC): Eluent: gradient 
from pure AcOEt to AcOEt/EtOH-70/30. Yield: 45% wt. Colourless oil. 1H NMR (300 MHz, MeOD) 
(δ = ppm): 6.14 (m, 1H), 5.71 (t, J = 5.4 Hz, 2H), 4.99 (t, J = 5.3 Hz, 2H), 4.62 (dd, J = 13.9, 4.7 Hz, 
1H), 4.41 (m, 3H), 4.21 (t, J = 7.0 Hz, 2H), 3.57 (s, 3H), 3.51 (s, 3H); FT-IR (cm-1): 3283, 3088, 
2933, 1725, 1631, 1542, 1427, 1373, 1345, 1297, 1216, 1184, 1126, 1041, 832; HPLC retention 
time: 6.58 min (Supporting information Figure S 8). 
N-acetyl-S-{3-[2-(acetylamino)ethoxy]-2-methyl-3-oxopropyl}cysteine (MA4-NAC): Eluent: 
gradient from pure AcOEt to AcOEt/EtOH-70/30. Yield: 48% wt. White solid. 1H NMR (300 MHz, 
MeOD) (δ = ppm): 4.53 (m, 1H), 4.15 (t, J = 5.1 Hz, 2H), 3.44 (t, J = 5.3 Hz, 2H), 3.05 (m, 1H), 2.85 
(m, 2H), 2.72 (m, 2H), 2.01 (s, 3H), 1.95 (s, 3H), 1.22 (d, J = 6.4 Hz, 3H); FT-IR (cm-1): 3292, 3087, 
2936, 1724, 1649, 1543, 1429, 1374, 1343, 1298, 1210, 1165, 1122, 1041; HPLC retention time: 
7.56 min (Supporting information Figure S 9).  
3.2.3.2.2 Synthesis of N-acetyl-S-(3-{[2-(acetylamino)ethyl]amino}-3-
oxopropyl)cysteine (MA5-NAC): 
82 mg of NAC (0.5 mmol, 1 eq.) and 78 mg of 5 (0.5 mmol, 1 eq.) were dissolved in 1 mL of 
degassed aqueous NH3 and the resulting solution stirred overnight at room temperature. The 
mixture was acidified with 1M HCl  (aq); the sample was freeze-dried and purified by column 
chromatography on Sephadex® G-10 (eluent: H2O/EtOH-50/50, flow 0.9 mL/min). Yield: 28% 
wt. White solid. 1H NMR (300 MHz, D2O) (δ = ppm): 4.44 (dd, J = 8.0, 4.5 Hz, 1H), 3.34-3.28 (m, 
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4H), 3.06 (dd, J = 13.9, 4.5 Hz, 1H), 2.90 (dd, J = 13.9, 8.1 Hz, 1H), 2.82 (t, J = 6.8 Hz, 2H), 2.53 (t, 
J = 6.8 Hz, 4H), 2.04 (s, 3H), 1.97 (s, 3H); FT-IR (cm-1): 3277, 3085, 1629, 1543, 1430, 1374, 1263, 
1221, 1040, 974, 585; HPLC retention time: 5.26 min (Supporting information Figure S 10).  
3.2.3.2.3 Synthesis of N-acetyl-S-(3-{[2-(acetylamino)ethyl]amino}-2-methyl-
3-oxopropyl)cysteine  (MA6-NAC): 
82 mg of NAC (0.5 mmol, 1 eq.) and 85 mg of 6 (0.5 mmol, 1 eq.) were dissolved in 1 mL of 
degassed aqueous NH3 and the resulting solution stirred for 3 days at room temperature. 
NaCNBH4 (0.5 mmol) was added every 24 h to reduce the possibly formed disulfides. The 
reaction mixture was then acidified with HCl 1M (aq); the sample was freeze dried. The white 
solid obtained was washed with AcOEt and then purified by column chromatography on 
Sephadex® G-10 (eluent: H2O/EtOH-50/50, flow 0.9 mL/min). Yield: 45% wt. White solid. 
1H 
NMR (300 MHz, D2O) (δ = ppm): 4.43 (m, 1H), 3.32 (m, 4H), 3.02 (m, 1H), 2.92 (m, 2H), 2.68 (m, 
3H), 2.04 (s, 3H), 1.97 (s, 3H), 1.15 (d, J = 6 Hz, 3H); FT-IR (cm-1): 3124, 3036, 2810, 1718, 1633, 
1556, 1387, 1302, 1239, 1119, 1043, 1008, 964; HPLC retention time: 5.72, 5.80 min 
(Supporting information Figure S 11).  
3.2.3.2.4 Synthesis of compounds N-acetyl-S-{1-[2-(acetylamino)ethyl]-2,5-
dioxopyrrolidin-3-yl}cysteine (MA7-NAC): 
82 mg of NAC (0.5 mmol, 1 eq.) and 91 mg of 7 (0.5 mmol, 1 eq.) were dissolved in 2 mL of 
degassed anhydrous MeOH under argon atmosphere and stirred overnight at room 
temperature. The reaction product was purified by column chromatography on Sephadex® G-
10 (eluent: H2O/EtOH-50/50, flow 0.9 mL/min). Yield: 30% wt. White solid.
 1H NMR (300 MHz, 
D2O) (δ = ppm): 4.53 – 4.41 (m, 1H), 4.10 – 3.99 (m, 1H), 3.71-3.60 (m, 2H), 3.49 – 3.41 (m, 1H), 
3.39 – 3.19 (m, 3.5H), 3.02 (dd, J = 13.7, 8.4 Hz, 0.5H), 2.72-2.61 (m, 1H), 2.05 (s, 3H), 1.91 (s, 
3H); FT-IR (cm-1): 3288, 1775, 1695, 1639, 1543, 1433, 1397, 1328, 1291, 1183, 1108, 1040, 950, 
686; HPLC retention time: 5.74 min (Supporting information Figure S 12). 
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3.2.4 Determination of thiol pKa 
The pKa of the thiols used as nucleophiles in Michael-type addition (3-MPA and NAC) and in 
thiol exchange studies (NAC and glutathione (GSH))  have been determined 
spectrophotometrically by recording the thiolate UV absorbance at 233 nm as a function of pH 
(ranging from 3.3 to 12.8)14,24 under the conditions used for the two sets of reactions. 
Specifically:  
pKa under the conditions for Michael-type addition; pKa values of 3-MPA and NAC: 100 mM Tris 
buffer solutions were prepared, and the pH was adjusted to the desired value by addition of 
concentrated NaOH (aq) or HCl (aq). Thiol solutions at different pH values were prepared in a 
mixture of the aforementioned Tris buffer solutions and EtOH (80:20 v/v) to a final 
concentration of 0.33 mM (NOTE: samples were analyzed at this stage to ensure a precise and 
reproducible preparation of the solutions). These freshly prepared solutions were incubated at 
30 °C for 30 min, and finally scanned in the UV absorbance region from 190 to 250 nm; 233 nm 
was the wavelength at which the thiolate showed an absorbance peak, while the contribution 
of the absorbance of the thiol was insignificant. The absorbance readings at 233 nm were 
plotted as a function of pH and the resultant titration curves were fitted using a sigmoid 
(Boltzmann) non-linear function, where the pH value at the inflection point corresponded to 
the pKa value of the thiol.  
pKa under the conditions for thiol exchange studies; pKa values of NAC and GSH: 50 mM 
phosphate buffer solutions were prepared from monobasic and dibasic sodium phosphate, and 
the pH was adjusted to the desired value by addition of concentrated NaOH (aq) or HCl (aq). 
Thiol solutions at different pH values were prepared in the aforementioned phosphate buffers 
to a final concentration of 1 mM (NOTE: samples were analyzed at this stage to ensure a precise 
and reproducible preparation of the solutions). These freshly prepared solutions were 
incubated at 37 °C for 30 min, and finally scanned in the UV absorbance region from 190 to 250 
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nm; the pKa values of the thiols were determined from the UV absorbance readings at 233 nm 
as described above.  
3.2.5 Thiol oxidation study 
To determine the extent of thiol oxidation (i.e. disulfide formation) over the course of the 
Michael-type addition reaction, the change in thiol concentration of different solutions of 3-
MPA (with pH 7.9, 8.1, 8.6 and 9.0) and NAC (with pH 7.9, 8.1 and 8.6) was measured via 
Ellman’s test at different time points. Briefly, different thiol solutions (with a final concentration 
of 1 mM) were prepared in a 80:20 v/v mixture of Tris buffer (100 mM, pH 7.9, 8.1, 8.6 or 9.0) 
and EtOH. 200 μL of each solution was then pipetted into a 96-well plate and left to incubate at 
30 °C for 30 min in the microplate reader. Subsequently, the first four reaction solutions of time 
point 0 (each with a different pH) were quenched by the addition of 100 μL of 250 mM HCl (aq). 
This step was repeated every 40 minutes for 4 hours, after which the Ellman’s test was carried 
out as described in 3.2.2.2. 
3.2.6 Validation of Ellman’s assay 
The reactivity of 2-nitro-5-thiobenzoate (NTB-), which results from DTNB reduction during 
Ellman’s assay, towards the different Michael-type acceptors used in this study (1-7) was 
determined in order to validate this assay for the determination of Michael-type addition 
reaction kinetics. Briefly, 25 µL of 3-MPA 2 mM (Tris 1 M, pH 7.0) and 250 µL DTNB 300 µM (Tris 
1 M, pH 7.0) were introduced and mixed for 1.5 min in a 96-well plate at 30 °C. The absorbance 
at 412 nm was recorded (as described in 3.2.2.2), then 25 µL of the desired Michael-type 
acceptor (18 mM for 1 and 3; 180 mM for 2, 4, 5 and 6; 2 mM for 7 in Tris 1 M, pH 7.0) were 
added, and the decay in absorbance at this wavelength was monitored at different time points 
for 20 minutes and compared to the one registered after the addition of 25 µL of buffer (Tris 1 
M, pH 7.0). 
Effects of Environmental Factors and Reactant Architecture on the Outcome of the 
Michael-Type Addition Used for Bioconjugation  
 
 
______________________________________________________________________________ 
175 
3.2.7 Determination of the observed Michael-type addition rate constants  
All Michael-type addition reactions between 3-MPA and NAC and various Michael-type 
acceptors were carried out at 30 °C in a 96-well plate at different pH values, including 7.9, 8.1, 
8.6, 9.0 (Tris buffer, 100 mM) and at three different thiol : Michael-type acceptor molar ratios 
(1:3, 1:6, 1:9 for compounds 1, 3 and 7, and 1:30, 1:60, 1:90 for compounds 2, 4, 5 and 6). The 
reaction kinetics were followed by measuring the unreacted thiol concentration via Ellman’s 
test at different time points. The observed Michael-type addition rate constants, kobs, were 
then calculated from Equation 8 and Equation 9 (taking into account the degree of thiol 
oxidation occurring during the course of the reaction; this was done by separately monitoring 
the change in thiol concentration under the same reaction conditions as the Michael-type 
additions and then subtracting the slope of a plot of ln([thiol]/[thiol0]) vs t from the slope of the 
Michael-type reaction plots found from Equation 8 (see 3.2.5 for a detailed description of the 
thiol oxidation study). 
 
   
                
                
        
Equation 8 
 
                              Equation 9 
 
As an example for the kinetic assay with 3-MPA acid and 2-hydroxyethyl acrylate at pH 7.9, the 
following steps were taken: three different acrylate solutions (with a final acrylate 
concentration of 6, 12 and 18 mM in a 40:60 v/v mixture of ethanol and Tris buffer, 100 mM, 
pH 7.9) and one thiol solution (2 mM in Tris buffer 100 mM, pH 7.9) were prepared. 100 μL of 
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each acrylate solution was then pipetted into 10 individual wells of a 96-well plate. On the 
same plate, around 300 μL of the thiol solution were pipetted into 15 further wells, and the 
whole plate was left to incubate at 30 °C for 30 min in the microplate reader. Thereafter, the 
Michael-type addition reactions were carried out: 100 μL of the thiol solution were added to 
the first three wells containing 100 μL of a 6, 12 or 18 mM acrylate solution (resulting in a final 
thiol:acrylate molar ratio of 1:3 in the first well, 1:6 in the second well, and 1:9 in the third well) 
and the reactants were mixed thoroughly by pipetting. This step was repeated every 5 minutes 
until all 30 wells contained the thiol/acrylate mixture. Subsequently, the reaction solutions 
were quenched by adding 100 μL of 250 mM HCl (aq), after which the Ellman’s test was carried 
out using 50 μL of each quenched reaction mixture. 
3.2.8 Stability of Michael-type acceptors  
3.2.8.1 1H NMR studies 
Compounds 1 and 7 (10 mM) were incubated at 30 °C in Tris buffer 100 mM (in D2O, the pH was 
adjusted at pH 7.4 and 7.9 with DCl in D2O)
25 recording spectra at different time points. 
3.2.8.2 Absorbance studies 
The hydrolysis of compound 7 was studied spectrophotometrically by monitoring its 
concentration at different pH values (7.9, 8.1, 8.6 and 9.0; Tris 100 mM/EtOH 80:20 v/v) and 
initial concentrations (2, 3 and 5 mM). The absorbance readings at 300 nm of the different 
solutions (150 µL in each well of a 96-well plate) were recorded at 30 °C. 
3.2.9 Stability of Michael-type adducts  
In order to evaluate the stability of the synthesised conjugates in reducing environement and 
determine if retro Michael reaction, leading to thiol exchange, occurs at physiological pH and 
temperature, Michael-type adducts MA1-5/NAC and MA7-NAC were dissolved at a 
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concentration of 1 mM in 50 mM phosphate buffers (pH 7.4 and 7.9, prepared from monobasic 
and dibasic sodium phosphate) containing 10 mM GSH. All samples were incubated at 37 °C. 
400 μL samples were collected periodically and added to 100 μL of 1.0 M hydrochloric acid 
solution to reduce the pH and quench the retro Michael reactions. Samples were stored at -20 
°C until analyzed using RP-HPLC; injections were carried out under the above-defined 
conditions (See 3.2.2.3) and areas of peaks were integrated to calculate conversion curves.   
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3.3 RESULTS AND DISCUSSION 
3.3.1 Thiol titration 
It is well known that the pKa value of a given compound is strongly dependent upon 
temperature, solvent and buffer system; hence we determined spectrophotometrically14,24 the 
pKa value of the thiol/thiolate equilibrium (Figure 55) for 3-MPA and NAC using the same 
experimental conditions of the studies in which they are involved. The titration curves were 
obtained by plotting the absorbance values at 233 nm as pH function (Figure 57); at this 
wavelength the absorbance of the thiolate showed a peak, while the absorbance of the thiol 
was negligible (Figure 56). Thus, it was possible to assume the thiolate concentration directly 
proportional to the absorbance values and calculating the pka from the inflection point of the 
titration curve. The pKa found for the GSH agrees with the commonly accepted value,
26 
validating the method. The results are summarised in Table 1 where it is possible to notice the 
great influence of temperature and medium on the pKa. 
 
Figure 55: Thiol/thiolate equilibrium 
 
Table 1: Measured pKa of the different sulphur containing nucleophiles 
Compound Temperature Solvent pKa 
3-MPA 30 °C Tris buffer 100 mM/EtOH 80:20 v/v 11.3 
NAC 30 °C Tris buffer 100 mM/EtOH 80:20 v/v 10.7 
NAC 37 °C Phosphate buffer 50 mM 9.8 
GSH 37 °C Phosphate buffer 50 mM 8.7 
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Figure 56: Recorded UV absorbance spectra of thiol (at low pH) and thiolate (at high pH) for 3-MPA in 
TRIS  buffer 100 mM/EtOH 80:20 v/v, at 30°C 
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Figure 57: Titration curve for 3-MPA in TRIS 100 mM/EtOH 80:20 v/v, at 30°C 
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3.3.2 Kinetic studies 
Michael-type addition reaction is a favourable tool for the conjugation of bioactive peptides 
onto polymeric carriers. The rate constants of Michael-type addition of two different sulphur 
containing nucleophiles (3-MPA and NAC) having different pKa values (See 3.3.1), onto the 
double bond of various α,β-unsaturated Michael acceptor compounds (the structures of the 
different Michael acceptors chosen for this study are depicted in Scheme 14), were determined. 
Various Michael-type acceptors featuring acrylate, methacrylate, acrylamide, methacrylamide 
and maleimide groups have been selected for this study. Considering that amino-terminated 
Michael-type acceptors might be required for their conjugation to macromolecules via amide 
bond formation, some compounds feature a terminal N-acetyl group, mimicking the structures 
(and therefore the kinetics and the hydrolysis properties) of the final Michael-type acceptor 
conjugates. 
The reaction kinetics of thiols towards Michael-type acceptors follow a second order rate 
law,7,14,27 meaning that the reaction rate is second order overall and first order with respect to 
both reactants (See Equation , where Nu = nucleophile and El = electrophile): 
               Equation 7 
The integrated rate law has been previously described in Equation 8 and Equation 9. 
In our experiments, monitoring of the Michael-type reaction at different pH values and thiol : 
alkene molar ratios was performed by measuring the concentration of the unreacted thiol via 
Ellman’s test at different time points. From the absorbance values measured during the 
Ellman’s test the amount of unreacted thiol (and then of the acceptor as well) in the reaction 
solutions could be calculated by using the calibration curves previously obtained (Supporting 
Information Figure S 13 and Figure S 14). 
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Scheme 14: General scheme of Michael-type addition and reactants employed for this study 
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3.3.2.1 Thiol oxidation study 
Thiols spontaneously undergo oxidation producing disulfur bonds, thus losing their 
nucleophilicity; this oxidation is pH and temperature dependant. In our case an overestimation 
of the reaction rate might occur by not taking into account this side reaction; hence, in order to 
determine the extent of thiol oxidation occurring over the course of the Michael-type reaction, 
the change in thiol concentration over time of different thiol solutions (with pH 7.9, 8.1, 8.6 and 
9.0) was measured via Ellman’s test. The thiol oxidation kinetics is expected to follow a first 
order rate law. Indeed, a representation of                           (Figure 58) results in a 
straight line. From this plot the amount of thiol oxidation occurring in the same time interval as 
the Michael-type addition reaction can be calculated: for pH 7.9, 8.1, 8.6 and 9.0 the amount of 
thiol oxidation after 1 h was 5%, 7%, 11% and 21%, respectively for 3-MPA; for pH 7.9, 8.1 and 
8.6 the amount of thiol oxidation after 1 h was 9%, 12%, and 14% for NAC. Thiolate oxidation is 
expectedly more rapid than thiol oxidation; in fact the rate constant is higher at more basic 
conditions (Table 2); moreover the lower pKa of NAC, with respect to 3-MPA, reflects a higher 
concentration of thiolate at the same pH, this is the reason why it more easily undergoes 
disulfide bond formation. In order to take into account this side reaction over the course of the 
Michael-type addition we subtracted the slope of the plot                           from the 
slope of the Michael-type addition reactions plots. 
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Figure 58: Oxidation of 3-MPA at different pH values 
Time-dependent oxidation of 3-MPA at different pH values was monitored by measuring the thiol concentration 
via Ellman’s test at different time points (in Tris buffer 100 mM/EtOH 80:20 v/v at 30 ⁰C). The slopes of the fitted 
lines represent the first order rate constant. Error bars represent standard deviations (n = 3). R
2
 values higher than 
0.97 were obtained in all cases. 
Table 2: Calculated thiol oxidation rate constants 
Compound pH Rate constant (10-5*s-1) 
3-MPA 7.9 -1.3 ± 0.1 
3-MPA 8.1 -2.0 ± 0.0 
3-MPA 8.6 -3.4 ± 0.2 
3-MPA 9.0 -5.2 ± 0.2 
NAC 7.9 -2.7 ± 0.0 
NAC 8.1 -3.4 ± 0.0 
NAC 8.6 -3.8 ± 0.0 
Thiol solutions (with a final concentration of 1 mM) were prepared in a 80:20 v/v mixture of Tris buffer (100 mM) 
and EtOH and left to incubate at 30 °C. 
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3.3.2.2 Validation of Ellman’s assay 
In order to check the feasibility of the Ellman’s test, used to determine the thiol concentration 
and then the rate constant of Micheal-type reactions, the reactivity of 2-nitro-5-thiobenzoate 
(NTB-), which results from DTNB reduction during Ellman’s assay, towards the different 
Michael-type acceptors used in this study (1-7) was determined. For this purpose 3-MPA was 
reacted with DTNB and the absorbance readings at 412 nm were recorded as already reported 
in 3.2.2.2, subsequently the different Michael-type acceptors 1-7 were added and the decrease 
in absorbance monitored at different time points (Figure 59: Evaluation of the stability of 
Michael-type acceptors towards NTB) Among the different Michael-type acceptors only 7, 
featuring a maleimide moiety, showed reactivity towards NTB-. So the kinetic evaluation of the 
Michael-type reaction can easily be performed using the Ellman’s test for compounds 1-6 but 
not for compound 7.  
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Figure 59: Evaluation of the stability of Michael-type acceptors towards NTB- 
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3.3.2.3 Determination of the observed Michael-type addition rate constant 
We monitored the kinetics of the Michael-type reaction between 3-MPA or NAC and various 
Michael-type acceptors (1-7) at different pH values and thiol : alkene molar ratios by measuring 
the concentration of unreacted thiol via Ellman’s test at different time points. From the data of 
unreacted thiol we backcalculated the amount of unreacted alkene, and then plotted 
                                           (an example of the graph obtained is reported in 
Figure 60). As expected, the data obtained perfectly fitted the lines demonstrating the second 
order kinetics. Furthermore the pH dependence underlines that the most reactive nucleophile 
is the thiolate, hence increasing its concentration (with higher pH values), the addition 
appeared to be faster.12   
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Figure 60 : Reaction between 3-MPA acid and 2-hydroxyethyl acrylate (1) 
The reaction was carried out at 30 ⁰C at different pH values and thiol : alkene molar ratios. By measuring the thiol 
concentration in the reaction wells via Ellman’s test at different time points (taking into account the degree of thiol 
oxidation occurring during the course of the reaction), it was possible to obtain keff. Error bars represent standard 
deviations (n = 3). R
2
 values higher than 0.95 were obtained in all cases. 
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Equation 8 and Equation 9 describe the integrated rate law for a second order kinetics: 
   
                
                
        
Equation 8 
                              Equation 9 
The slopes obtained from the plot in Figure 60 are keff (expressed in s
-1 - Equation 8) from wich 
is possible to calculate kobs (expressed in M
-1s-1 - Equation 9) that is the real rate constant 
observed, independent from initial concentration. Figure 61 shows the relationship between 
kobs and pH for compounds 1-6 in the reactions with 3-MPA (with our experimental settings was 
not possible to measure the rate constant for compound 7, since the reaction reached 
quantitative conversion even at the first time point10). As expected,8,12 the reactivity of 
compounds featuring the same functional groups (acrylates 1 and 3 or methacrylates 2 and 4) 
was almost the same. Not surprisingly both steric hindrance and electronic availability of the 
double bond play an important role in determining the reactivity scale and the combination of 
both factors in methacrylamide 6 is responsible for its very slow kinetic behaviour in Michael-
type reaction. From these results, it is possible to establish a trend of reactivity: acrylates >> 
methacrylates > acrylamides >> methacrylamides. Table 3 summarises the calculated kobs of all 
Michael-type acceptors studied at different pH values, with both 3-MPA and NAC as donors; 
NAC, in particular, showed to be a better nucleophile. This can be explained by considering 
that, at the same pH, there is a higher amount of NAC in its deprotonated form respect to the 
3-MPA (refer to the pKa reported in Table 1) and thiolates are better nucleophiles than thiols. 
  
Effects of Environmental Factors and Reactant Architecture on the Outcome of the 
Michael-Type Addition Used for Bioconjugation  
 
 
______________________________________________________________________________ 
187 
7.8 8.0 8.2 8.4 8.6 8.8 9.0 9.2
1E-3
0.01
0.1
 compound 1
 compound 2
 compound 3
 compound 4
 compound 5
 compound 6
k
o
b
s
  
(M
-1
s
-1
)
pH
 
Figure 61 : kobs as a function of pH for Michael-type addition reaction between compounds 1-6 and 3-
MPA 
The plot illustrates the pH-dependence of kobs of the Michael-type addition between 3-MPA and different Michael 
acceptors. Each point is the average value obtained from the three different thiol : alkene molar ratio and error 
bars represent standard deviations. 
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Table 3: Experimental rate constants (kobs) for Michael-type addition reaction  
 
 kobs (10
3
/M
-1
s
-1
) 
Acceptor pH 7.9 pH 8.1 pH 8.6 pH 9.0 
1 44.7 ± 5.1 79.1 ± 23.8 173.9 ± 8.5 305.5 ± 26.2 
2 1.6 ± 0.3 1.8 ± 0.2 4.2 ± 0.5 8.0 ± 1.0 
3 58.8 ± 13.3 92.7 ± 8.1 239.9 ± 7.4 477.0 ± 52.5 
4 2.0 ± 0.1 - ± - 4.0 ± 0.2 7.3 ± 1.1 
5  -  2.2 ± 0.3 2.5 ± 0.4 3.8 ± 1.2 
6  -  0.6 ± 0.1 0.7 ± 0.2 0.8 ± 0.2 
7a  -   -   -   -  
 
 kobs (10
3
/M
-1
s
-1
) 
Acceptor pH 7.9 pH 8.1 pH 8.6  
1 263.1 ± 0.0 357.4 ± 0.0 1235.0 ± 0.0    
2 1.7 ± 0.0 2.1 ± 0.1 7.5 ± 0.0    
3 262.6 ± 0.0 430.3 ± 0.0 750.0 ± 0.0    
4 0.9 ± 0.0 1.8 ± 0.0 9.6 ± 0.0    
5 1.7 ± 0.0 2.2 ± 0.0 4.2 ± 0.0    
6 0.4 ± 0.0 0.8 ± 0.0 1.0 ± 0.0    
a The Michael-type addition between compound 7 and 3-MPA was conducted in a 96-well plate as described in 
3.2.7 and then analysed by HPLC; the conversion showed to be quantitative even at the first time point (40 s). 
Hence we decided not to repeat the experiment with NAC. 
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Taking into account that thiols, in solution, are in equilibrium between the protonated and 
deprotonated form (i.e. the thiol and thiolate), the contribution of both these reactive species 
towards the rate constant of the Michael-type addition reaction should be evaluated finding an 
absolute rate constant. The rate of this type of reaction is pH dependent and the value of kobs is 
given by Equation 10, that was used to determine the individual Michael-type addition rate 
constants (i.e. the rate constants of the thiol and thiolate, kthiol and kthiolate, respectively): 
                                                            Equation 10 
                                           
        Equation 11 
Where   a is the fraction of nucleophile in the ionized form, as defined by Equation 11; k is the 
reaction rate constant of thiol and thiolate respectively and Ka is the dissociation constants for 
the equilibrium thiol/thiolate of 3-MPA  or NAC. This clearly explains and demonstrates that, 
since, pKa
3-MPA = 11.3 and pKa
NAC = 10.7 (See 3.3.1), at the same pH: kobs
3-MPA < kobs
NAC. Figure 62 
shows the plot of kobs vs α for the reaction between 1 and 3-MPA, which is characterised by a 
linear trend and can be fitted with a line to obtain the reaction rate constant of the protonated  
3-MPA or NAC (kthiol), from the intercept of the plotted lines; instead, the values of kthiolate can 
be calculated from the slope. 
Effects of Environmental Factors and Reactant Architecture on the Outcome of the 
Michael-Type Addition Used for Bioconjugation  
 
 
______________________________________________________________________________ 
190 
0.000 0.001 0.002 0.003 0.004 0.005
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
k
o
b
s

 
Figure 62: kobs vs α obtained from the results of the Michael-type addition of 3-MPA and 2-
hydroxyethyl acrylate 1 
The four points are relative to the different pH. The error bars refer to the error in the calculated kobs. R
2
 = 0.98. 
 
The use of Equation 10 and Equation 11 in combination with the calculated pKa of 3-MPA and 
NAC (See 3.3.1), allowed us to determine kthiol and kthiolate. Table 4 summarises the results of the 
rate constants determined for the Michael-type acceptors 1-6. 
As expected, it was calculated that kthiolate >> kthiol, since the thiolate is a much more powerful 
nucleophile than the thiol. However, these results demonstrate that the contribution of the 
thiol as a nucleophile cannot be neglected, especially when the pH < pKa (that is, when the 
concentration of thiol in solution is higher than that of the thiolate).  
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Table 4: Individual rate constants of thiol and thiolate of the Michael-type addition between 3-MPA or 
NAC and Michael-type acceptors 1-6 
 Reaction with 3-MPA Reaction with NAC 
Acceptor kthiol (10
3/M*s) kthiolate (10
3/M*s) kthiol (10
3/M*s) kthiolate (10
3/M*s) 
1 35.6 ± 11.3 62125.1 ± 4572.8 11.4 ± 52.9 154404.5 ± 10927.3 
2 0.9 ± 0.1 1587.7 ± 36.7 0.1 ± 0.4 927.1 ± 88.9 
3 28.4 ± 6.1 101670.3 ± 2462.5 204.7 ± 64.3 70466.8 ± 13269.0 
4 1.5 ± 0.1 1297.5 ± 25.3 0.0 ± 0.4 1377.6 ± 87.4 
5 1.8 ± 0.2 434.3 ± 81.3 1.2 ± 0.1 387.3 ± 16.9 
6 0.6 ± 0.1 40.7 ± 20.9 0.5 ± 0.2 72.6 ± 49.9 
 
3.3.3 Stability of Michael-type acceptors 
Maleimide containing compouds (e.g. 7) might seem the best choice for bioconjugation 
because of their rapid Michael-type reaction with sulfhydryl group of proteins. 
Despite the fast reaction rate, the use of this functionality involves relevant disadvantages; it 
has already been reported in literature17 that the resulting succinimide thioether formed during 
the Michael-type addition of thiols to maleimide, previously accepted as stable, undergoes 
retro and exchange reactions in the presence of other thiol compounds at physiological pH and 
temperature. If on the one hand this can be used to design a strategy of controlled release of 
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bioactive molecules,18,28 on the other hand it does not allow to have stable adducts. Moreover, 
the adduct can be easily hydrolysed bringing to the formation of the ring-opened product and, 
after ring-opening, the resultant thioether is stable, hence the planning of a controlled release 
becomes even more difficult.  
Another issue that needs taking into account is that the reaction with thiol compounds is 
generally carried out in aqueous media, so the thiol will have to compete with the hydrolytic 
reaction of the maleimide ring that can leadto a maleamic acid (Figure 63) and to an 
undesirable heterogeneity.19,29-32 
 
 
 
Figure 63: Hydrolysis of maleimide based compounds 
 
In order to clearly established the liability of the maleimide-ring, we investigated  the stability 
of compound 7 in front of hydrolysis by using different techniques; after incubation at different 
pH values, the ring opening was monitored either by 1H NMR or by measuring the UV 
aborbance of the maleimide at 300 nm (See 3.2.8.1 and 3.2.8.2). We chose to study the 
hydrolytic behaviour of this compound in the same environment present in the kinetic studies 
concerning the Michael-type addition (i.e. Tris buffer 100 mM/EtOH 80:20 v/v at 30 °C). 
The spectrum of 7 displays an absorbance peak at 300 nm,30 wavelength at which the 
hydrolised product (obtained after incubation of 7 at pH 12 for 24 h) does not show a relevant 
absorbance (Figure 64). Recording the absorbance readings at 300 nm of the different 
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solutions, it was possible to measure the amount of hydrolysed product (Figure 65) referring to 
a previously obtained calibration curve (Supporting information Figure S 15).  
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Figure 64: Spectra of maleimide 7 and hydrolysed form 
The spectrum of compound 7 (1 mM) was recorded in water at 30°C (●), while the squares (□) are relative to the 
ring opened product obtained after incubation of 7 (1mM) at pH 12 for 24 hours. 
 
To double check the results, we incubated compound 7 (10 mM) in Tris buffer 100 mM (in D2O, 
see 3.2.8.1) recording spectra at different time points. Almost the same results were obtained 
from the ratio of the integrated peaks of the initial and the hydrolysed compounds (Figure 66).  
As expected, we found that the maleimide moiety is highly unstable even at the lowest pH used 
during our kinetic study. This means that, despite its high reactivity towards nucleophiles in 
Micheal-type addition reaction, the control of the reaction outcome using maleimide-
containing compounds is scarcely predictable and particular care has to be taken to minimize 
the undesired side-reactions and to preserve the integrity of the Michael-type acceptor 
structure until the bioconjugation uccurs.     
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Figure 65: Spectrophotometrical study of the hydrolysis of compound 7 
The ring opening of compound 7 was monitored by recording the absorbance velues at 300 nm at different times 
after incubation of a 2 mM solution in Tris buffer (100 mM)/EtOH 80:20 v/v at 30 °C. 
 
The hydrolysis rate of different acrylates and methacrylates was already studied8 
demonstrating that the neutral hydrolysis rate is negligible compared to the basic one. 
Moreover it was established that the hydrolysis does not interfere with the reactivity towards 
thiols. We confirmed these data by repeating the 1H NMR experiment to follow the hydrolysis 
of acrylate 1; by incubating the Michael acceptor (10 mM) in Tris buffer 100 mM (in D2O, see 
3.2.8.1) the amount oh hydrolised product was under the detection limit even after 12 hours.  
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Figure 66: 1H NMR study of the hydrolysis of compound 7 
Maleimide derivative 7 (10 mM) was incubated at 30°C in Tris buffer 100 mM (in D2O) at pH 7.4 and 7.9
25
 recording 
spectra at different time points. 
 
3.3.4 Stability of Michael-type adducts 
Michael-type adducts with acceptors 1-7 and NAC were synthesised as reported in Scheme 15. 
We focused our attention on the cysteine containing compounds because they better mimic 
the structure, and hence the chemical behaviour, of peptide-polymer bioconjugates.    
A preliminary screening devoted to select the most suitable experimental conditions (See 
Supporting information 3.7.1), performed with the acrylate 1 and 3-MPA, highlighted that polar 
protic solvent, i.e. methanol, and triethyl amine as organic base represent the best combination 
to reach high level of conversion in short times. These experimental conditions were 
maintained for the synthesis of the adducts with compounds 1-4 and NAC.  
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We found that the use of TEA with compound 7 promoted the formation of several by-
products, but, fortunately, the reaction did not require any catalyst: hence the reagents were 
simply mixed in methanol as solvent.  
To force the conversion to completeness in a shorter time period, harsher conditions were used 
with compound 5. In fact, after 12 h, using the aforementioned method, the Michael-acceptor 5 
was still present in the reaction mixture while, with the experimental setting already reported 
by Adediran,33 the conversion was quantitative after 12 h and no by-products were revealed by 
HPLC analysis.  
To the best of our knowledge, the stability of Micheal-type adducts with acrylates, 
methacrylates, acrylamides and methacrylamides, in front of hydrolysis or retro Michael 
reaction has never been studied in detail. Recently maleimide-conjugates, commonly employed 
due to maleimide specificity to thiols, fast aqueous reaction kinetics, lack of byproducts and the 
supposed stability of the thioether addition products, were shown to undergo thiol exchange in 
reducing environement at physiological pH and temperature.17 Reports about this kind of 
investigation with all the different Michael-type acceptors used for this study are very limited, 
despite their large use as homobifunctional cross-linkers, heterobifunctional cross-linkers, as 
well as in PEGylation ractions and for the conjugation of peptides or other bioactive 
molecules.21 
So we focused our attention on the stability of the synthesised thioethers (Scheme 15) at 
physiological temperature and pH value, i.e. 37 °C and pH 7.4, in a reducing environment using 
a solution containing GSH 10 mM; an higher pH value was used as well, i.e. 7.9, to have a 
clearer idea about the reaction mechanism and the factors influencing the adduct-stability. To 
determine the selectivity of these retro and thiol-exchange or hydrolysis reactions, and to 
obtain a quantitative measure of the time scales of these reactions, we designed an 
experimental procedure to follow the evolution of the system using HPLC analysis (See 3.2.9). 
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Michael-adduct MA1-7/NAC 1 mM were incubated at 37 °C in a solution of phosphate buffer, at 
pH 7.4 or 7.9, containing GSH 10 mM. Periodically, small aliquots of the mixture were quenched 
by adding hydrochloric acid and rates of consumption of the thioethers, under these various 
conditions, determined by monitoring the changes in peak areas by HPLC experiments. In order 
to determine the identities of the compounds present in the final fractions HPLC-MS analysis 
was performed. 
 
Scheme 15 : Synthesis of Michael-type adducts with NAC 
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The kinetic analysis revealed a pseudo-first order kinetics for the consumption of the Michael 
adduct, hence the rate constant (k) can be measured by plotting the natural logarithm of the 
thioethers concentration vs time and considering the slopes of the fitted line. The data 
obtained (Figure 67 and Table 5) perfectly follow the trend observed for the rate constants 
(kobs) relative to the addition reaction (Figure 61) which means the higher the pH value is the 
higher the rate constant is, and the reactivity scale observed for the Michael acceptor is the 
same for the relative Michael adducts. Moreover both the reaction products deriving from the 
two acrylates (1 and 3) and the two methacrylates (2 and 4) exhibit basically the same rate 
constant  indicating a negligible influence of the amide moiety at the γ-position to the carbonyl 
group. 
To identify the chemical species present in each solution HPLC-MS analysis was performed; for 
compound MA1-4/NAC the peaks relative to the hydrolysed Michael acceptor were found, 
furthermore no traces of the adducts with GSH indicating a retro-Michael pathway were found. 
For compound MA5-NAC nothing else apart from the starting compound was observed, thus 
indicates a very high stability of amidic bonds to hydrolysis. While the decomposition of 
compound MA7-NAC is much more complicate and both the reaction of hydrolysis or thiol 
exchange could be observed, but a detailed study about the different mechanism involved and 
their kinetics has already been reported,17 so there was no need to singularly calculate each 
single rate constant.   
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Figure 67: Measured rate constants for the disappearance of Michael-type adducts in 50 mM 
phosphate buffer at pH 37°C with 10 times molar excess of GSH 
Michael-type adducts were dissolved at a concentration of 1 mM in 50 mM phosphate buffers (pH 7.4 and 7.9, 
prepared from sodium phosphate monobasic and sodium phosphate dibasic) containing 10 mM GSH. All samples 
were incubated at 37 °C for 15 days. Samples were collected periodically and quenched with 1.0 M hydrochloric 
acid solution. Samples were stored at -20 °C until analyzed; areas of peaks were integrated to calculate conversion 
curves. The pseudo-first order kinetic rate constant is reported. Error bars refer to the standard error on the slope 
of the fitted lines.   
 
So we demonstrated that, among the Michael adduct synthesised with the NAC, only the one 
containing a succinimide moiety is susceptible to undergo retro-Michael reaction, on the 
contrary the other adduct does not show thiol exchange even after 15 days of incubation and 
high amount of GSH. Hence what we calculated for compounds MA1-6/NAC is the kinetics of the 
hydrolysis of the Michael adducts. The acrylate-deriving compounds showed to be three times 
faster hydrolised than the ones deriving from methacrylates, while compounds containing 
amides are hydrolised with a rate constant lower than the detection limit of our experimental 
setting.  
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This scale of reactivity can be used to rationally chose the best Michael acceptor in terms of 
reactivity and stability required for each particular application, furthermore the possibility to 
tune the released of bioactive molecules can be achieved by varying the α,β-unsaturated 
system. 
 
Table 5: Pseudo-first order rate constants measured for the disappearance of Michael-type adducts 
with NAC incubated in reducing environment 
 pH 7.4 pH 7.9 
Compound k*107 (s-1) k*107 (s-1) 
MA1-NAC 3.6 ± 0.2 6.0 ± 0.1 
MA2-NAC 1.1 ± 0.1 1.9 ± 0.1 
MA3-NAC 4.5 ± 0.1 7.4 ± 0.1 
MA4-NAC 1.4 ± 0.1 2.2 ± 0.1 
MA5-NAC -0.2 ± 0.3 0.1 ± 0.3 
MA6-NAC -0.2 ± 0.4 0.6 ± 0.6 
MA7-NAC 43.7 ± 1.5 45.2 ± 3.7 
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3.4 CONCLUSION 
We performed a complete quantitative study in order to investigate all the environmental 
factors, including the reactants architecture, having an effect on the reaction outcome of 
Michael-type addition on unsaturated double bonds. This has been possible by using high-
throughput experimental settings taking advantages of tools such as 96-well plates, in which 
spectroscopic experiments were carried out, automated HPLC analysis and parallel reactors.  
In particular we focused our attention on thiol containing nucleophiles, in fact Michael-type 
addition is a helpful tool for bioconjugating polymers with cysteine-containing peptides. For this 
study we considered seven different Michael acceptors featuring acrylic, methacrylic, 
acrylamidic, methacrylamidic or maleimidic moieties and thiol compounds with different pKa 
values, i.e. 3-mercaptopropionic acid, N-acetyl cysteine and glutathione. 
We observed that the addition follow a second order kinetics. Hence we were able to calculate 
the individual rate constants for both thiol and thiolate, the one relative to the thiol revealed to 
be at least two orders of magnitude smaller than the one of the deprotonated nucleophile. 
Thus the reaction rate is strongly influenced by the difference between the pH and pKa values, 
which is to say to the relative concentration of thiolate in the reaction mixture. We also 
established a trend of reactivity for the different Michael acceptors that is maleimide >> 
acrylates >> methacrylates > acrylamides >> methacrylamides. 
The investigation regarding the stability of the Michael acceptors revealed that maleimide is 
highly susceptible to hydrolysis also at physiological pH, so even if it immediately reacts with 
thiolated nucleophiles, precautions are necessary to prevent ring opening before Michael 
addition occurs. The other reagents showed to be stable enough to be handled without any 
particular care; moreover the hydrolysis rate is completely negligible in the time frame of the 
Michael-type addition.  
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Michael adducts between the seven acceptors and NAC as benchmark peptido-mimetic were 
synthesised. A long term study (15 days) was carried out on these adducts to determine 
whether retro-Michael reaction might occur in physiological environment (pH 7.4 and 37 °C) in 
the presence of an excess of GSH, an antioxidant widely present extra- and intra-cellularly. The 
latter demonstrated that only succinimide-containing undergo thiol exchange, while for the 
other compounds only hydrolysis was observed and the kinetics of this reaction was measured 
allowing a perfect knowledge of the stability of the adducts and allowing indeed the planning of 
a defined strategy for controlled released of bioactive molecules or to ensure the bioconjugate 
stability.  
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3.7 SUPPORTING INFORMATION 
3.7.1 SCREENING DIFFERENT CONDITIONS FOR MICHAEL-TYPE REACTION 
BETWEEN 3-MERCAPTOPROPIONIC (3-MPA) ACID AND 
2-HYDROXYETHYL ACRYLATE (1) 
 
 
 
Scheme S 2:  Michael-type reaction between 3-MPA and compound 1 
 
The reaction between 3-MPA acid and 2-hydroxyethyl acrylate (1) (Scheme S 2) was performed 
under different experimental conditions in order to determine which one was leading to the 
highest conversion in the shortest time. Table S 1 summarises the results.  
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Table S 1: Different experimental condition tested for the Michael-type reaction between 3-MPA and 
compound 1 
Entry Substrate Solvent Base/Catalyst Base or catalyst (mol/mol) Time Conversion 
1 1 MeOH K2CO3 60% 12 h <50%
a 
2 1 MeOH K2CO3 60% 48 h 87%
b 
3 1 MeOH phosphine resin 5% 12 h <50%a 
4 1 MeOH phosphine resin 5% 48 h 76%b 
5 1 DCM phosphine resin 5% 12 h <50%a 
6 1 DCM phosphine resin 5% 48 h 3%b 
7 1 MeOH TEA 110% 12 h 89%b 
8 1 MeOH TEA 110% 48 h 89%b 
9 1 DCM TEA 110% 12 h <50%a 
10 1 DCM TEA 110% 48 h 94%b 
11 1 H2O/EtOH Tris (pH 8.1) - 12 h 85%
b 
a evaluated by TLC         b evaluated by 
1
H NMR  
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3.7.2 HPLC ANALYSIS OF THE SYNTHESISED COMPOUNDS 
Figure S 1: HPLC analysis of 2-(acetylamino)ethyl acrylate (3) 
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Figure S 2: HPLC analysis of 2-(acetylamino)ethyl 2-methylacrylate (4) 
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Figure S 3: HPLC analysis of N-[2-(acetylamino)ethyl]acrylamide (5) 
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 Figure S 4: HPLC analysis of N-[2-(acetylamino)ethyl]-2-methylacrylamide (6) 
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Figure S 5: HPLC analysis of N-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl]acetamide (7) 
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Figure S 6: HPLC analysis of N-acetyl-S-[3-(2-hydroxyethoxy)-3-oxopropyl]cysteine (MA1-NAC) 
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Figure S 7:  HPLC analysis of N-acetyl-S-[3-(2-hydroxyethoxy)-2-methyl-3-oxopropyl]cysteine (MA2-
NAC) 
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Figure S 8:  HPLC analysis of N-acetyl-S-{3-[2-(acetylamino)ethoxy]-3-oxopropyl}cysteine (MA3-NAC) 
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Figure S 9: HPLC analysis of N-acetyl-S-{3-[2-(acetylamino)ethoxy]-2-methyl-3-oxopropyl}cysteine 
(MA4-NAC) 
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Figure S 10: HPLC analysis of N-acetyl-S-(3-{[2-(acetylamino)ethyl]amino}-3-oxopropyl)cysteine (MA5-
NAC) 
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Figure S 11: : HPLC analysis of N-acetyl-S-{1-[2-(acetylamino)ethyl]-2,5-dioxopyrrolidin-3-yl}cysteine 
(MA6-NAC) 
 
  
Effects of Environmental Factors and Reactant Architecture on the Outcome of the 
Michael-Type Addition Used for Bioconjugation  
 
 
______________________________________________________________________________ 
221 
Figure S 12: HPLC analysis of N-acetyl-S-{1-[2-(acetylamino)ethyl]-2,5-dioxopyrrolidin-3-yl}cysteine 
(MA7-NAC) 
 
 
  
Effects of Environmental Factors and Reactant Architecture on the Outcome of the 
Michael-Type Addition Used for Bioconjugation  
 
 
______________________________________________________________________________ 
222 
0.00000 0.00007 0.00014
0.0
0.7
1.4
A
b
s
o
rb
a
n
c
e
 @
 4
1
2
 n
m
 (
a
.u
.)
Thiol conc (M)
3.7.3 Calibration curves of 3-MPA and NAC via Ellman’s assay 
The evaluation of the thiol concentration necessary to evaluate the kinetic of Michael-type 
addition reactions with different electrophiles was performed via Ellman’s test. So, first of all, a 
calibration curve relating absorbance (at 412 nm) and concentration was plotted. Hence, 
several solutions with different concentration of thiol (3-MPA or NAC with concentrations 
ranging from 4.8 mM to 1.2*10-4 mM) were reacted with excess of DTNB.  
 
 
 
Equation: y = a + b*x 
Adj. R-Square: 0.99957 
Intercept: 0.00523 ± 0.002 
Slope: 10640.02643 ± 49.518 
 
 
 
 
 
 
Figure S 13: Calibration curve of 3-MPA 
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Equation: y = a + b*x 
Adj. R-Square: 0.99979 
Intercept: -0.140 ± 0.001 
Slope: 2106.982 ± 15.259 
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Figure S 14: Calibration curve of NAC 
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3.7.4 Calibration curve of maleimide 7 
The stability of the maleimide moiety contained in compound 7 was checked recording 
absorbance at 300 nm and calculating the concentration of the starting compound referring to 
this calibration curve recorded in Tris buffer 100 mM/EtOH 80:20 v/v at 30 °C. 
 
Equation: y = a + b*x 
Adj. R-Square: 0.99991 
Intercept: 0.0022 ± 
0.002 
Slope: 203.5182 ± 0.809 
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Figure S 15: Calibration curve of 7 
